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Abstract 
Athletic performance, regardless of activity or mammalian species, is determined by a combination 
of many genetic and environmental factors. Indeed, the functions of mammalian cardiovascular 
systems are greatly influenced by genetic factors that can have substantial phenotype variations 
between individuals and consequently variations in athletic performance. While many human 
studies have identified genomic regions of significance to cardiac-specific genes potentially 
involved in athletic performance, equine research linking genotype to particular equine phenotypes 
is deficient. 
It is currently thought that the abnormally large heart sizes (a non-disease state cardiac hypertrophy) 
seen in some Thoroughbred horses may contribute positively to athletic performance. Preliminary 
pedigree analysis suggests that the larger-than-average heart size and altered electrocardiograms 
(ECG) observed in some Thoroughbred horses may be a familial and/or breed-specific trait and thus 
have a genetic component, however to date no further molecular genetic analysis has been 
performed. Genes responsible for, or associated with, cardiac development, regulation, size, and 
function have been identified in both human and laboratory animal model species. These genes 
include MYH7, CASQ2, AKT1, PTEN, and PI3K. These genes are conserved across vertebrate and 
invertebrate species and have been shown to play crucial, equivalent roles in determining cardiac 
rhythm, growth, and function. Furthermore, these genes have not previously been characterised in 
Thoroughbred horses.  
It is hypothesised that genetic variation within these orthologous genes plays a major role in breed-
specific equine cardiac size determination, regulation, and function. Therefore, this study aims to 
determine the genetic variation in genes involved in cardiovascular function, development, and size 
in the Australian Thoroughbred horse population, and investigate whether this variation may 
contribute on a molecular level to the high level of athletic performance characteristic of this breed. 
We determined the novel sequence variants of the above five equine orthologues in a panel of non-
related Thoroughbred horses (n = 93). This has revealed several novel INDELs and SNPs that are 
potentially responsible for the large heart phenotype and the classification of previously 
undocumented variations. Key findings include novel SNPs that result in nonsense mutations in 
MYH7 suggesting multiple allele variants at several locations, and several insertions of premature 
stop codons (locations 40, 63, 64, 94, and 97) resulting in premature protein truncation. Also found 
was a non-conservative amino acid change in CASQ2 affecting calcium binding and protein 
polarity; a 3-base pair deletion in the 5’ UTR (un-translated region) of AKT1 possibly resulting in 
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changes to transcription factor binding regions or other regulatory binding sites; several variants in 
both 5’ and 3’ UTR of PTEN and a PI3K variant causing substitution of glutamine with a STOP 
codon, resulting in complete loss of an SH2 domain and severe truncation of the remaining protein. 
Catastrophic variants found in this study show correlation to poor racing performance, which may 
suggest that the higher than expected level of genetic variation within these genes may not be 
beneficial to good performance. The large number of variants found within the (usually conserved) 
candidate genes within this population may suggest that current breeding strategies are not 
maintaining the genetic health of the population.  
This research provides a preliminary basis for the development of genetic testing for gene variants 
associated with improved athletic performance. It also provides insight into the genetic variability 
of the Australian Thoroughbred population. Further research and development is needed regarding 
the applicability of genetic testing for improved breeding strategies to maintain the genetic health of 
the Australian Thoroughbred population without compromising athletic performance. 
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CHAPTER 1: INTRODUCTION & LITERATURE REVIEW 
1.1 Equus ferus caballus: Evolution, domestication, and breed emergence 
Equus ferus caballus, also known as the common domesticated horse, is a subspecies of the species 
Equus ferus, a member of the Equidae family. The Equidae family diverged from its earliest shared 
common ancestor with the Hyracotherium and was domesticated through accumulation of 
concurrent domestication events in areas it co-inhabited with Homo sapiens between 4000–3000 
BCE (Jordana, Pares & Sanchez 1995; Bowling & Ruvinsky 2000; Foster 2005; Gu et al. 2009; 
Lauschke & Maisch 2009). The Equus ferus species includes extant subspecies ferus caballus and 
ferus przewalskii, as well as the recently extinct ferus ferus (Figure 1.1). E. f. przewalskii is the sole 
remaining wild sub-species of the Equus ferus, and closest living relative to E. f. caballus. Unlike E. 
f. caballus, E. f. przewalskii has never undergone a domestication event and wild populations are 
currently small and endangered. E. f. caballus includes all breeds and types of domesticated horse, 
including ponies and other miniature horses. 
 
 
Figure 1.1: Equidae family. 
As subspecies, E. f. caballus and E. f. przewalskii share a close evolutionary relationship. Due to 
this there has been some discourse about the exact difference between the two in subspecies 
classification. Unlike other equids, hybridisation between E. f. caballus and E. f. przewalskii result 
in fertile offspring. The uncertainty surrounding the exact evolutionary relationship comes from this 
fact as well as many other issues conflicting with the traditional way in which we classify species 
and subspecies. E. f. caballus and E. f. przewalskii differ in both phenotype and genotype, with a 
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chromosome count of 64 and 66 respectively (Lau et al. 2009). This chromosome difference could 
be a result of either fission of the E. f. caballus domestic chromosome 5 resulting in the E. f. 
przewalskii, or by fusion of E. f. przewalskii’s chromosomes 23 and 24 resulting in the E. f. 
caballus domestic (Lau et al. 2009). This chromosomal difference is significantly less than the 
differences between other Equidae species (Lau et al. 2009) (Figure 1.2).  
 
 
Figures 1.2a and 1.2b: Horse breed phylogenetic relationships in comparison to the donkey (E. a. asinus).  
Figure 1.2a: Approximate genetic distance between some common equine breeds (Orlando et al. 2013).      
Figure 1.2b: Phylogenetic tree of prehistoric equids. The E. a. asinus (donkey) is a subspecies of the Equus 
africanus group, and an early Middle Pleistocene horse, as compared to ancient samples from 
approximately 735,000 years ago (Millar & Lambert 2013).  
Determination of a genetic relationship or lack thereof tends to depend on the exact genetic aspect 
chosen for the study. Unless taken holistically as a body of research, individual interpretations of 
data sets will invariably have different outcomes, whether the approach be average heterozygosity 
(Bowling et al. 2003), autosomal and X chromosomal microsatellite examination (Bowling et al. 
2003), Y chromosomal haplotype analysis (Wallner et al. 2003; Wallner et al. 2004; Wallner et al. 
2013), or mitochondrial analysis (Vila et al. 2001; Aberle & Distl 2004),  
Due to near extinction events (discussed later in this chapter) the current population of E. f. 
przewalskii stems from 13 founder members (8 females, 5 males). Uneven sex ratios and extremely 
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low founder population numbers could explain the difficulties in establishing a solid evolutionary 
picture. Natural changes such as mutation rate and genetic flow from co-inhabiting E. f. caballus 
populations tend also not to be taken into consideration, making species comparisons difficult. 
Modern genetic studies use post-wild extinction individuals for most research, not taking into 
account the potential lost genetic diversity or the possibility of undocumented E. f. caballus gene 
flow from undocumented mating. This may also confound subspecies classification. As research is 
still undecided, the E. f. przewalskii horse currently remains as it was originally classified as an 
independent subspecies. For the purpose of this study, use of the terms equine and horse will refer 
solely to the E. f. caballus subspecies. 
Whilst natural selection and environmental conditions have unarguably driven many of the breed 
specific adaptations currently seen in modern equine breeds, human domestication of the horse has 
also placed a major selective pressure on equine phenotype and genetic diversity (Vila et al. 2001; 
Gu et al. 2009). The Equus genus originally evolved as herbivorous herd species, naturally selected 
over time for speed, strength, and stamina by the constant need to evade predators. Both the E. f. 
caballus and the E. f. przewalskii have experienced the influence of population bottlenecks over 
time in the form of environmental and predation conditions. These events act on populations to 
reduce numbers, thus limiting the number of individuals able to contribute to the genetic diversity 
of future generations. However, the E. f. caballus underwent further significant population changes 
at the initial stages of domestication (Millar & Lambert 2013). 
Genetic analysis of mitochondrial DNA isolated from prehistoric fossil records of early equine 
populations indicate that multiple genetic origins contributed to domestic equine populations 
(Orlando et al. 2013). This suggests that domestication occurred through the accumulation of 
multiple small independent domestication events (Jansen et al. 2002). Subsequent analysis of 
modern equine DNA samples, sourced from 25 different regional populations (encompassing both 
Oriental and European domestic breeds) showed that as few as 77 mares from original pre-
domesticated populations were needed to account for the genetic diversity found in today’s global 
domestic horse population (Jansen et al. 2002). Similarly, the Orlando group (Orlando et al. 2013) 
found comparable levels of genetic diversity between the E. f. przewalskii and domestic equine 
populations. This is unexpected because, whilst both populations have undergone historic and 
recent population bottlenecks, E. f. przewalskii is currently considered to be recovering from a mass 
wild extinction and has a far smaller population than its domestic cousin. E.f. przewalskii has never 
been successfully domesticated and became extinct in the wild (mid-twentieth century) due to 
weather extremes, hunting, heightened military activity, and competition for habitat with 
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domesticated livestock (Lau et al. 2009). E.f. przewalskii narrowly escaped full extinction through 
the intervention of a rigorous breeding programme and reintroduction of captive-bred individuals 
into their native habitat of the Mongolian Steppe (Orlando et al. 2013). In contrast, E. f. caballus 
has not been subjected to any similar species-threatening conditions, suggesting that the lack of 
genetic diversity can be accounted for by human selective breeding.  
The comparable genetic diversity of E. f. przewalskii and E. f. caballus shows the significant impact 
that selective pressure can have on a domesticated species. From this, it can be suggested that 
despite the apparent abundance of domestic equine breeds currently listed, the actual genetic 
diversity of individual equine breed populations may be lower than expected (Binns et al. 2012). 
Since initial domestication events, human selective pressure has placed greater and more prolonged 
pressure on characteristics suited to human uses. Human practises of selective breeding, such as 
mating few males to many females, produce a desired phenotype reliably, but tends to limit genetic 
diversity within a population, thereby reducing the population’s ability to adapt to changing 
conditions (Mc Parland, Kearney & Berry 2009; Orlando et al. 2013). Artificial selective pressure 
in this way shapes populations to be more suited for human use and has been the driving cause for 
development of equine phenotypes of significant social and economic value (Bowling & Ruvinsky 
2000). Adaptations for speed and other athletic performance phenotypes are seen in many modern 
racing equine breeds, and the most significant example of this is the Thoroughbred horse 
(Cunningham et al. 2001).  
1.2 Defining the ‘Thoroughbred’ equine as an independent breed  
Quantitative measurement of the equine anatomy and physiology of almost all modern equine 
breeds has been carried out previously by many groups (Brooks et al. 2010). Thoroughbreds have 
been bred for speed and are most commonly used in flat sprint racing over multiple distances. 
Human selection for athletic performance phenotypes in Thoroughbreds has directly influenced 
many structural, functional, and physiological adaptations reported consistently in this breed. In 
comparison to other equine breeds, Thoroughbreds are well-documented to have greater anaerobic 
and aerobic metabolism, larger lung capacity, greater muscle mass to body weight ratio, lighter and 
finer skeletons, and increased pulmonary and cardiovascular system capacities (Gu et al. 2009).  
The international Thoroughbred breed standard outlines an adult individual to be between 15 to 18 
hands (equivalent to between 152.4–182.88 cm at the shoulder), and a fine-featured, medium-build 
horse (Brooks et al. 2010). Like most athletic equine breeds, the Thoroughbred has a low fat mass 
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of ~ 8.4% of total body mass. However, they differ from other breeds in that their total muscle mass 
percentage ranges between 53%–57% of total body mass, a much greater percentage than the 
average of 43% for other athletic equine breeds (Kearns, McKeever & Abe 2002). This highly 
muscular body composition, in combination with slender legs and hooves, gives a significant 
athletic advantage. A deep-set chest to compensate for a greater lung capacity and higher 
vascularisation of the cardiopulmonary system – allowing a greater supply of oxygen to tissues 
during extreme exercise – is also characteristic of this breed (Brooks et al. 2010). Colours such as 
bay, dark bay or brown, chestnut, black, and grey are common in racing stock, due to human 
selection for colour preference. Coat colour, whilst not synonymous with racing performance, is 
selected to produce a horse as close as possible to the racing standard. Over time, significant coat 
colour deviations from simple block colour have been selected against, thus removing them from 
most “purebred” breeding stock (Ludwig et al. 2009). Thoroughbreds can also display face and 
lower-leg markings as well as most colours and patterns of the general equine colour spectrum. The 
Thoroughbred is an excitable and quick-responding breed, well-known for athletic prowess, and 
racing ability.  
Both the international breed standard and the Australian breed standard give a range of easily 
observable phenotypical specifications for identification of a Thoroughbred horse. In addition to 
this, Thoroughbred breed registries offer parentage testing and other pedigree information. 
However, no breed-specific markers have been identified to date that are possessed by every 
individual within a specific breed (Bowling 2001). Current parentage tests and other genetic tests 
available (for example, tests for specific coat colour genes) have the expected allelic frequencies 
usually displayed in different equine populations, however these are not indicative of breed heritage 
or breed pedigree alone without close relatives of confirmed breeding for comparison (Bowling 
2001).  
The establishment of international breed registries and the regulation of the racing industry have 
imposed significant influence on the further development of Thoroughbreds to meet breed standards 
of phenotype. This influences on domesticated species such as the horse have gradually, yet 
distinctly, changed the physical characteristics of breeding stock. Through the selective breeding of 
specific animals with desirable traits, human-controlled breeding has produced an animal for a very 
specific purpose, in this case racing. As a result of this process, the Thoroughbred now differs 
greatly both anatomically and physiologically from other equine breeds (Brooks et al. 2010) . 
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1.3 Modern economic importance through racing, breeding, and associated 
industries 
The Thoroughbred originated in seventeenth and eighteenth century England, when native mares 
were crossbred with imported stallions of Arabian, Barb, and Turkoman breeding. The General 
Studbook was founded soon after in the late eighteenth century to document the breeding pedigrees 
of Thoroughbreds – horses used in racing and related foundation bloodstocks, such as Arabians 
(Australian Jockey Club & Victorian Racing Club 2014). The General Studbook later became 
instrumental in the development of the breed and to this day has significant influence on 
Thoroughbred breeding and racing. In the late nineteenth century, the studbook closed its general 
registry to only include progeny from already registered Thoroughbreds. This step limited the 
breeding population and added further selective pressure for successful racing phenotypes 
(Cunningham et al. 2001). 
Thoroughbreds were imported into North America from 1730 and later into Australia, parts of 
Europe, Japan, and South America during the nineteenth century. The breed became established in 
Australia in 1830 with the importation of three foundation sires to breed with local mares, and the 
Australian Studbook was established in 1878 (Australian Jockey Club & Victorian Racing Club 
2014). In Australia, a horse is registered as a Thoroughbred only if a pedigree can be established. 
This means a foal must have both parents already registered in the studbook as a Thoroughbred, and 
this must be supported by parentage tests (Australian Jockey Club & Victorian Racing Club 2014). 
This in effect limits new genetic contributors to the Australian population, other than members of 
other Thoroughbred studbooks worldwide. Control of the studbook in this way has significant 
influence on the development of the breed and its genetic diversity generally. Historically, 
Thoroughbred racing and breeding was a hobby sport of affluent English aristocracy. However, 
there is now a growing trend of Thoroughbred racing and breeding as a profession in a “for profit” 
business model. This modern progression from a hobby to income source has had one of the most 
significant influences on the breed since it was first established. Economic reliance on stud fees, 
and the over-demand for a “tried and tested” comparatively safe economic investment on part of 
professional breeders, may inevitably see an over-representation of a popular individual’ genetic 
contribution to forthcoming generations. This trend already results in successfully raced stallions 
being bred to many mares, thus further compounding population diversity, albeit unintentionally 
due to lack of awareness of genetic impact (Wilson & Rambaut 2007; Binns et al. 2012).  
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Thoroughbred racing is highly competitive and often involves large financial investments combined 
with a degree of risk. Current evaluation of potential racing success relies mostly on pedigree 
evaluation by the breeder and physical evaluation by an experienced veterinarian (Hill et al. 2012). 
In the absence of genetic testing for performance-enhancing genes, breeders rely heavily on 
pedigree information to select individuals for breeding potentially successful foals. Today, the 
Thoroughbred industry is primarily comprised of two key sectors – breeding and racing. The 
relevance of the Australian Stud Book as a selective pressure and influence on further development 
of the breed is evidenced by the Thoroughbred industry’s reliance on accurate breeding records for 
the domestic and global trade of Thoroughbreds for racing and breeding stock.  
The Thoroughbred industry contributes more than AUD$125 million annually to the Australian 
economy (Australian Jockey Club & Victorian Racing Club 2014). This comes in the form of direct 
revenue (breeding, racing, and gambling for example) and indirect benefit (support of sporting 
venues, and employment of support staff, for example). Thoroughbred pedigree registries and 
studbooks have significantly influenced the development of Thoroughbred breeding in Australia 
and internationally, therefore economic development and education of industry members goes hand-
in-hand with development of the breed, to both maintain the breed’s health and genetic diversity 
without compromising the industry’s internal economy. 
1.4 Genetic testing in the Thoroughbred industry 
Due to the considerable economic importance of the Thoroughbred racing industry, significant 
resources have been invested into the research and development of both physical and physiological 
characteristics of Thoroughbreds, as well as the care, maintenance, disease, and injury management, 
diet, metabolism and general husbandry of the racing animals. Whilst the industry itself recognises 
that continual research supports the long-term survival of the Thoroughbred industry, progress in 
the area of equine genetic research has been limited by the traditional views held by the racing 
community, which are generally resistant to change. Thoroughbred breeding and racing rules reflect 
this conservatism as the use of artificial reproductive technologies (ART) and other laboratory 
technologies in breeding are strictly prohibited. This approach has limited the way in which 
research is conducted and the application of advancements in technology to the industry. 
Traditionally, coat colour and establishment of parentage have been considered particularly 
important in the maintenance of breeding and racing standards. Consequently, genetics research has 
to date focused on explaining inherited, easily-observable traits and the development of genetic tests 
for them. Significant research has been undertaken to explain the genetic inheritance of complex 
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coat colour genes (such as tobiano, overo, and sabino1), parentage markers (equine microsatellite 
markers for pedigree confirmation), and to a lesser extent hereditary disease traits such as 
hyperkalemic periodic paralysis (HYPP), severe combined immunodeficiency disease (SCID), and 
overo lethal white foal syndrome (OLWFS) (Finno, Spier & Valberg 2009; Bellone 2010).  
Genetic testing has developed a significant role in the Thoroughbred breeding sector for the 
accuracy of pedigree records. However, the effect of this testing on the overall genetic diversity and 
fitness of the population is dubious, due in part to the way in which test results are used. For 
example, in other equine breeds, despite widespread genetic testing for foal parentage and some 
disease traits, alleles for inheritable disease can still be passed on to the next generation as breeders 
actively select for specific variants associated with particular coat colour or other physical 
phenotypic traits. In the case of OLWFS, one parental copy of the gene variant causes distinct white 
markings through a base coat colour, which is a desirable phenotype for some equine breeds. Two 
copies of this variant however are lethal. Genetic testing for individuals with this variant has 
reduced the incidence of homozygous lethal individuals, but has not increased the overall genetic 
fitness of this population as carriers are still selected. Whilst this condition is less common in the 
Thoroughbred, this well-known variant provides an excellent example that without significant 
owner and breeder education, genetic testing alone does not have a significant impact on breed 
genetic fitness and diversity. In the case of Thoroughbred breeders, this information is not strictly 
used for limiting inbreeding or disease, but rather for athletic performance.  
The Thoroughbred industry currently allows all pedigree-based pairings regardless of close family 
ties. Cousin, sibling, and parent-offspring pairings are considered a useful strategy for producing 
individuals as close to the Thoroughbred racing type as possible. Breeders have used this technique 
extensively in an effort to increase the probability of producing an individual capable of high 
athletic performance and large economic returns. Selective breeding and propagation of carrier 
individuals of hereditary disease traits may produce a reliable phenotype in the short term, but it 
may also have undesirable effects in the long-term. The use of selective inbreeding (mating between 
immediate family members) has been found to have negative effects on many populations of 
domesticated species (Brooks et al. 2010) by reducing genetic diversity and the overall genetic 
fitness of the entire population. This effect is further amplified in the Thoroughbred due to an 
already closed breeding population.  
The international Thoroughbred industry currently uses routine genetic testing for parentage and 
pedigree confirmation as well as for the identification of homozygous lethal disease traits. 
However, the ability to use genetic screening tools for beneficial traits (such as athletic 
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performance-enhancing genetic variants) or to monitor genetic diversity and genetic health of the 
breeding population has not been investigated as a possible candidate for industry-wide routine 
genetic testing.  
To date, variants from two genes have been positively associated with athletic performance in 
Thoroughbred horses (Table 1.1).  
Gene and type of variant Influence on athletic performance Reference 
MSTN (g.66493737C/T) 
Marketed as “The Speed Gene” 
Responsible for muscle mass development, and 
muscle fibre type. C/C associated with fast short-
sprint ability, C/T associated with middle-distance 
ability, T/T associated with enhanced stamina over 
mid- to long-distance races.  
(Hill et al. 2010a; Hill et al. 2010c; 
Tozaki et al. 2011; Hill et al. 2012; 
McGivney et al. 2012) 
LCORL/NCAPG gene region Gene expression levels and known SNP is 
associated with adult height (as measured at the 
withers) and body size: 
A/A small (161- 163cm) 
G/A medium (163- 166cm) 
G/G tall (168cm and over) 
(Makvandi-Nejad et al. 2012; 
Signer-Hasler et al. 2012; Metzger 
et al. 2013) 
Several research groups have 
proposed candidate gene lists of 
groups of genes or gene variants 
that may be associated with 
athletic performance. 
Non-specific influence on athletic performance. 
Groups of genes are identified as candidate genes 
for equine athletic performance by genome-wide 
association studies in human, equine, and other 
species research.  
(Bray et al. 2009; Gu et al. 2009; 
Schroder, Klostermann & Distl 
2011) 
Table 1.1: Equine genes with known positive correlation to successful athletic performance.  
Current testing for inbreeding and athletic performance traits, whilst not widespread, is offered as 
an optional extra by a select few commercial genetic testing facilities. Companies such as Equinome 
and Performance Genetics LLC offer commercial screening tests for groups of genes and SNP 
variants generally associated with different aspects of athletic performance, whilst other companies, 
such as Animal Genetics Inc, promise to do offer such test in the near future. 
Genetic screening companies that advertise genetic screening tests for athletic performance stipulate 
that they screen a panel of SNP variants associated in combination with successful racing ability or 
potential, however, not all research cited as supporting evidence is Thoroughbred-specific, publicly 
available, or peer-reviewed. These commercial tests are often offered as “in-house” premium 
genetic testing products, supported by current equine research. However, not all research cited as 
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supporting evidence is Thoroughbred-specific, condition-specific, or its relevance clearly linked to 
the genetic test in question. Nor is all testing parameters are adequately described. Furthermore, not 
all tests marketed by these companies as “athletic performance testing” involve actual genetic 
testing, and many actually involve “in-house” methods that rely heavily on statistical probability 
and projected computer modelling as analysis tools to evaluate a horse’s potential for success, 
measuring observable features such as age, sex, phenotypic measurements (physical body 
measurements), pedigree, and parentage statistics.  
If athletic performance gene variants were identified and reliably incorporated into current genetic 
testing protocols, then larger percentages of the Thoroughbred population could be more accurately 
tested for beneficial traits for the wider inclusion of individuals in the breeding population (Hill et 
al. 2010b; Hill et al. 2010c; Hill et al. 2012). To enable the use of genetic testing in this way, 
specific genes must be identified that can act both as a measure of athletic performance and an 
indicator of the genetic fitness of a population. By collecting genetic data from Thoroughbreds 
during routine testing, we can monitor the level of inbreeding in this population year-to-year, and 
use this as a marker of genetic diversity within the breeding population. This data could then also be 
used to track the mobility of athletic performance-enhancing variants throughout the breeding 
population, allowing selection for beneficial traits without compromising genetic diversity. This 
would lead to the continued development of the Thoroughbred for racing and industry purposes and 
also the conservation of equine genetic variability in this population.  
The widespread racing of Thoroughbred horses has revealed many different combinations of 
seemingly advantageous traits which are well suited to a high level of athletic performance. One 
such potentially advantageous phenotype, observed in some highly-successful Thoroughbred 
racehorses throughout racing history, is that of an unusually large heart. Heart genes are critically 
important to species evolution and as such are usually highly conserved. Thoroughbreds, however, 
have a known, breed-specific heart difference associated with superior athletic performance that 
may be gene regulated. Heart health and function under exercise is widely accepted by the 
Thoroughbred industry as an important selection parameter for identifying potential Thoroughbreds 
for racing and breeding. Currently, heart health checks are performed routinely as part of the 
general veterinary checks required to assess an animal’s suitability or potential for racing or 
breeding success. However, to date the genetic component of heart size, development, and function 
during exercise has yet to be identified.  
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1.5 Historical research and characterisation of a large heart phenotype in 
Thoroughbred racing horses, as a non-disease state  
Breed-specific differences have been extensively documented throughout history, and clinical 
equine cardiology is now well-documented for many horse breeds. Cardiovascular morphological 
differences between Thoroughbred and non-thoroughbred horses also been documented as early as 
1953 (Quiring & Baker 1953) if not earlier, and continue to be further investigated and used in both 
the commercial and non-commercial sectors of the equine industry. Due to the high economic value 
of horses, anatomical and physiological comparisons have been performed extensively, particularly 
amongst high-value racing breeds such as the Quarter Horse, Standardbred and Thoroughbred. 
These comparisons not only track adaptations for athletic performance, but also provide 
standardised cardiovascular limits to help identify cardiovascular disease and other related 
conditions in horses (Voros, Holmes & Gibbs 1991; Kritz, Hodgson & Rose 2000; Young & Wood 
2000; Begg, Hoffman & Begg 2006; Young, Rogers & Wood 2008). 
The Thoroughbred has developed a highly-adapted cardiovascular system and a highly-vascularised 
pulmonary system to cope with the increased oxygen demands placed on these systems during 
exercise due, in part, to a high ration of skeletal muscle percentage to body weight (approximately 
55%) (Hinchcliff, Geor & Kaneps 2008; Gu et al. 2009). To accommodate an increased need for 
oxygen to supply an increased muscle mass, Thoroughbred racehorses have developed a naturally 
larger heart relative to body weight than other equine breeds (Buhl et al. 2005; Oliehoek et al. 
2006). As well as an overall size difference, Thoroughbreds generally have greater heart symmetry 
than non-thoroughbred breeds. Other slight anatomical differences of the ventricles’ shape and size 
have also been identified, such as the flattening and truncation of the ventricular walls (Quiring & 
Baker 1953). These small differences are not indicative of a disease state, and when combined with 
other anatomical differences, such as a larger spleen (ratio of spleen weight to body weight) and 
blood volume, provide a significant advantage in athletic performance.  
The anatomical differences between Thoroughbreds and other breeds of horse, whilst small 
individually, have a cumulative effect on heart function. Ventricular ejection fraction or stroke 
volume is the amount of blood pumped by the ventricles per heartbeat. This volume is directly 
proportional to the size of the ventricles. The frequency with which blood is pumped is regulated by 
heart rate, which ranges between 20–240 beats per minute depending on the level of physical 
exertion (Patteson 1996). With a significant amount of muscle mass, under extreme exertion 
Thoroughbreds have an increased need for oxygen perfusion of the tissues. A Thoroughbred has a 
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resting oxygen consumption of approximately 130 ml/kg/min with a peak performance oxygen 
consumption that ranges between 160–220 ml/kg/min. This increased oxygen demand during 
exercise is likely to be one of the many contributing factors to the development of a larger heart and 
extreme athletic performance (Kamiya et al. 2003; Hinchcliff, Geor & Kaneps 2008). 
The link between an increased heart size, ventricular stroke volume, and oxygenation of muscle 
mass during extreme athletic performance is documented in human athletes, and this phenomena is 
also seen in other species known and bred for athletic performance such as whippets and 
greyhounds (della Torre et al. 2000). Although maximal heart rate and ventricular stroke volume 
can be altered by exercise, training, and age as it is in humans, Thoroughbreds show this phenotype 
to some extent throughout their life regardless of race training, suggesting this characteristic is a 
product of genetic variation rather than exercise-induced hypertrophy. The observations of elite 
racing individuals within the Thoroughbred population displaying these characteristics to an even 
greater extent than that of other Thoroughbreds triggered further studies to investigate its impaction 
on athletic performance. 
Subsequent investigations showed that in Thoroughbreds this phenotype was not associated with 
exercise-induced hypertrophy as it was in humans, but was associated with increased athletic 
performance and cardiac electrical conductance irregularities. In an effort to categorise and study 
this phenotype further in Thoroughbreds and other breeds, the “heart score” index was developed. 
The heart score is an index of cardiac muscle mass derived from the QRS duration of a resting 
electrocardiogram and, despite the method’s questionable validity (Moodie & Sheard 1980), the 
technique became popular as a non-invasive approximate measure of a Thoroughbred’s racing 
potential. This technique has become outdated as new clinical techniques have become available, 
however investigation of the phenotype itself has not progressed further. Despite the abundance of 
anatomical and physiological data already utilised in the Thoroughbred industry, the strong 
adherence to traditional breeding and racing practises has limited the way in which molecular 
genetic technologies are applied to breeding.  
1.6 Adaptive versus disease state hypertrophy 
Whilst much cardiovascular research to date has focused on characterising the Thoroughbred heart 
and correlating this to racing performance, the work to define equine cardiovascular limits has been 
key in identifying cardiovascular disorders and conditions that can negatively influence racing 
performance. Under normal physiological conditions, the mammalian heart naturally increases in 
size as an adaptation to an increased workload. There are cases however, where this size increase 
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continues and becomes the more serious condition of cardiac hypertrophy (Lauschke & Maisch 
2009). Many prominent race champions have significantly heavier hearts than the average 
Thoroughbred heart weight. This could be due to normal athletic adaptation to extreme work states 
or a sign of disease; either case would present with similar initial cardiac changes. It is therefore 
important to distinguish between a disease state (hypertrophic heart) and that of a genetically-
controlled, athletically-enhanced heart. 
Cardiac hypertrophy usually arises as a normal compensation for pump inefficiency, caused by 
increased cardiac pressure through hypertension or exercise. This increased stress triggers an initial 
hypertrophy of the cardiac wall muscle to increase the force of contraction (Crackower et al. 2002). 
This normal adaptation is seen widely amongst elite athletes, however it has the potential to develop 
into a disease state if a significant constant hypertrophy is maintained (Lauschke & Maisch 2009). 
Once at a pathological state, cardiac hypertrophy causes permanent ventricular remodelling on both 
a whole-organ and cellular level, leading to an overall decrease in cardiac function and an increased 
risk of sudden cardiac death (Konno et al. 2010). 
Whilst adaptive cardiac hypertrophy also involves some moderate cardiac remodelling, these 
changes do not appear to be detrimental. As well as physical changes, adaptive cardiac hypertrophy 
also has beneficial physiological changes that enhance overall cardiac performance during exercise. 
A decrease in cardiac output and heart rate at rest due to an increased parasympathetic tone, as seen 
in adaptive cardiac hypertrophy, leads to maximal cardiac output and peak oxygen consumption, 
further refining an already highly-efficient system (Young 2003).  
Cardiac murmurs and valvular regurgitation are amongst the most common causes of cardiovascular 
disease states in Thoroughbred horses. In extreme cases, these can severely impede racing 
performance and result in a reduced work life for the animal (Young & Wood 2000; Young, Rogers 
& Wood 2008). Whilst on the surface the practise of selective breeding for a large heart (and thus 
inferred athletic ability) may seem beneficial, the current practice of selective breeding for racing 
potential in horses may also have hidden side effects. It is possible that detrimental mutations 
favouring the early development of cardiac hypertrophy may be mistakenly selected, producing a 
disease phenotype in later life, similar to that seen in many high profile human athletes (Lauschke 
& Maisch 2009).  
Known cardiovascular dimensions and functional data in Thoroughbreds and other racing breeds 
have greatly increased the identification of individuals with an elite athletic performance phenotype. 
If used correctly, this information, combined with detailed pedigree analysis, could be used to select 
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a more robust Thoroughbred breeding population. However, without thorough genetic analysis 
there is the potential to select characteristics detrimental to the breed, such as disease state cardiac 
hypertrophy. A study by Young et al 2002, found higher aerobic activity (i.e. racing) caused a 
greater left ventricular mass resulting from a greater chamber size and wall thickness. Similar 
adaptive eccentric hypertrophy also occurs in humans, which is well-documented in other studies. 
This is in contrast to the phenotype under investigation in this thesis, which is a larger ratio of heart 
muscle mass to body mass, with completely normal heart anatomy (Young et al. 2002). 
1.7 Correlation between increased heart size and racing performance 
There is a current belief in the racing industry that the abnormally large hearts seen in some 
Thoroughbred horses and Thoroughbred crosses, may contribute to racing performance by 
providing a naturally larger cardiac output and thus a greater level of oxygen available to the 
muscles during exercise (Buhl et al. 2005). The presence of the larger than average heart was 
originally discovered in Thoroughbred individuals post-mortem. As an alternative to post-mortem 
dissection, electrocardiography (ECG) is now used as a non-invasive technique to investigate 
equine heart function and to predict heart size. More recently, other techniques such as Doppler 
sonography and echocardiography have been used to actively measure all anatomical and 
physiological aspects of the functioning heart (Voros, Holmes & Gibbs 1991; Voros 1997; Zucca et 
al. 2008).  
Early research from Steel (1963) proved fundamental in triggering Thoroughbred cardiovascular 
research. Up until this time, observations of a greatly enlarged heart in successful racehorses had 
been seldom documented. Steel (1963) concluded that the larger heart was a breed-specific 
characteristic of Thoroughbred horses. On comparison of both successful and unsuccessful racers, 
Steel showed a correlation between an individual’s racing status and their ECG results, which he 
stipulated could be indicative of heart size (Figure 1.3).  
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Figure 1.3: ECG comparison between Thoroughbreds of different racing success.  
A) and B) ECG electrode placement on the horse. C) Comparison reads of two Thoroughbreds – a 
successful horse (215, left) and unsuccessful (177, right). Nine measurements were taken from the potential 
difference between different combinations of ECG leads (in this case named: I, II, III, aVR, aVL, aVF, 
CF.LA, CR.LA, CV.LA) (Steel 1963). D) Lead readouts are combined to form an overall read more 
commonly associated with an ECG readout.  
 
Steel coined the term Heart Score to characterise equine ECG results, and furthermore correlated 
these heart score values to heart size and racing performance. In Steel’s original research (1963), 
the Heart Score was the correlation coefficients between the mean QRS interval of an 
electrocardiograph and the ability to win races. Monetary earnings throughout racing life were used 
as a measure of racing success. Generally speaking, larger hearts were found to have a wider QRS 
complex (in milliseconds) and this data was used to predict heart weight and consequently stroke 
volume and cardiac output (Figure 1.4) (Steel 1963).  
 
 
 
A) 
B) 
D) 
C) 
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Figure 1.4: example of QRS complex.  
Heart Score is calculated by the width of the QRS complex in milliseconds. The height of this peak was 
considered an indicator of the time it took for electrical signal to travel from the AV node to the ventricular 
epicardium, causing depolarisation of the myocardium and thus ventricular contraction. It was believed 
that a larger heart would have larger ventricles and thus have further for the signal to travel before 
depolarisation. 
Steel concluded that there was a positive correlation between the mean of the QRS interval (as 
measured with standard limb leads only) and heart weight. The height of this peak was considered 
an indicator of the time it took for electrical signal to travel from the AV node to the ventricular 
epicardium, causing depolarisation of the myocardium and thus ventricular contraction. It was 
believed that a larger heart would have larger ventricles and thus have further for the signal to travel 
before depolarisation. This research also concluded that P wave duration, QRS interval, Q-T 
interval, and heart rate were significantly correlated with good racing performance. Steel later went 
on to describe the measurement of the QRS interval as a Heart Score, and developed its use as a 
predictive method of athletic performance.  
Despite such thorough initial research into refining a physical technique to measure heart size in 
Thoroughbreds via ECG, there is contradictory evidence as to the actual usefulness of the Heart 
Score in predicting a potentially successful racer. However, it is considered useful in identifying 
cardiac disease in horses, and this perhaps is why horse owners and breeders still continue with this 
practise. It is conceivable that through the use of the Heart Score measure, diseased horses are 
naturally avoided and therefore any poor performance from this aspect is also avoided (Marr 1999).  
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Whilst Steel’s 1963 finding began a much larger cardiovascular investigation of the Thoroughbred 
horse at the time, it was only much later that preliminary pedigree analysis was performed. This 
analysis suggests that a larger than average heart may be a familial or breed-specific trait, and thus 
have a genetic component (Field & Cunningham 1976; Buhl et al. 2005; Wilson & Rambaut 2007). 
In 2001 this idea was taken up by a racing writer (Haun 2001), who chronicled the pedigree of a 
group of notable racehorses. Haun claimed that this trait was inherited through the X chromosome 
(sex-linked) however to date no molecular or genetic research has been undertaken to substantiate 
these claims (Haun 2001).  
1.8 Limitations of current phenotype classification 
Following Steel’s 1963 findings numerous groups began to investigate the correlation between QRS 
interval and heart weight, with mixed results. Most found some correlation between heart 
size/weight and racing performance, although mostly only in Thoroughbred horses and crosses 
thereof (Moodie & Sheard 1980; Nielsen & Vibe-Petersen 1980; Stewart 1980, 1981; Gunn 1989; 
Hanson, Kline & Foreman 1994; Blakely & Blakely 1995; Bakos et al. 2002; Buhl et al. 2005).  
Despite an inundation of anatomical and physiological data, as well as numerous correlation studies 
using both Thoroughbred and other breeds of horse, no genetic analysis was performed. Currently, 
some genetic predictions have been made as to the exact cause and heritability of equine heart size 
and its influence on racing performance. Most studies to date have used race performance results 
and statistical models to forecast genetic heritability; however, these predictions have yet to be 
substantiated by direct genetic analysis (Field & Cunningham 1976; Gaffney & Cunningham 1988; 
Willham & Wilson 1991; Wilson & Rambaut 2007). Despite the successful sequencing of a 
Thoroughbred mare and the publishing of the equine genome in 2007, further annotation of 
functional information and gene nomenclature has been lacking (Genome Assembly Team 2007; 
Wade et al. 2009).  
1.9 Overview of project and objectives 
1.9.1 Research overview and hypothesis 
Whilst the horse genome has been published, information linking genotype to particular equine 
phenotypes associated with racing outcomes is deficient. There is a current belief that the 
abnormally large heart sizes seen in some Thoroughbred horses and Thoroughbred crosses (as a 
non-disease cardiac hypertrophy) may contribute to racing performance, and this is associated with 
a greater cardiac output and QRS amplitude as measured by ECG. Preliminary pedigree analysis 
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suggests that the larger than average heart and altered ECG observed in some racehorses may be a 
familial and/or breed-specific trait, and thus have a genetic component. Orthologeous genes, 
conserved across vertebrate and invertebrate species, have been shown to play crucial, equivalent 
roles in determining cardiac rhythm and growth. 
Genes responsible for, or associated with, cardiac development, regulation, and function identified 
in both human and laboratory animal model species are predicted to play a major role in cardiac 
size determination, regulation, and function of the Thoroughbred heart. Therefore identification and 
classification of heart-specific genes and their expression in Equus ferus caballus would contribute 
to a greater cardiac trait awareness, as well as provide an analytical tool that could be used to 
improve breeding practices and racing performance outcomes.  
It is hypothesised that the increased cardiac size and altered ECG seen in many 
Thoroughbred horses is genetically controlled via breed-specific mutations in these genes.  
This project has been designed to address this hypothesis by amplifying and sequencing five 
candidate equine orthologues of human genes associated with cardiac function and development 
within the Australian Thoroughbred population. Candidate genes for this project include:  
 Myosin, heavy chain 7, cardiac muscle, beta (MYH7) 
 Calsequestrin 2, cardiac fast twitch muscle (CASQ2) 
 Phosphatase and tensin homologue (PTEN) 
 Phosphoinositide-3-kinase, regulatory subunit 1 (alpha) (PI3K) 
 V-akt murine thymoma viral oncogene homologue 1 (AKT1). 
1.9.2 Significance, aims and objectives 
1.9.2.1 Research overview and hypothesis 
The Thoroughbred population of Australia is comprised of a tightly regulated, closed studbook 
breeding population. Due to current breeding practises the total number of stallions has been 
steadily declining in recent years (Castle 2007) (Table 1.9.2.1). 
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Year Total Stallions Total Mares 
1991/92 2,643 31,733 
1995/96 1,776 26,988 
2000/01 1,241 26,273 
2004/05 967 26,607 
2009/10 824 24,304 
2014/15 646 20,115 
Table 1.2: The total number of stallions siring Australian Thoroughbred foals  
Breeding statistics show a significant reduction in the number of sires per breeding year; mare numbers 
have also seen reductions but not to the same extent as sire numbers (Board 2010). 
Research into the wider implications of this gradual reduction in (particularly male) genetic 
diversity is currently lacking, as is a full understanding of the impact of current breeding practises 
on the Australian Thoroughbred by the broader Thoroughbred breeding and racing industry (Castle 
2007).  
This study aims to address these trends and provide a strong experimental basis on which to build 
further genetic research of high athletic performance traits specific to the Australian Thoroughbred. 
This study also aims to provide preliminary research to assist in the development of genetic testing 
tools, which could be used to preserve and enrich current Thoroughbred genetic diversity by 
allowing selection for athletic genes from all areas of the Thoroughbred population. Identification 
of performance-related gene variants and development of genetic testing protocols for the industry 
may allow the use of the entire Thoroughbred population for breeding – regardless of pedigree 
prestige – for the benefit of genetic diversity without compromising athletic performance. Inclusion 
of individuals based solely on such tests may also provide new variants potentially important to 
athletic performance, as well as increase the overall hardiness of the entire population.  
1.9.2.2 Aim 
To determine the genetic variation in genes involved in cardiovascular function, development, and 
size in the Australian Thoroughbred horse population, and investigate whether this may contribute 
on a molecular level to the high level of athletic performance characteristic of this breed. 
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Objectives: 
 Compile a list of candidate genes using detailed pre-existing research of genes known to be 
involved in human cardiovascular function, development, and size. 
 Sequence candidate genes from a panel of unrelated Thoroughbred horses to identify genetic 
variants within the breed. 
 Use publicly-available genomic information from multiple species to identify candidate 
gene orthologues in the equine genome.  
 Design and optimise oligonucleotides for polymerase chain reaction (PCR) and sequencing 
of candidate gene exons and their flanking regions. 
 Select a panel of unrelated Thoroughbred horses and sequence the candidate genes in these 
individuals. 
 Identify and document genetic variations within the panel population. 
 Compare identified genetic variations in the study population to the published reference 
sequence.  
 Analyse gene-specific variation data for the Thoroughbred sample population and compare 
to known gene mutations found in human and other species. Use these comparisons to 
search for a potential correlation to, or influence on, heart size and functional phenotypes. 
 Combine all data for a population-wide genetic diversity analysis and variation linkage 
analysis.  
1.9.2.3 Experimental approach to achieve objectives 
Objective 1: Compile a list of candidate genes using detailed knowledge of genes known to be 
involved in human cardiovascular function, development, and size. 
Candidate genes were selected based on their role in normal cardiac regulation and development as 
well as for their causative mutation types found in inherited human cardiac disease.  
From an initial list of 60 genes, the following five genes were prioritised for full sequence analysis:  
Genes involved in human cardiac hypertrophic disease 
-- Myosin, heavy chain 7, cardiac muscle, beta (MYH7): Producer of myosin in the adult 
heart, and also important for foetal heart development (van Rooij et al. 2009). In humans, 
MYH7 has 261 mutations currently documented. Of these, 245 are missense or nonsense 
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mutations shown to be causative of hypertrophic or dilated cardiomyopathy (public HGMD, 
2011).  
-- Calsequestrin 2, cardiac fast-twitch muscle (CASQ2): A cardiac sarcoplasmic reticulum 
calcium-binding and transport protein, essential for regulating calcium concentration within 
cardiomyocytes (Kalyanasundaram et al. 2011) The protein has seven disease-causing 
mutations in humans (public HGMD, 2011) found to be responsible for induced cardiac 
arrhythmias, and disturbance to electrical conductance and heart muscle contraction.   
Genes involved in exercise hypertrophy  
-- Phosphoinositide-3-kinase regulatory subunit 1 (alpha) (PI3K): Important enzymatic 
modulator of several extracellular signalling pathways (NCBI, 2011). Can initiate 
hypertrophic responses via the PI3K-PTEN signalling pathway (Crackower et al. 2002). 
Role in cardiomyocyte size and contraction (in combination with pathway) documented in 
mice (Crackower et al. 2002). The PI3K family is highly conserved in evolution and plays a 
regulatory role in many important cellular responses including cell proliferation, adhesion, 
and cell size (NCBI 2011).  
-- Phosphatase and tensin homologue (PTEN): Membrane-bound lipid phosphatase 
functions as a negative regulator of PI3K in cardiomyocyte and endothelial cells. Loss of 
PTEN can result in hypertrophy (Oudit & Penninger 2009). It is an important regulator of 
the AKT/ PKB signalling pathway, which mediates cell proliferation and survival (Ivetac et 
al. 2009).  
-- V-akt murine thymoma viral oncogene homologue (AKT1): A serine-threonine protein 
kinase important for PI3K regulation (Shiojima & Walsh 2006).  
GenBank reference gene sequences of human and several other vertebrate species accessed from the 
National Centre of Biotechnology Information web site (NCBI: http://www.ncbi.nlm.nih.gov, 
accessed March 2009) were used to identify candidate gene orthologues within the horse genome. 
This step was critical to ensuring amplification of the orthologeous equine gene.  
Objective 2: Sequence candidate genes from a panel of unrelated Thoroughbred horses to identify 
genetic variants within the breed.  
Objective 2.1: Use publicly-available genomic information from multiple species to identify 
candidate genes orthologues in the equine genome.   
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Important gene functions are generally conserved across wide genetic distance. GenBank reference 
gene sequences from several vertebrate species were used to identify candidate gene orthologues 
within the horse genome. Identification of candidate genes in the equine genome was achieved by 
multiple sequence alignment of species with known gene regions. Conserved gene regions between 
species helped to identify gene sequences and probable coding regions (exon-intron boundaries) of 
the orthologeous gene in Equus ferus caballus. This step was critical in ensuring amplification of 
the orthologeous equine gene.   
Objective 2.2: Design and optimise oligonucleotides for PCR and sequencing of candidate 
gene exons and their flanking regions. 
Equine-specific PCR and sequencing oligonucleotides were designed using the orthologeous gene 
from the equine reference sequence as found through Objective 2.1. All exons of each of the 
candidate genes were individually amplified and sequenced for each sample in the research panel. 
Also included in the amplification area were exon-intron boundaries as well as five prime and three 
prime untranslated regions (5 and 3 UTR). Experimental procedures were designed and optimised 
to be compatible with genomic DNA sourced from equine hair follicles. 
Objective 2.3: Select a panel of unrelated Thoroughbred horses and sequence the candidate 
genes in these individuals. 
Detailed publicly-available pedigree information was used to select a genetically diverse Australian 
Thoroughbred population of non-related individuals (sharing no common ancestors to three 
generations). All study horses were registered with the Australian Studbook and have confirmed 
parentage. This step ensures a maximum probability of detecting genetic variation within the 
Australian Thoroughbred equine population. The candidate genes were sequenced using 
oligonucleotides designed and developed in Objective 2.2.  
Objective 3: Identify and document genetic variations within the panel population.  
Gene sequences from Objective 2.3 were compiled and aligned against the published equine 
reference sequence for all candidate genes. This established the genetic diversity of the 
Thoroughbred horse population with respect to the candidate genes. Sequence variations were 
identified and documented.  
Objective 4: Compare identified genetic variations in the study population to the published 
reference sequence.  
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Sequence alignments were compared to the published equine reference sequence in alignment 
analysis software. Genetic variations found in Objective 3 were then further compared to the 
published equine reference sequence and annotated in detail (nucleotide, protein, protein function 
etc) to document changes from the published nucleotide and amino acid sequence. 
Objective 4.1: Analyse gene-specific variation data for the sample population and compare 
to known human (and other species) gene mutations for a potential correlation to, or 
influence on, heart size and functional phenotypes. 
Sequence variations identified were analysed to predict their impact on the function and expression 
of associated genes and proteins. These predictions will be made on the basis of the known effects 
of a variety of mutations found in human and animal homologues of candidate genes. The outcome 
of this stage is to identify both breed-specific and individual mutations that may contribute to 
Thoroughbred genetic diversity and athletic performance, and discuss potential clinical outcomes 
for Thoroughbreds with identified variations.  
Objective 4.2: Combine all data for a population-wide genetic diversity analysis in relation 
to athletic performance as measured by lifetime earnings.  
All data attained in previous aims were combined and analysed as a sample population indicative of 
the genetic variation within the wider Australian Thoroughbred population. Correlation between 
variations and athletic performance as measured by racing performance was also investigated. 
Genetic variation as a marker of breed fitness is also discussed, as well as possible implications of 
genetic variations for the Australian Thoroughbred industry and current equine breeding practises. 
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CHAPTER 2: MATERIALS & METHODS 
2.1 Introduction 
The materials and methods outlined in this chapter were developed for and used in Chapters 3 to 6. 
2.2 Candidate gene list creation 
A candidate gene list was created using current human and animal cardiac research. Potential genes 
were identified using peer-reviewed scientific literature sourced from the National Centre for 
Biotechnology Information (NCBI) and the ISI Web of Science. Analysis of the literature and 
creation of the candidate gene list is discussed in Chapter 3. This approach was chosen based on 
limited laboratory resources and funding opportunities – there are other approaches that may be 
more optimal to use such as whole genome scans or SNP chip analysis, however these were 
unavailable at the time this research was undertaken.  
2.3 Bioinformatics and alignment of sequences 
GenBank reference gene sequences from several vertebrate species were used to identify candidate 
gene orthologues within the horse genome. This step was critical to ensuring amplification of the 
orthologeous equine gene. Gene sequences for the species Mus musculus (mouse), Rattus norvegius 
(rat), Homo sapiens (human), Bos taurus (cow) and Sus scrofa (pig) were obtained from the 
National Centre of Biotechnology Information web site (NCBI: http://www.ncbi.nlm.nih.gov, 
accessed March 2009). The Equus ferus caballus genome (EquCab2.0, NCBI) was searched using 
gene sequences from the Homo sapiens genome using the BLAST utility. Equus ferus caballus 
sequences with more than 90% sequence similarity were then downloaded and homology between 
genomic sequences was performed using the ClustalW algorithm with manual adjustments in 
alignment software Mega 5. Alignments were performed a second time using the MUSCLE 
algorithm in alignment software Mega 5 to insure accuracy of alignment (Tamura et al. 2011) 
(Appendix 10.3). Once the Equus ferus caballus sequence was verified as homologous (by 
identification of conserved gene regions between species) the sequence was then used to design 
PCR oligonucleotide (primer) pairs flanking each exon. 
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2.3 Oligonucleotide development 
Using the programme AmplifX 1.5.4 (Jullien 2004-2008) forward (5-3) and reverse (3-5) primers 
were designed to sit approximately 150 base pairs either side of exon boundaries (depending on 
suitability of sequence), within intronic regions. PCR primers were designed using standard 
techniques. The average PCR primer length was 20 to 23 nucleotides long with an average GC 
content of 50-60%. Annealing between 53C and 60C degrees, the resulting primers were then 
tested to ensure binding specificity against Thoroughbred Equus ferus caballus DNA samples. 
Amplicon product length was between 300 to 1000 base pairs long. Nested primers for sequencing 
were designed to sit inside the PCR primers (with location dependant on suitability of sequence). 
Nested primer lengths were between 16-20 nucleotides long with a GC content of 50-60%. The 
designed primers were then ordered from GeneWorks Pty Ltd. (The full primer list is available in 
Appendix 10.1) All oligonucleotides were designed and experimentally optimised by the author, 
with the exception of eight PCR and eight sequencing oligonucleotides for the CASQ2 gene, as well 
as 12 PCR and 20 sequencing oligonucleotides for the AKT1 gene, which were initially designed by 
AT and experimentally optimised by the author as outlined in Appendix 10.1.  
2.4 Sample selection 
Individuals were selected based on their genetic profile (DNA microsatellite parentage analysis), 
breed society registration, non-relatedness to other panel samples, and quality of DNA sample. 
DNA microsatellite parentage analysis was used to limit relatedness and ensure all samples met 
Thoroughbred breed standards for parentage and pedigree. Members selected were from the same 
year’s cohort of Thoroughbreds being parentage-tested by microsatellite analysis (year 2008). All 
samples were assigned a random plate position to protect sample anonymity. Permission was 
obtained from the Australian Studbook to use archived Thoroughbred hair samples stored at the 
AEGRC, after which 175 individuals were randomly selected by the AEGRC for research. Both the 
AEGRC database and external pedigree databases (2010) were searched for each individual’s 
pedigree. The top 93 least-related individuals with the best possible sample quality were selected, 
made up of 37 males and 56 females. All horses were registered with the Australian Studbook and 
had confirmed parentage. Pedigree data was obtained from the Pedigree Online All Breed Database 
(http://www.allbreedpedigree.com/) and confirmed to five generations. 
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2.5 Genomic DNA handling: Isolation, quantification, and storage 
The DNA extraction process from hair follicles, dilution of DNA, and long-term sample storage 
conditions were optimised before beginning extraction of samples selected for the Thoroughbred 
panel. This was to ensure the successful extraction of usable genomic DNA from hair follicle 
samples of limited quantity and quality. 
2.5.1 Isolation of genomic DNA 
Genomic DNA (gDNA) was isolated from equine hair follicles (Dissing, Rudbeck & Marcher 
1996). Between 6–8 follicles (depending on hair shaft thickness and follicle quality) were selected 
for each sample; follicle ends were then cut from the hair shaft into a 96-well plate. Hair shafts were 
discarded. Genomic DNA was chemically extracted from the hair follicles using 80 l of 200 mM 
NaOH incubated at 97C for 10 minutes after a gradual temperature increase spanning 4 minutes. 
The samples were then vortexed until hair follicles had dissolved. After centrifugation of the 
samples (3000 rpm for 3 minutes) 80 l of 200 mM HCl, a 100 mM Tris-HCl solution (pH 7.5) was 
added, and the samples vortexed again thoroughly. The samples were then centrifuged at 3000 rpm 
for 3 minutes. The resulting solution contained genomic DNA; centrifugation ensured minimal hair 
fibre by-products remained in the solution. The DNA solution was then measured for concentration 
and diluted into aliquots for immediate use and long-term storage. 
2.5.2 Quantification and storage of Genomic DNA 
Concentrations of gDNA were determined using a NanoDrop (ND-100, Analytical Technologies, 
BioLab) with spectrophotometer absorbance values of 260 nm and 280 nm. The samples were 
then siphoned off from remaining hair shaft waste (remaining in the bottom of wells from 
centrifugation) and diluted with 10 mM Tris, pH 8 to a concentration of 60 ng/l. The DNA 
samples were then aliquoted into 96-well plates (with caps to ensure non-contamination and sample 
safety) and stored at -20C. Aliquots not in use were stored carefully to avoid unnecessary 
freeze/thawing. Aliquots in use were kept on ice for the duration of experiment and refrozen 
immediately afterwards. 
2.6 DNA amplification and quantification protocols 
Primer pairs for all exons of the target genes have been designed, tested, and amplified a single 
target sequence from horse genomic DNA. Primer pairs amplified products of the expected size as 
determined by agarose gel electrophoresis. Due to the difficult nature of genomic DNA sourced 
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from hair follicles, PCR conditions were optimised not only for each individual primer pair but also 
in combination with the difficult sample type. 
2.6.1 Standard PCR protocol. 
AmpliTaq Gold DNA polymerase had more than 90% success rate for amplification of singular 
PCR products. PCR was performed in 20 l reaction volumes using AmpliTaq gold DNA 
polymerase and reagents (Applied Biosciences). 20 l reactions consist of: 2.0 l 10x PCR buffer 
II, 2.4 l 25 mM MgCl2+, 0.4 l 25 mM dNTP mix (Bioline), 1.0 l 10 M forward primer, 1.0 l 
10 M reverse primer, 0.2 l 100x BSA (Thermo Scientific), 1.0 l DMSO (dimethyl sulfoxide, 
Sigma-Aldrich), 0.3 l 5 U/l Taq polymerase, 9.7 l DNAse RNAse free water (Gibco). Sample 
gDNA was used at a concentration of 120 ng per reaction (2.0 l of sample aliquot). 
AmpliTaq PCR thermal cycling conditions consisted of 95C for 10 minutes, followed by 42 
cycles of: 95C for 1 minutes, annealing temperature for specific primer set for 1 minute, and 72C 
for 1 minute 30 seconds, followed by a final extension time of 15 minutes at 72C. All PCRs were 
optimised for DNA concentration and primer function. Primer details and primer pair annealing 
temperatures are listed in the appendices. 
2.6.2 Non-standard PCR protocols. 
Some difficult PCR primer and template combinations required further optimisation for successful 
PCR amplification and singular product. The following non-standard PCR protocols were used to 
PCR regions with GC or AT-rich regions, non-defined difficult templates, secondary structure, and 
mono-, di-, and trinucleotide repeats. 
 AmpliTaq Gold DNA polymerase 
PCR was performed in 20 l reaction volumes using AmpliTaq Gold DNA polymerase and 
reagents (Applied Biosciences). 20 l reactions consist of: 2.0 l 10x PCR buffer II, 2.0–2.4 l 
25 mM MgCl2+, 0.4 l 25 mM dNTP mix (Bioline), 0.4–1.0 l 10 M forward primer, 0.4–1.0 l 
10 M reverse primer, 0.2 l 100x BSA (Thermo Scientific), 0.0–1.0 l DMSO (Sigma-Aldrich), 
0.3–0.4 l 5 U/l Taq polymerase, 9.7 l DNAse RNAse free water (Gibco). Sample gDNA was 
used at a concentration of 120 ng per reaction (2.0 l of sample aliquot). 
AmpliTaq PCR thermal cycling conditions consisted of 95C for 9–10 minutes, followed by 30–
42 cycles of: 95C for 30–60 seconds, annealing temperature for specific primer set for 1 minute, 
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and 62C–72C for 1 minute 30 seconds, followed by a final extension time of 15 minutes at 62C–
72 C. 
 Mango Taq DNA Polymerase 
Mango TaqTM DNA polymerase (Bioline) was used in a 20 l PCR reaction: 4.0 l of 5x Mango 
TaqTM Reaction buffer, 1.0 l of 50 mM MgCl2+ solution, 0.4 l of 100 mM dNTP mix (Bioline), 
0.8 l 10 M forward Primer, 0.8 l 10 M reverse Primer, 0.2 l (1 unit) Mango TaqTM DNA 
Polymerase, 10.8 l DNAse RNAse free water (Gibco) 10.8 l. Sample gDNA was used at a 
concentration of 120 ng per reaction (2.0 l of sample aliquot). 
Mango TaqTM DNA Polymerase thermal cycling conditions were: 95C for 4 minutes, then 35–42 
cycles of: 95C for 30 seconds, annealing for 40 seconds, 62C–72C for 1 minute, and final 
extension at 62C–72C for 10–12 minutes. 
 Phire Hot Start II DNA Polymerase 
Phire Hot Start II DNA Polymerase (Thermo Scientific) was used in a 20 l reaction comprised 
of: 4.0 l 5x Phire reaction buffer, 0.16 l 25 mM dNTP mix (bioLine), 0.8 l 10 M forward 
primer, 0.8 ul 10 M reverse primer, 0.2–0.4 l Phire Hot Start II DNA Polymerase, 0.0–0.6 l 
DMSO (Thermo Scientific, 3% for GC rich regions), 11.44–12.04 l DNAse RNAse free water 
(Gibco). Sample gDNA was used at a concentration of 120 ng per reaction (2.0 l of sample 
aliquot). 
Phire Hot Start II DNA Polymerase thermal cycling conditions were: 98C for 30 seconds, then 
35–42 cycles of: 98C for 5–15 seconds, annealing temperature for 5–15 seconds, 72C for 15–30 
seconds, with a final extension of 72C for 1–7 minutes. 
 Phusion DNA Polymerase: 
Phusion (New England BioLabs Inc) was used in 20 l reactions containing: 4.0 l of 
Phusion GC or HF 5x buffer, 0.4 l 25 mM MgCl2+, 0.16 l 25 mM dNTP mix (BioLabs), 1.0 l 
10 M forward primer, 1.0 l 10M reverse primer, 0.0–0.6 l DMSO (Sigma-Aldrich), 0.0–0.2 l 
100% BSA (Thermo Scientific), 0.2 l Phusion High-Fidelity DNA Polymerase, 10.44–11.24 l 
DNAse RNAse free water (Gibco). Sample gDNA was used at a concentration of 120 ng per 
reaction (2.0 l of sample aliquot). 
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Phusion thermal cycling conditions consisted of 98C for 30 seconds, then 35 cycles of 98C for 
5 seconds, annealing temperature for 30 seconds, 72C for 30 seconds, and then 72C for 5 minutes. 
Phusion thermal cycle conditions for AT-rich templates consisted of 98C for 30 seconds, then 35 
cycles of 98C for 5 seconds, annealing temperature for 30 seconds, 62C for 1 minute, and then 
62C for 10 minutes. 
 Hotstar Taq protocols: 
1. HotStar Taq and Q solution (Qiagen) was used in a 20 l reaction: 2.0 l 10x HotStar 
PCR buffer, 4.0 l 5x Q solution, 0.16 l 25 mM dNTP mix (Bioline), 0.5 l 10 M 
forward primer, 0.5 ul 10 M reverse primer, 0.1 l (2.5 U/ reaction) HotStar DNA 
polymerase, 10.74–12.65 l DNAse RNAse free water (Gibco), gDNA was used at a 
concentration of 120 ng per reaction (2.0 l of sample aliquot). HotStar Taq and Q 
solution thermal cycle consisted of 95C for 5 minutes, then 3–-40 cycles of 94C for 30–45 
seconds, annealing for 1 minute, 72C for 1 minute, then a final extension time of 10 
minutes for 72C. 
2. HotStar Taq (Qiagen) was used in a 20 l reaction: 2.0 l 10x HotStar PCR buffer, 0.0–
1.2 l 25 mM MgCl2+, 0.16–0.2 l 25 mM dNTP mix (Bioline), 0.5 l 10 M forward 
primer, 0.5 l 10 M reverse primer, 0.1 l (2.5 U/ reaction) HotStar DNA polymerase, 
0.0–1.0 l DMSO (Sigma-Aldrich), 12.5–14.37 l DNAse RNAse free water (Gibco), 
gDNA was used at a concentration of 120 ng per reaction (2.0 l of sample aliquot). HotStar 
Taq thermal cycle consisted of 95C for 5 minutes, then 35 cycles of 94C for 30–45 
seconds, annealing for 1 minute, 72C for 1 minute, then a final extension time of 10 
minutes for 72C. 
3. HotStar Taq plus Master Mix Kit (Qiagen) was used in a 20 l reaction consisting of: 
10.0 l HotStar Taq Plus Master Mix 2x, 1.5 l 10 M forward primer, 1.5 l 10 M 
reverse primer, and 4.0 l 5x Q-Solution. Sample gDNA was used at a concentration of 
120 ng per reaction (2.0 l of sample aliquot). HotStar Taq thermal cycle consisted of: 
95C for 5 minutes, 35 cycles of 94C for 30 seconds, 60C for 30 seconds, 72C for 1 
minute, then 72C for 10 minutes. 
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2.6.3 Agarose gel electrophoresis and band visualisation. 
DNA fragments were visualised on 2% agarose gels in 1X TAE solution (40 mM Tris, 20 mM 
Glacial Acetic Acid, 1 mM EDTA, distilled water), containing 1.0 l per 2 ml agarose mixture of a 
10 mg/ml stock solution of Ethidium Bromide. All gels were run at 90 volts for between 30 to 40 
minutes, in a running solution of 1% TAE. A 1 kb DNA ladder was included in each run (Fermentas 
Life Sciences GeneRulerTM 1 kb DNA Ladder Plus, 0.5 g/l). 5.0 l of sample was mixed with 
2.0 l load dye (Bromo-blue) for standard band visualisation. Agarose gel photos were taken in an 
enclosed UV transilluminator using a standard digital camera with external computer control 
(Appendix 10.5). 
2.6.4 PCR product purification 
PCR products were purified of any remaining PCR remnants (primers, nucleotides, polymerases, or 
salts) using an enzymatic clean-up reaction (Dorit et al. 2001). A master mix was made on ice 
before each PCR clean up using enzymes from New England BioLabs Inc. Exonuclease I (6 units, 
or 0.3 l per sample) and Antarctic Phosphatase (1.5 units, or 0.3 l per sample) were made up to 
volume (2.0 l per sample) with associated buffers. 2.0 l of master mix was added to 5.0 l of 
PCR product and centrifuged before incubation at 37C for 20 minutes and then a further incubation 
at 80C for 15 minutes. 
2.7 Sequencing Quantification and Analysis Protocols 
PCR products were sequenced in both forward and reverse directions to produce two individual 
sequence reads for each sample PCR product. 
2.7.1 Standard Sanger sequencing protocol 
BigDye Terminator v3.1 (Applied Biosystems) was used in a 20 l reaction comprised of: 0.5–
0.75 l Big Dye Terminator v3.1, 3.75 l 5x Big Dye Terminator Sequencing Buffer, 3.2 l 
1 pmol/l sequencing primer (nested or standard primer), 9.3–9.55l DNAse RNAse free water 
(Gibco), 3.0 l of purified PCR product. The standard sequencing thermal cycle consisted of 95C 
for 5 minutes, then 30 cycles of 96C for 10 seconds, 50C for 5 seconds, and 60C for 4 minutes. 
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2.7.2 Non-standard Sanger Sequencing Protocol 
Non-standard Sanger sequencing was performed on template and primer combinations with non-
specific sequencing issues, as well as samples with hairpin or other secondary structures, GC or 
AT-rich regions, and templates with mono-, di-, or trinucleotide repeat areas. 
 Alternative sequencing plan for non-specific sequencing difficulties 
BigDye Terminator v3.1 (Applied Biosystems) was used in a 20l reaction comprised of: 0.5–
0.75 l Big Dye Terminator v3.1, 3.75 l 5x Big Dye Terminator Sequencing Buffer, 0.0–1.0 l 
Glycerol (sterile), 0.0–0.6 l DMSO (Sigma-Aldrich), 3.2 l 1 pmol/l sequencing primer (nested 
or standard primer), 7.7–11.05 l DNAse RNAse free water (Gibco), 1.5–4.0 l of purified PCR 
product. 
The non-standard sequencing thermal cycle consisted of: 94C–98C for 5 minutes, then 30 cycles 
of: 96C –98C for 10 seconds, 50C for 5 seconds, 60C for 4 minutes. 
 Hairpin or other secondary structures 
A dye master mix comprised of 0.9 l BigDye Terminator v1.1, and 0.3 l 7-deaza-dGTP mix 
totalling 1.2 l per sample reaction was made for use in the sequencing master mix comprised of: 
0.6–1.2 l 7-deazaG-dGTP BigDye v1.1 Terminator mix, 3.75 l 5x Big Dye Buffer, 3.2 l 
sequencing primer (3.2 pmol), 3.0 l template (PCR clean up), 8.85-9.45 l DNAse RNAse free 
water (Gibco). Cycle temperatures and times were further optimised for difficult sequencing. Hot 
start 94C–98C for 5 minutes, 25–30 cycles of 96C–98C for 10–30 seconds, 50C–65C degrees 
for 5–30 seconds, 50C–60C for 4 minutes. For AT-rich regions: hot start 94C–96C for 5 
minutes, 25–30 cycles of 96C –98C for 5–30 seconds, 50C–60C degrees for 4 minutes. 
2.7.3 Sequencing Purification Protocol 
Unincorporated dye terminators and salts were removed using a BigDye XTerminatorTM 
Purification kit (Applied Biosystems). BigDye XTerminatorTM Solution (10 l per sample) and 
SAMTM Solution (45l per sample) were made into a master mix on ice before clean-up. 10 l of 
sequencing product was mixed with 55 l of the clean-up master mix and vortexed for 30 minutes 
(under refrigeration, -4C). Plates were then left to sit for 20 minutes at -4C before placing on the 
plate reader. Samples found to have excessive signal strength were diluted with 100 l of DNAse 
and RNAse free water (Gibco) and re-read. 
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2.7.4 Sequencing Data Collection and Analysis Method 
Sample sequencing was analysed by either a 16-capillary 3130 Genetic Analyser Applied 
Biosystems or 48-capillary 3730 DNA Analyser Applied Biosystems and associated sequence 
data collection software programmes (3130-Series Data Collection Software v3.1 or 3730-Series 
Data Collection Software v3.1 –Applied Biosystems). Sequences were automatically collected by 
sequence scanner software (Applied Biosystems) and imported to GeneMapper® ID Software v4.1 
for auto analysis (calling of nucleotide bases). Sequences were stored in ab1 format until further 
manual reading and analysis. Sequencing Analysis Software 4Peaks v1.7.1 (A. Griekspoor & Tom 
Groothuis, mekentosj.com), and FinchTV v1.4.0 (2004-2006, Geospiza Inc) was used to check 
sequence read quality. 
2.8 Sequencing Variation identification and Chromatogram Analysis Method 
2.8.1 Primary Analysis Method and Data Handling. 
Both forward and reverse sequence chromatograms for each PCR product for each sample were 
compiled in CLC Main Workbench v6 (2013 CLC bio). All sequences were aligned against the 
appropriate equine reference sequence (EquCab2.0, NCBI) using CLC’s inbuilt “assemble 
sequences to reference” algorithm set with the following parameters: minimum assembly read 
length = 50 bp, alignment stringency = medium, conflict resolution = insert unknown nucleotide 
(N) (2013 CLC bio). Once aligned to the reference sequence, individual chromatographs were 
manually trimmed of poor quality sequence ends, checked for nucleotide call accuracy, and 
annotated for variations by hand. A consensus sequence for each sample was made from a 
combination of all reads for each exon of a gene (Appendix 10.4). Each variation found was given a 
unique location number for ease of data handling and documented using standard nomenclature for 
genomic and protein positions. Each individual was genotyped at each variant location, and 
population statistics for each variation was also recorded, including allelic frequency of both the 
reference and variant alleles.  
2.8.2 Variation Identification, naming and documentation 
Variations were classified based on their difference from the equine reference sequence (EquCab2.0 
NCBI). Variations were compared to the equine reference sequence (NCBI), the Homo sapiens 
reference sequence (NCBI), and other model organisms to extrapolate possible outcomes or effects 
of specific variations identified. All variants were assigned a “location number” (e.g. Location 1, 
Location 2, etc) for author ease of data manipulation. Variants were then fully classified at both the 
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DNA and protein level using Human Genome Variation Society (HGVS) endorsed nomenclature 
guidelines, due to the absence of an equine-specific genomic nomenclature society (den Dunnen & 
Antonarakis 2001). All variants were tabulated for ease of presentation in accordance with HGVS 
guidelines. All variants were identified on the DNA level experimentally by direct sequencing. The 
potential of genomic variants to cause changes at the amino acid and protein level were 
theoretically predicted using known nucleotide coding amino acid conventions. Full gene maps 
including annotated variants are located in Appendix 10.6, and tabulated variation information is 
located in Appendices 10.11 – 10.15. 
2.9 Racing data collection. 
Racing data was collected for each individual from Racing Information Services Australia Pty Ltd 
(http://www.risa.com.au/home.aspx). Lifetime racing statistics collected include: 
 Number of races run. 
 Number of first, second, third, and fourth placings. 
 Minimum distance won. 
 Maximum distance won 
 Total lifetime earnings.  
Total monetary earnings was taken as an indicator of racing success; this was confirmed by the 
other racing statistics. Racing data for the entire study population can be found in Appendix 10.8 . 
2.10 Statistical analysis and bioinformatics methods 
Each sample was genotyped at each variant location from direct sequencing. Genotype data was 
used to calculate allelic frequency at each variant location. Each variant location was analysed 
individually, and considered to be representative of an Hardy-Weinberg equilibrium (HWE) 
population for the purposes of this study. The influence of other factors such as potential variant 
linkage, selective breeding, skewed gender balance, and inbreeding (for example) was not corrected 
for. The expected allele distribution according to HWE proportions was calculated for the sample 
population (n = 93). Actual allelic distribution was calculated for all variant locations separately 
using the Hardy Weinberg equation [(p + q)2 = p2 + 2pq + q2 = 1] and the quantitative allele 
frequencies attained directly from sample sequencing (Corbin et al. 2010; McCue et al. 2012; 
Winton et al. 2015). The deviation of actual variant distribution from the theoretical variant 
distribution was tested for significance by a two-way t-test (Graph Pad Prism) with a significance 
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level of P < 0.05 (Wigginton et al. 2005; Hill et al. 2010b). The significance of deviation from 
HWE (as P values) and HWE normal distribution result for each variant within exons or 3 and 5 
UTRs are listed within the variants table for each gene.  
Multiple species protein alignments were performed in CLC Main Workbench 6 to attain potential 
conservation levels for each of the of the five candidate genes-encoded protein (Appendices 10.16 – 
10.20). Species used in these alignments were: Equus caballus, Bos Taurus, Felis catus, Homo 
sapiens, Mus musculus, Rattus norvegicus (Sus scrofia, Danio rerio, and Xenopus tropicalis were 
included where reference sequences were available). The resulting multiple-species alignments 
were used to select parameters for further SIFT protein analysis. SIFT was used to perform 
functional protein predictions for whether the DNA variants found during sequencing could cause 
an amino acid or protein modification event potentially resulting in a functional effect (Ng & 
Henikoff 2003). SIFT analysis was performed for gene variants in the MYH7 gene with the 
following parameters: Select database to search – UniProt-SwissProt2010_09, median conservation 
of sequences – 3, remove sequences – more than 97% identical to query (set at this level due to the 
high degree of conservation between neighbouring species in multiple-species protein alignments). 
SIFT analysis was performed for gene variants in the CASQ2 and PI3k genes with the following 
parameters: Select database to search – UniProt-SwissProt + TrEMBL 2010_09, median 
conservation of sequences– 3, remove sequences – more than 97% identical to query (set at this 
level for the same reasons as the first SIFT analysis). Chapter 7 analysis of racing and earnings data 
(including population distributions) was performed in Graph Pad Prim. Analysis of earnings groups 
in relation to variant types and occurrences was performed in Excel. Poisson regression analysis 
was performed for Figure 7.5 and Figure 7.6 in Excel. Preliminary haplotype analysis was 
performed in Excel using Chi Squared test for random distribution, significance level of P < 0.05 
corrected for multiple testing by Bonferroni. Statistical analysis will be discussed further, where 
necessary, in the relevant chapter.      
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CHAPTER 3: SELECTION OF CANDIDATE GENES 
3.1 Candidate gene list approach 
This study was designed to use a candidate gene approach over a broader genome-wide study 
approach to provide breed- and gene-specific polymorphism information with respect to important 
cardiovascular genes potentially involved in an athletically-important equine phenotype. Previous 
studies of equine and other species within the literature provide sufficient whole genome data to 
support the genetic basis of athletic performance (Gu et al. 2009; Schroder, Klostermann & Distl 
2011; Park et al. 2012). Most importantly, many genome-wide studies call for further gene-specific 
research to confirm study results and provide important functional information (Tozaki et al. 2010; 
Park et al. 2012).  
In candidate gene studies, suitable candidate genes are selected based on known biological, 
physiological, and functional relevance of the gene to the phenotype in question. Where sequence or 
functional information is lacking, data from related species (such as mouse models or human 
studies) can be used to infer genetic causation of the condition. In this case, there is excellent 
characterisation of the phenotype of interest and its underlying impact on equine physiology (i.e. 
large heart size and its influence on athletic performance), however direct genetic causation and 
protein functional information is lacking (literature review, Section 1.5) (Quiring & Baker 1953; 
Voros, Holmes & Gibbs 1991; Kritz, Hodgson & Rose 2000; Young et al. 2002; Young 2003; 
Young, Rogers & Wood 2005). Direct sequencing and analysis of candidate genes or candidate 
genomic regions can provide new sequence information and characterisation of previously 
uncharacterised gene regions, as well as lead to protein-functional information and a greater 
understanding of resulting phenotypes.  
Athletic performance and breed development in Thoroughbred racing has been extensively 
investigated, ranging from the molecular, cellular, and physiological mechanisms to foetal 
developmental, and the impacts of environmental conditions such as training and exercise on the 
general athleticism of horses (Young 1999; Buhl et al. 2005). There is a significant amount of 
research-based literature supporting the large heart as a distinct Thoroughbred equine phenotype 
(Quiring & Baker 1953; Moodie & Sheard 1980; Young, Rogers & Wood 2005). Genome Wide 
Association Studies (GWAS), performed both internationally and domestically by several 
independent groups, provide a strong link to a genetic basis for equine athletic performance (Hill et 
al. 2010c; Tozaki et al. 2010; Park et al. 2012). In this case, the candidate gene approach has proven 
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useful in that it allows a targeted study in a situation where a large GWAS is financially 
unattainable. 
Whilst the candidate gene approach relies heavily on researcher skill at gene selection and strong 
supporting evidence in the form of previous research, it can still prove successful at identifying 
gene variants associated with athlete performance, such as in the research performed by Hill’s 
group, successfully validating two identified SNPs from a list of five candidate genes for 
association with elite athletic performance (Hill et al. 2010b). 
One potential difficulty of the candidate gene approach is the lower sample sizes generally 
associated with it, due in part to its generally more time-consuming techniques. Whilst genetic 
screening of an equine sample population using the candidate gene approach will invariably use a 
lower sample size than comparative studies in humans or other experimental species that make use 
of other study methods, the relatively low genetic variation seen in Thoroughbreds due to intense 
human selection for athletic traits means that smaller sample sizes can still provide reliable and 
statistically significant results (Hill et al. 2010b; Hill et al. 2012).  
This current study investigates less common cardiac gene variants with (likely) low allelic 
frequency in the Australian Thoroughbred population. GWAS as a technique would not be likely to 
prove any more accurate than standard sequencing via the candidate gene method, as variant 
detection is solely limited by its actual presence in the sample population to begin with. 
Furthermore, results attained by a GWAS are likely to require standard re-sequencing and other 
candidate gene approaches to reliably identify actual causative variants and demonstrate the 
associations of rare polymorphisms with athletic performance (Wilkening et al. 2009). 
3.2 Candidate Gene List 
A candidate gene list was created using current human and animal cardiac research. Potential genes 
were identified using peer-reviewed scientific literature sourced from the National Centre for 
Biotechnology Information and the ISI Web of Science. 
Cardiovascular research consulted in the compilation of candidate genes had proven links to 
cardiovascular processes or size in either members of the wider Equidae family or other ungulates 
(Bos taurus), as well as human and human disease-model species such as rodents. Individual genes 
and groups of related genes (gene family) that were added to the candidate gene list are broadly 
categorised into the following groups: 
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 Adaptive hypertrophy. 
 Cardiac myopathy. 
 Embryonic and foetal heart development. 
 Cardiac function and electrical regulation. 
Any gene found to fit these categories – with supporting evidence linking it to heart size – was 
included in the candidate gene list. 
The literature was searched extensively for information on genes related to or involved in cardiac 
hypertrophy, adaptive cardiac hypertrophy, athletic performance, heart size, cardiac development, 
and regulation. These were then ranked in importance based on how likely they were to be a 
candidate gene for the specific Thoroughbred phenotype under investigation. Gene importance was 
weighted based on the quality of supporting evidence for potential involvement. Good supporting 
evidence was considered to be primary, published, peer-reviewed literature supported with 
experimentally-derived quantifiable data, with research independently established by at least two or 
more independent studies, and confirmed (where possible) with animal experimentation by at least 
one study. Correlation studies and computer-based modelling or predictions were not weighted 
heavily as supporting evidence. New or novel claims of a gene’s involvement in heart size, 
development, or regulation had to be experimentally derived and supported by animal studies from 
at least one independent source (if claims were recent) or several (if novel claim research was older 
than five years). Sixty genes were identified and weighted in importance in this way.  
Selected individual gene investigation was prioritised based on the weight of published evidence, 
genes of interest were than categorised into groups (Table 3.1) and the top five most likely 
influential genes selected for prioritisation (Table 3.2). 
The five candidate genes selected for further investigation were: 
 Myosin, heavy chain 7, cardiac muscle, beta (MYH7) 
 Phosphoinositide-3-kinase regulatory subunit 1 (alpha (PI3K) 
 Phosphatase and tensin homologue (PTEN) 
 V-akt murine thymoma viral oncogene homologue 1 (AKT1) 
 Calsequestrin 2, cardiac fast-twitch muscle (CASQ2).  
All five of the candidate genes, in addition to their well-characterised traditional functions, have 
been shown to play a new or novel role in cardiovascular development as well as in organ size and 
contractibility in Drosophila and other model species.  
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Gene Category Candidate genes 
Ion channel genes SCN5A, SCN9A, RYR2, CACNA1C, KCN Family, Loc731231 
Transporters, handlers of and genes 
associated with Ca2+ and other ions. 
TPM1, CASQ2, ASPH, ATP2A2, JSRP1, CALR, PLN, PRKCA 
Developmental and functionality genes. HAND1, HAND2, NKX2-5, SRF, LBH, GJA1, CDH13, ZNF18, ADRB1, 
ADRB2, HOPX, CDK5RAP3, IL6, HEY1, HEY2, TBX5, MEF2C, MSTN1, 
MSTN2, Z1C3, JAG1, ANKRD1 
Cell-signalling pathway genes. PTEN, PIK3CG, AKT1, ADRB3, ADRB2, ADRA2A, ADRA2C, UAP56 
Sarcomere protein genes. MYH7, MYPBC3, TNNT2, TNNI3, ACTC, TPM1, MYL3, MYL2 
Table 3.1: Gene groups. 
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Gene name and equine 
accession number. 
Alternate names and 
abbreviations. 
Human location and equine 
orthologue location 
Function Reference 
Myosin, heavy chain 7, cardiac 
muscle, beta. 
ENSECAG00000019844 
MYH7, MyHC-alpha 14q12 (human) 
Chromosome 1: 161,506,573-
161,527,244 reverse strand 
(Equine). 
Protein found in cardiac muscle, forms part of larger protein called type 
II myosin. Type II myosin is a slow twitch muscle fibre type, resistant to 
fatigue. Responsible for the mechanical force needed for muscles to 
contract, including the regular contractions of cardiac muscle. 
Rivero et al. 2006; Dall'Olio et al. 
2007; Coto et al. 2013 
Phosphoinositide-3-kinase. 
ENSECAG00000019837 
PI3K, PIK3CG, PIK3R1, p85-
ALPHA, p85, GRB1, PI3K-
Alpha, P110alpha, PI3-Kinase 
P110 subunit Alpha 
7q22.3 (Human) 
Chromosome 21: 5,673,136-
5,741,577 reverse strand (Equine). 
PI3K is a lipid kinase that mediates many cellular processes including 
cell growth, proliferation, differentiation, motility, cell survival, and 
intracellular trafficking. Also involved in the promotion of organ growth 
and size in mammals via the PI3K/PTEN/AKT1 regulatory pathway.  
Scanga et al. 2000; Shioi et al. 2000; 
Shioi et al. 2002; Alloatti et al. 2004; 
Shiojima & Walsh 2006; Yano et al. 
2008; Gu et al. 2009) 
Phosphatase and tensin 
homolog. 
ENSECAG00000017012 
PTEN, TEP1, BZS, MMAC1, 
PTEN1, MHAM 
10q23.3 (Human) 
Chromosome 1: 40,515,961-
40,601,946 reverse strand (Equine) 
PTEN is a multifunctional phosphatase whose major substrate is PI3K 
within the PI3K/PTEN/AKT1 pathway. PTEN activates numerous 
downstream targets, including the PI3K/AKT1 pathway and acts to 
dephosphorylate PI3K and negatively regulate PI3K AND PTEN 
expression. This process is particularly important in embryonic 
cardiovascular development and post-natal neovascularisation, as 
expression levels of PI3K are known to influence heart size.  
(Scanga et al. 2000; Crackower et al. 
2002; Sun et al. 2006; Oudit et al. 
2008; Oudit & Penninger 2009 
v-akt murine thymoma viral 
oncogene homolog1. 
ENSECAG00000008264 
AKT1, RAC, PRKBA, PKB, 
AKT, Protein Kinase B Alpha, 
Proto-Oncogene C-Akt RAC-
PK-Alpha, EC 2.7.11.1, PKB-
Alpha, CWS6, PKB, RAC, 
RAC-Alpha, Serine/Threonine-
Protein Kinase  
14q32.32 (Human). 
Chromosome 24: 46,109,751-
46,133,097 reverse strand (Equine). 
Regulatory and signalling molecule involved in many different 
biological pathways including metabolism, proliferation, cell survival, 
growth, and angiogenesis.  
Plays signaling role in the heart including cardiac growth and contractile 
function.  
May induce an increase in heart size through the PI3K pathway.  
Scanga et al. 2000; Shioi et al. 2002; 
Yang et al. 2005; DeBosch et al. 
2006; Morissette et al. 2006; 
Schiekofer et al. 2006; Vandoorne et 
al. 2013 
Calsequestrin 2, cardiac fast 
twitch muscle. 
ENSECAG00000021854 
CASQ2, PDIB2 1p13.3-p11 (Human). 
Chromosome 5: 53,134,872-
53,195,934 forward strand (Equine). 
Calcium-binding and storage protein, found in the sarcoplasmic 
reticulum of cardiac muscle cells. Stores and releases calcium for 
repetitive muscular contractions (heart beat). 
Park et al. 1998; Reyes-Juarez et al. 
2007; Knollmann 2009; 
Kalyanasundaram et al. 2011; Olojo 
et al. 2011 
Table 3.2: List of top five candidate genes. 1 
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CHAPTER 4: ANALYSIS OF THE MYH7 GENE 
4.1 Introduction 
As athletic performance is considered to be an amalgamation of many contributing factors (both 
genetic and environmental), a significant number of genome-wide association studies have been 
performed to identify likely candidate genes or candidate genomic regions involved or responsible 
for athletic performance traits (Bray et al. 2009; Gu et al. 2009; Tozaki et al. 2010; Schroder, 
Klostermann & Distl 2011). Muscle tissue is seen as playing a major role in both the natural ability 
and exercise-induced development of athletic performance in the Thoroughbred horse.  
To date a significant amount of research has focused primarily on identifying specific skeletal 
muscle genetic traits associated with a greater ability to excel in certain race types. Of particular 
interest is a collection of work by the Hill group and other collaborators (Hill et al. 2010c), 
positively correlating a sequence variant in the equine myostatin gene to optimal racing distance for 
the Thoroughbred (Binns, Boehler & Lambert 2010; McGivney et al. 2012). However, whilst the 
majority of current research has focused primarily on skeletal muscle traits, genome-wide 
association studies in both equines and humans have identified other genomic regions of 
significance to athletic performance, as well as cardiac-specific genes potentially involved in 
athletic performance. 
The larger ratio of heart size to body mass seen in some Thoroughbred horses has been linked to 
athletic performance (Young, Rogers & Wood 2005). One gene of particular interest is the MYH7 
gene. Other genes within the same family (myosin) have been shown to play a role in extreme 
athletic performance associated with skeletal muscle (Eizema et al. 2003). In humans, variants in 
the MYH7 gene are associated with hypertrophic cardiomyopathy, and other disease-state cardiac 
phenotypes (Coto et al. 2013). However, myosin gene regions (including MYH7) have also been 
shown to encode related intronic microRNAs important for the control of muscle myosin content, 
myofibre identity, and muscle performance (van Rooij et al. 2009). This apparent contradictory 
evidence in humans, between a beneficial and non-beneficial causative effect, is of interest due to 
the close evolutionary ties between humans and equines.  
Preliminary polymorphism identification in exons 30 to 31 of MYH7 by Dall’Olio et al. (2007) 
established four different alleles spread across the multiple-breed study. Inheritance of the variants 
was confirmed and it was postulated that the markers identified could be used for further athletic 
performance association studies. However, to date no further association studies or Thoroughbred-
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specific studies have been performed (Dall'Olio et al. 2007). Members of the myosin family are the 
fundamental functional units of striated muscles. Each myosin unit is a heterohexamer protein 
composed of two myosin-heavy chains (MyHC) and two non-identical pairs of myosin-light chains. 
Important in both the adult and developing heart, MYH7 encodes for “slow twitch” or slow 
oxidative type one muscle fibres that give muscles resistance to fatigue. The equine MYH7 gene has 
40 exons in total and is located on horse chromosome 1 within region 1q25–q26. There are three 
transcripts of this gene, all coding a functional protein (listed below) (Dall'Olio et al. 2007).  
MYH7 protein is primarily expressed in the heart and has been identified as a candidate gene by 
others for high athletic performance (Petersen et al. 2013). MYH7 has been chosen as a candidate 
gene for this study due in part to its history of association with performance, but also for its role in 
cardiomyocyte function during development and its prolonged role in heart muscle maintenance and 
function in the adult.  
The equine MYH7 gene has three known protein coding transcripts (splice variants). MYH7-201 
(ENSECAT00000023357) is comprised of 39 exons (38 are coding exons) and is the longest of the 
three transcripts at a transcription length of 5999bp and translation of length 1941aa. MYH7-202 
(ENSECAT00000023389) and MYH7-203 (ENSECAT0000023469) each have an extra exon (40 
exons each, 39 are coding exons) as a result of a splicing event. MYH7-202 has a transcription 
length of 5993bp and a translation length of 1938aa. MYH7-203 has a transcription length of 
5990bp and translation length of 1937aa.  
4.2 Results and discussion 
In total 125 variant locations were found for the gene MYH7 in the study population. All of these 
variants were novel and had not been identified previously. Figure 4.1 shows graphically the 
distribution of variants over the entire gene region. It can be seen that the majority of variants 
affecting larger percentages of the population were distributed in the first four exons as well as in 
the middle region of the gene. These regions correspond to the myosin head motor domain and the 
myosin tail, coiled regions respectively (Figure 4.2).  
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Figure 4.1: Graphical overview of variant distribution over total MYH7 gene length.  
Green boxes denote gene exons; stacked green boxes denote alternate transcript exons at that location. 
Red boxes stacked above green boxes denote 3 and 5 UTR. Blue box denotes the region in the MYH7 gene 
intron 30 that codes for the microRNA eca-mir-208b. No variants were found within the microRNA-coding 
region. Each bar on the graph represents the number of individuals different from the published equine 
reference sequence (n = 93).  
 
Figure 4.2: MYH7 protein domains. 
Domain structures were found using publicly-available information at Ensembl (http://asia.ensembl.org 
2014).  
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Of the variants identified, 61 were found in protein-coding regions or 5 and 3 UTR (Figure 4.3). 
Each sample in the study population was genotyped at each location and allele frequencies were 
calculated. This result was then used to identify any population distribution patterns which would 
be an indicator of whether the variant at that location was the product of normal genetic variation or 
a less-common random mutation event. Figure 4.3 shows the population breakdown of genotypes 
for each variant location in a protein-coding region, 5 UTR or 3 UTR. Table 4.1 shows specific 
variant information as well as confirmation of allelic distribution patterns where present. The 
unknown dominant or recessive nature of each variant has been taken into consideration with all 
frequency distribution calculations, using the Hardy-Weinberg equation. P values were used as a 
measure of conformity to Hardy-Weinberg distributions with a significance of P= 0.05. 
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Figure 4.3: Number of individuals with variants found in the protein-coding region of MYH7 gene.  
Each variant found in the study was given a location number for ease of analysis. At each location, samples were identified as heterozygous, homozygous reference or homozygous 
variant. Absolute numbers of individuals genotype is on the graph n = 93. Dominant or recessive nature of variants was unknown so traditional significance level statistical tests 
were invalid for this data set. Hardy-Weinberg equilibrium distribution analysis of variant distribution was performed in the following tables. Half of the variants found in the gene-
coding region were SNP variants affecting low numbers of the population. 
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MYH7  
BUILD: EquCab2.0, GENE: MYH7, GENE TRANSCRIPT: ENSECA00000019844. 
CHROMOSOME AND GENE REGION: 1: 161,506,573-161,527,244, STRAND: MINUS. ALTERNATE SPLICE TRANSCRIPTS: ENSECAT00000023357, 
ENSECAT00000023389, ENSECAT000000023469. 
Location Exon 
Anomaly Position; 
Chromosome 
Position 
Exon : 
Position 
Nucleotide Sequence 
Variant  
Codon 
Position 
Amino Acid  
Sequence 
Amino Acid 
Change* 
Variant 
Allele 
Frequency  
Reference 
Allele 
Frequency  
P Value   
(two 
tailed) 
HWB Normal 
Distribution (P 
< 0.05) 
1 1/ 5' UTR g.161527202A>G c.1:43A>G GTAGACACATTTG(A/G)GAAGCCAAGGTAA N/A N/A - 0.237 0.763 0.0488 YES 
7 4 g.161525691T>C c.4:135T>C CCATCTCTGACAA(T/C)GCCTACCAGTACA AA* FSISD(N)AYQYM - 0.247 0.753 0.0452 YES 
11 10 g.161523485G>A c.10:95G>A CTGAGGAGCTCAT(G/A)GCCACTGATGTAA AT* EEL(M/I)ATD p.Met331Ile 0.011 0.989 0.1791 NO 
17 21 g.161518675C>T c.21:43C>T GCTGGAGGAGATG(C/T)GAGATGAGAGGCT *GA LLEEM(R)DERLS - 0.011 0.989 0.1791 NO 
18 22 g.161518102C>T c.22: 232C>T TGCAGGAGAAGAA(C/T)GACCTACAGCTCC AA* SLLQEK(N)DLQLQ - 0.253 0.747 0.0439 YES 
19 23 g.161517370T>C c.23:90T>C TGAAGGAGATGAC(T/C)GAGAGGCTGGAG AC* QALDD(L)QAEED - 0.108 0.892 0.1044 NO 
21 24 g.161516922C>T c.24:108C>T CCCTGGATGACCT(C/T)CAGGCTGAAGAGG CT* KVKEM(T)ERLED - 0.113 0.887 0.1032 NO 
27 27 g.161513922C>T c.27:45C>T AGGCCGAGCGCAC(C/T)GCCAGGGCCAAGG AC* LEAER(T)ARAKVE - 0.086 0.914 0.1183 NO 
29 27 g.161513802T>C c.27:165T>C TGAACAAGAAGCG(T/C)GAGGCCGAGTTCC CG* MNKKR(R)EAEFQ - 0.242 0.758 0.0485 YES 
30 27 g.161513712T>C c.27:255T>C GCAAGAAGCACGC(T/C)GACAGCGTGGCTG GC* LRKKH(A)DSVAE - 0.398 0.602 0.0217 YES 
31 27 g.161513676T>C c.27:291T>C AGCAGATCGACAA(T/C)CTGCAGCGCGTGA AA* GEQID(N)LQRVK - 0.113 0.887 0.1012 NO 
37 30 g.161512025A>G c.30:81A>G ACGAGGAGGAGAC(A/G)GAGGCCAAGGCG AC* QYEEE(T)EAKAE - 0.392 0.608 0.0208 YES 
39 31 g.161511409C>T c.31:12C>T AGGAAGAAGCTGG(C/T)GCAGCGGCTGCAA G*G KKL(A/V)QRL p.Ala1400Val 0.005 0.995 0.1791 NO 
40 31 g.161511398C>T c.31:23C>T GGCGCAGCGGCTG(C/T)AAGACGCCGAGGA *AA QRL(Q/STOP)DAE p.Gln1404Stop 0.005 0.995 0.1791 NO 
41 31 g.161511396A>G c.31:25A>G CGCAGCGGCTGCA(A/G)GACGCCGAGGAG CA* LAQRL(Q)DAEEA - 0.043 0.957 0.1662 NO 
42 31 g.161511393C>T c.31:28C>T AGCGGCTGCAAGA(C/T)GCCGAGGAGGCCG GA* AQRLQ(D)AEEAV - 0.097 0.903 0.1234 NO 
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Table 4.1 continued. 
Location Exon 
Anomaly Position; 
Chromosome 
Position 
Exon : 
Position 
Nucleotide Sequence 
Variant  
Codon 
Position 
Amino Acid  
Sequence 
Amino Acid 
Change* 
Variant Allele 
Frequency  
Reference 
Allele 
Frequency  
P Value   
(two 
tailed) 
HWB Normal 
Distribution (P 
< 0.05) 
43 31 g.161511366T>C c.31:55T>C TGGAGGCCGTCAA(T/C)GCCAAGTGTTCGT AA* VEAV(N)AKCSS - 0.091 0.909 0.1274 NO 
44 31 g.161511357T>C c.31:64T>C GCCAAGTG(T/C)TCGTCTCTTGAG TG* AVNAK(C)SSLEK - 0.059 0.941 0.1529 NO 
45 31 g.161511348T>G c.31:73T>G AGTGTTCGTCTCT(T/G)GAGAAGACCAAGC CT* AKCSS(L)EKTKH - 0.086 0.914 0.1356 NO 
46 31 g.161511309C>T c.31:112C>T ATGAGATCGAGGA(C/T)CTGATGGTGGATG GA* QNEIE(D)LMVDV - 0.027 0.973 0.1619 NO 
47 31 g.161511282C>T c.31:139C>T TGGAGCGCTCCAA(C/T)GCGGCCGCCGCGG AA* DVERS(N)AAAAA - 0.005 0.995 0.1791 NO 
48 31 g.161511266C>T c.31:155C>T GCCGCGGCC(C/T)TGGACAAGAAGC *TG AAAAA(L)DKKQR - 0.005 0.995 0.1791 NO 
60 32 g.161511066C>T c.32:4C>T ATCCCCGTAGATC(C/T)TGGCCGAGTGGAA *TG NFDKI(L)AEWKQ - 0.011 0.989 0.1791 NO 
61 32 g.161511062C>T c.32:8C>T CCGTAGATCCTGG(C/T)CGAGTGGAAGCAG G*C KIL(A/V)EWK p.Ala1460Val 0.016 0.984 0.1705 NO 
62 32 g.161511061C>T c.32:9C>T CGTAGATCCTGGC(C/T)GAGTGGAAGCAGA GC* FDKIL(A)EWKQK - 0.016 0.984 0.1747 NO 
63 32 g.161511051C>T c.32:19C>T GGCCGAGTGGAAG(C/T)AGAAGTACGAGG *AG EWK(Q/STOP)KYE p.Gln1464Stop 0.005 0.995 0.1791 NO 
64 32 g.161511033C>T c.32:37C>T ACGAGGAGTCG(C/T)AGTCGGAGCTG *AG EES(Q/STOP)SEL p.Gln1470Stop 0.005 0.995 0.1791 NO 
65 32 g.161511029C>T c.32:41C>T CGAGGAGTCGCAGT(C/T)GGAGCTGGAGTC T*G ESQ(S/L)ELE p.Ser1471Leu 0.005 0.995 0.1791 NO 
66 32 g.161511017C>T c.32:53C>T TCGGAGCTGGAGT(C/T)CTCGCAGAAGGAG T*C ELE(S/F)SQK p.Ser1475Phe 0.005 0.995 0.1791 NO 
67 32 g.161510994C>T c.32:76C>T GGAGGCGCGCTCC(C/T)TCAGCACCGAGCT *TC ARS(L/F)STE p.Leu1483Phe 0.005 0.995 0.1791 NO 
68 32 g.161510989C>T c.32:81C>T CGCGCTCCCTCAG(C/T)ACCGAGCTCTTCA AG* EARSL(S)TELFK - 0.005 0.995 0.1791 NO 
69 32 g.161510986C>T c.32:84C>T GCTCCCTCAGCAC(C/T)GAGCTCTTCAAGC AC* ARSLS(T)ELFKL - 0.016 0.984 0.1747 NO 
70 32 g.161510950C>T c.32:120C>T CCTATGAGGAGTC(C/T)CTGGAGCACCTGG TC* NAYEE(S)LEHLET - 0.011 1.000 0.1748 NO 
71 32 g.161510943C>T c.32:127C>T GGAGTCCCTGGAG(C/T)ACCTGGAGACCTT *AC SLE(H/Y)LET p.His1500Tyr 0.005 0.995 0.1791 NO 
72 32 g.161510941C>T c.32:129C>T AGTCCCTGGAGCA(C/T)CTGGAGACCTTCA CA* EESLE(H)LETFK - 0.005 0.995 0.1791 NO 
73 32 g.161510933C>T c.32:137C>T GAGCACCTGGAGA(C/T)CTTCAAGCGGGAG A*C HLE(T/I)FKR p.Thr1503Ile 0.005 0.995 0.1791 NO 
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Table 4.1 continued 
Location Exon 
Anomaly 
Position; 
Chromosome 
Position 
Exon : 
Position 
Nucleotide Sequence 
Variant  
Codon 
Position 
Amino Acid  
Sequence 
Amino Acid 
Change* 
Variant 
Allele 
Frequency  
Reference 
Allele 
Frequency  
P 
Value   
(two 
tailed) 
HWB Normal 
Distribution 
(P < 0.05) 
74 32 g.161510929C>T c.32:141C>T ACCTGGAGACCTT(C/T)AAGCGGGAGAACA TT* EHLET(F)KRENK - 0.011 0.989 0.1791 NO 
75 32 g.161510911C>T c.32:159C>T GGGAGAACAAGAA(C/T)CTCCAGGGTGTGC AA* KRENK(N)LQEEI - 0.011 0.989 0.1791 NO 
76 32 g.161510908C>T c.32:162C>T AGAACAAGAACCT(C/T)CAGGGTGTGCTGG CT* RENKN(L)QEEIS - 0.005 0.995 0.1791 NO 
86 34 g.161509950A>G c.34:168A>G CCCTGGACGCGGA(A/G)ACACGCAGCCGCA GA* TSLDA(E)TRSRN - 0.581 0.409 0.02 YES 
87 34 g.161509947A>G c.34:171A>G TGGACGCGGAAAC(A/G)CGCAGCCGCAACG AC* SLDAE(T)RSRNE - 0.581 0.409 0.0203 YES 
89 35 g.161509404T>C c.35:153T>C CTCGGAAGCTGGC(T/C)GAGCAGGAGCTGA GC* RSRKL(A)EQELI - 0.220 0.780 0.0594 NO 
91 36 g.161509226C>T c.36:6C>T CTCCTCAGAACAC(C/T)AGCCTCATCAACC AC* LHSQN(T)SLINQ - 0.011 0.989 0.1791 NO 
92 36 g.161509185C>A c.36:47C>A GACGCAGACCTGT(C/A)CCAGCTTCAGACT T*C ADL(S/Y)QLQ p.Ser1741Thr 0.011 0.989 0.1791 NO 
93 36 g.161509180C>T c.36:52C>T AGACCTGTCCCAG(C/T)TTCAGACTGAAGT *TT LSQ(L/F)QTE p.Leu1743Phe 0.011 0.989 0.1748 NO 
94 36 g.161509177C>T c.36:55C>T CCTGTCCCAGCTT(C/T)AGACTGAAGTGGA *AG SQL(Q/STOP)TEV p.Gln1744Stop 0.011 0.989 0.1748 NO 
95 36 g.161509173C>T c.36:59C>T TCCCAGCTTCAGA(C/T)TGAAGTGGAGGAG A*T QLQ(T/I)EVE p.Thr1745Ile 0.011 0.989 0.1791 NO 
96 36 g.161509158C>T c.36:74C>T GAAGTGGAGGAGG(C/T)AGTGCAGGAGTG G*A VEE(A/V)VQE p.Val1750Ala 0.005 0.995 0.1791 NO 
97 36 g.161509153C>T c.36:79C>T GGAGGAGGCAGTG(C/T)AGGAGTGCAGGA *AG EAV(Q/STOP)ECR p.Gln1752Stop 0.005 0.995 0.1791 NO 
98 36 g.161509145C>T c.36:87C>T CAGTGCAGGAGTG(C/T)AGGAATGCCGAGG TG* EAVQE(C)RNAEE - 0.011 0.989 0.1791 NO 
99 36 g.161509136C>T c.36:96C>T AGTGCAGGAATGC(C/T)GAGGAGAAGGCCA GC* QECRN(A)EEKAK - 0.011 0.989 0.1748 NO 
100 36 g.161509133G>A c.36:99G>A GCAGGAATGCCGA(G/A)GAGAAGGCCAAG GA* ECRNA(E)EKAKK - 0.011 0.989 0.1791 NO 
101 36 g.161509116C>T c.36:116C>T AAGGCCAAGAAGG(C/T)CATCACGGACGTG G*C AKK(A/V)ITD p.Val1764Ala 0.016 0.984 0.1747 NO 
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Table 4.1 continued. 
Location Exon 
Anomaly Position; 
Chromosome 
Position 
Exon : 
Position 
Nucleotide Sequence 
Variant  
Codon 
Position 
Amino Acid  
Sequence 
Amino Acid 
Change* 
Variant Allele 
Frequency  
Reference 
Allele 
Frequency  
P Value   
(two 
tailed) 
HWB Normal 
Distribution (P 
< 0.05) 
102 36 g.161509106C>T c.36:126C>T AGGCCATCACGGA(C/T)GTGAGTCCCCTCA GA* KKAIT(D)AAMMA - 0.022 0.978 0.1748 NO 
108 37 g.161508984T>C c.37:3T>C CCCGCCCACAGGC(T/C)GCCATGATGGCGG GC* KAITD(A)AMMAE - 0.392 0.608 0.0208 YES 
109 38 g.161507732T>C c.38:48T>C AGGACCTGGTGGA(T/C)AAGCTGCAGCTGA GA* LQDLV(D)KLQLK - 0.677 0.763 0.0497 YES 
121 3' UTR g.161506608C>T c.40:19C>T GAATGAGGAGTAG(C/T)TGTGCCACATCTT N/A N/A - 0.005 0.995 0.1791 NO 
122 3' UTR g.161506680C>T c.40:27C>T AGTAGCTGTGCCA(C/T)ATCTTCTTGACCT N/A N/A - 0.011 0.989 0.1748 NO 
123 3' UTR g.161506664C>T c.40:43C>T CTTCTTGACCTGC(C/T)CAGTCCTGAGGGT N/A N/A - 0.005 0.995 0.1791 NO 
124 3' UTR g.161506648C>T c.40:59C>T GTCCTGAGGGTGC(C/T)AATGGAGTTCCAG N/A N/A - 0.005 0.995 0.1791 NO 
125 3' UTR g.161506581C>T c.40:126C>T TAAAGCAATTTTC(C/T)TTGAAGTGAGATC N/A N/A - 0.005 0.995 0.1791 NO 
Table 4.1: List of variants found in MYH7 genomic exon regions.  
Reference and variant allele frequency for each new variant location was used to calculate allelic distributions for the study population. Reference and variant allele 
distribution was tested for normal distribution as defined by HWE. Nonconformity of newly-identified allelic variants to normal HWE distribution was tested for statistical 
significance by two-tailed t-test, with a significance level of P < 0.05. Locations 40, 63, 64, 94, and 97 all resulted in a STOP codon substitution resulting in a truncated 
protein. Red data sets are variants resulting in a protein-coding change. *Deduced by CLC. 
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Nucleotide changes identified in this study were mapped to the gene-coding region with 
corresponding amino acid translation (Figure 4.4). Nucleotide changes that result in an amino acid 
change are catalogued in the variant Table (4.2). 
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Figure 4.4: MYH7 variants mapped to reference sequence. 
All variants mapped to the published reference sequence build EquCab2.0. MYH7 gene chromosome 
location = 1: 161,506,573–161,527,244. Ensembl accession number: ENSECAG00000019844. Long 
purple bars are coding regions; long green bars mark exons. The MYH7 has three published transcripts. 
Long red bars are indicative of 5 and 3 UTR, variants are marked with small red boxes. MicroRNA eca-
mir-208b is marked as a long blue box. This microRNA sequence was within the intronic region of the 
MYH7 gene between exons 30 and 31. No variants were found within the microRNA sequence. 
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Changes in amino acid and their corresponding protein domains are depicted in Figure 4.5. 
Deleterious amino acid changes were only seen in the variants with low allele frequency in this 
population. None of the amino acid-changing variants had normal Hardy-Weinberg allele frequency 
distribution, suggesting these variants were randomly occurring as opposed to being the normal 
genetic variation within a population. 
 
Figure 4.5: Approximate location of amino acid changes in protein domains of the MYH7 protein.  
Domain structures were found using publicly available information at Ensembl (http://asia.ensembl.org 2014).  
MYH7 is found predominantly in cardiomyocytes, and is involved in muscle contraction through 
cyclic interactions with actin filaments creating a contractile force by converting chemical energy in 
the form of ATP to mechanical force. Amino acid-changing variants have been found in both the 
myosin motor domain and the coiled myosin tail domain. Changes in these regions can cause 
fundamental changes to the function of the protein by altering initial folding and altering or 
inhibiting two heavy-chain and two light-chain proteins from forming a functional unit. 
Furthermore, changes in the myosin head domain such as those that occur at location 11 
(g.161523485G>A) can cause ineffective actin filament binding and thus inhibition of, or 
difficulties in, muscular contraction.  
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Whilst usually less severe and more common, changes in the amino acid sequence of the MYH7 
coiled tail region could alter binding domains for other proteins and inhibit MYH7 tail complexes 
from occurring normally (as could the majority of the changes found within this region of the 
MYH7 gene in this study). The insertion of premature stop codons (locations 40, 63, 64, 94, and 97; 
g.161511398C>T, g.161511051C>T, g.161511033C>T, g.161509177C>T and g.161509153C>T 
respectively), had by far the largest effect by causing premature truncation of the coiled tail region, 
thus altering the ability of this region to form complexes with other MYH7 tail regions and binding 
to proteins.  
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MYH7  
BUILD: EquCab2.0, GENE: MYH7, GENE TRANSCRIPT: ENSECA00000019844. 
CHROMOSOME AND GENE REGION: 1: 161,506,573–161,527,244, STRAND: MINUS. ALTERNATE SPLICE TRANSCRIPTS: ENSECAT00000023357, 
ENSECAT00000023389, ENSECAT000000023469. 
Location 
Anomaly Position; 
Chromosome Position 
Exon: Position Amino acid change SIFT amino acid predictions. Threshold for intolerance 0.05 Seq Rep* SIFT Score 
Sequences in SIFT 
Alignment 
11 g.161523485G>A c.10:95G>A p.Met331Ile Tolerated 1.00 0.16 49 
39 g.161511409C>T c.31:12C>T p.Ala1400Val Tolerated** 1.00 0.29 49 
40 g.161511398C>T c.31:23C>T p.Gln1404Stop Not tolerated -  - 
61 g.161511062C>T c.32:8C>T p.Ala1460Val Tolerated 1.00 0.07 49 
63 g.161511051C>T c.32:19C>T p.Gln1464Stop Not tolerated -  - 
64 g.161511033C>T c.32:37C>T p.Gln1470Stop Not tolerated -  - 
65 g.161511029C>T c.32:41C>T p.Ser1471Leu Tolerated 1.00 0.25 49 
66 g.161511017C>T c.32:53C>T p.Ser1475Phe Not tolerated, predicted to affect protein function** 1.00 0.01 49 
67 g.161510994C>T c.32:76C>T p.Leu1483Phe Not tolerated, predicted to affect protein function** 1.00 0.05 49 
71 g.161510943C>T c.32:127C>T p.His1500Tyr Tolerated 1.00 1.00 49 
73 g.161510933C>T c.32:137C>T p.Thr1503Ile Not tolerated, predicted to affect protein function. 1.00 0.02 49 
92 g.161509185C>A c.36:47C>A p.Ser1741Thr Tolerated 1.00 0.05 49 
93 g.161509180C>T c.36:52C>T p.Leu1743Phe Not tolerated, predicted to affect protein function** 1.00 0.02 49 
94 g.161509177C>T c.36:55C>T p.Gln1744Stop Not tolerated -  - 
 
 
 54 
Table 4.2 continued. 
Location Anomaly Position; 
Chromosome Position 
Exon: Position Amino acid change SIFT amino acid predictions. Threshold for intolerance 0.05 Seq Rep* SIFT Score Sequences in SIFT 
Alignment 
95 g.161509173C>T c.36:59C>T p.Thr1745Ile Tolerated 1.00 0.09 49 
96 g.161509158C>T c.36:74C>T p.Val1750Ala Tolerated 1.00 0.95 49 
97 g.161509153C>T c.36:79C>T p.Gln1752Stop Not tolerated --  - 
101 g.161509116C>T c.36:116C>T p.Ala1764Val Not tolerated, predicted to affect protein function** 1.00 0.00 49 
 
Table 4.2 SIFT Predicted amino acid-changing variants in the MYH7 gene.  
Locations 40, 63, 64, 94, and 97 all result in a STOP codon substitution resulting in a truncated protein.  
* Fraction of sequences that contain one of the basic amino acids. A low fraction indicates the position is either severely gapped or unalignable and has little information. 
** SIFT-predicted tolerance or intolerance, variant does not appear within SIFT alignments. 
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CHAPTER 5: ANALYSIS OF THE CASQ2 GENE 
5.1 Introduction 
The larger than average heart identified in some Thoroughbreds has also been associated with slight 
differences in the bioelectric currents of the heart as seen in electrocardiograms (ECG) performed 
on these individuals (Stewart 1981). A larger than average Thoroughbred heart has also been 
associated with a greater peak at the QRS complex of each electrical impulse wave of the cardiac 
cycle (Blakely & Blakely 1995). The QRS complex correlates to the depolarisation of both right 
and left ventricles allowing the contraction and emptying of the heart. The relative height of the 
QRS complex peak in relation to other electrical events within each heartbeat has been directly 
correlated to the proportionate size of the ventricles in relation to other chambers and anatomical 
features of the heart (Young, Rogers & Wood 2005). Whilst this peak has been used to infer the size 
of the heart in Thoroughbreds and thus predict athletic performance, it can also be indicative of 
other underlying factors involved with the successful functioning and electrical conductance of a 
much larger heart than average.  
For normal electrical conductance and contraction of the heart to occur, large stores of calcium must 
be available to cardiomyocytes. Calsequestrin 2 (CASQ2) is a calcium storage and transporter 
protein found in the sarcoplasmic reticulum of cardiomyocytes. Cardiac muscular contraction and 
relaxation occurs when pacemaker cells (SA node cells) send a spontaneous electrical signal to the 
AV node after which it is dispersed to the ventricles. This induces the opening of voltage-gated ion 
channels, allowing positively-charged calcium ions to enter the cell causing depolarisation. 
Depolarisation causes the opening of voltage-gated calcium channels and a substantial release of 
calcium from the sarcoplasmic reticulum, allowing muscle contraction and emptying of the 
ventricles. This process corresponds with the QRS interval on an ECG, and is followed by a short 
delay before the re-sequestering of calcium back to the sarcoplasmic reticulum and potassium 
channel-mediated repolarisation of the cells back to resting state. CASQ2 performs this role in 
conjunction with the RYR2 calcium ion channel to control the flow of calcium ions in and out of the 
sarcoplasmic reticulum during contraction. In this way, CASQ2 performs a critical role to regulate 
the electrical conductance of the heart and calcium-controlled muscle contraction 
(Kalyanasundaram et al. 2010; Kornyeyev et al. 2011; Olojo et al. 2011). In humans, mutations in 
the CASQ2 gene have been associated with ventricular arrhythmias and other heart regulatory and 
function disorders (including death) despite normal cardiac anatomy (Kalyanasundaram et al. 
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2010). Mutations to CASQ2 coding regions can reduce the protein’s calcium-binding affinity or 
cause complete disruption of the protein altogether.  
As CASQ2 is also a regulator of the RYR2 channel, loss of function may also disrupt the channel’s 
function, resulting in inappropriate calcium release from the sarcoplasmic reticulum. It is this 
calcium regulation disruption that can cause abnormal heart rhythm and muscular contraction 
(Knollmann et al. 2006). Recent studies investigating the relationship between CASQ2 and its local 
environment in mice suggest that whilst the sarcoplasmic reticulum can initially make up for the 
loss of CASQ2 function by increasing its size and thus calcium-carrying ability, it cannot mediate 
the loss of CASQ2-mediated RYR2 channel regulation. It was also found that under stressful 
conditions (such as exercise or adrenergic stimulation) CASQ2 gene knockout mice were unable to 
maintain normal cardiac rhythm (Knollmann et al. 2006).  
In the heart, functional CASQ2 is important to prevent premature calcium release, and to maintain 
heart rhythm and contraction during stressful situations. In the Thoroughbred racehorse, CASQ2 
function is particularly important due to the high level of stress associated with competitive racing. 
The identification of a larger QRS complex in individuals presenting with a larger ratio of heart 
weight to body weight and above-average athletic performance suggests that electrical regulation 
and calcium homeostasis could play a role in racing success. It for this reason that CASQ2 was 
selected for further study to potentially identify gene variants that may account for the unusual ECG 
observations recorded in some individuals. The CASQ2 gene has one transcript in the equine; it 
features 12 exons (all coding) with a transcription length of 1502bp, which is translated into a 
protein length of 456aa. 
5.2 Results and discussion 
In total 18 variant locations were found for the CASQ2 gene within the study population. Of these, 
all were of a novel nature and had not been identified previously. It can be seen that eight of the 18 
variant locations were present in 10% or greater of the sample population. Of these eight, three were 
in protein-coding regions, and presented in approximately 12% of the sample population. Figure 5.1 
shows the distribution of variants over the entire gene region. It can be seen that of all the variants 
one, g.53192420A>G (c.11:-7A>G), was present in more than 50% of the population (variant allele 
frequency = 0.51, reference allele frequency = 0.50). This variant was located in an intronic region 
not involved in protein production. Five variants were located in protein-coding regions, with the 
remainder distributed over non-coding intron regions. The majority of variants were located along 
the 3 end of the gene within the intronic regions between exons 8 and 11. CASQ2 has not been 
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fully structurally annotated in the equine, however sequence homology between humans and horses 
allows some inferred comparisons and predictions about how this protein will function and interact 
with calcium and other proteins in the horse. CASQ2 codes for a relatively simple protein, which in 
the equine is expected to consist of two thioredoxin-like domains forming random, coiled structures 
(Figure 5.2). This structure is key for binding calcium, which on doing so causes structural changes 
in these coiled regions. In the absence of any distinct structural pockets for particle binding, calcium 
binds to the CASQ2 protein via charged surface domains.  
 
 
Figure 5.1: Graphical overview of variant distribution over total CASQ2 gene length.  
Green boxes denote gene exons. Red boxes stacked above green boxes denote 3 and 5 UTR. Each bar on 
the graph represents the number of individuals different from the published equine reference sequence  
(n=93).   
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Figure 5.2: Expected protein domains of CASQ2.  
Domain structures were found using publicly-available information at Ensembl (http://asia.ensembl.org 
2014).  
 
Of the 18 variants identified, five were found in protein-coding regions. Each sample in the study 
population was genotyped at each location and allele frequencies were calculated. This result was 
then used to identify any population distribution patterns, which would be an indicator of whether 
the variant at that location was the product of normal genetic variation or a less common random 
mutation event. Figure 5.3 shows the population breakdown of genotypes for each variant location 
in a protein-coding region. Table 5.1 shows specific variant information as well as confirmation of 
allelic distribution patterns where present. The unknown dominant or recessive nature of each 
variant has been taken into consideration with all frequency distribution calculations, using the 
Hardy-Weinberg equation. P values were used as a measure of conformity to Hardy-Weinberg 
distributions with a significance of P < 0.05.
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Figure 5.3: Number of individuals with variants found in the protein-coding region of CASQ2 gene.  
Each variant found in the study has been given a location number for ease of analysis. At each location, 
samples were genotyped as either heterozygous, homozygous reference or homozygous variant. Absolute 
numbers of individual’s genotype is depicted on the graph (n = 93). The dominant or recessive nature of 
variants were unknown so traditional significance level statistical tests were invalid for this data set. 
Hardy-Weinberg equilibrium distribution analysis of variant distribution was performed in following 
tables. Variants found in the gene-coding region were SNP variants affecting low numbers of the 
population. 
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CASQ2 (F621R3)  
BUILD: EquCab2.0, GENE: F621R3-HORSE (CASQ2). 
GENE TRANSCRIPT: ENSECAG00000021854, CHROMOSOME AND GENE REGION: 5:53131872…53192934, STRAND: FORWARD.  
Location Exon 
Anomaly Position; 
Chromosome 
Position 
Exon : Position Nucleotide Sequence 
Variant  
Codon 
Position 
Amino Acid  
Sequence 
Amino Acid 
Change* 
Variant Allele 
Frequency  
Reference 
Allele 
Frequency  
P Value   
(two 
tailed) 
HWB Normal 
Distribution (P < 
0.05) 
2 3 g.53156085A>G c.3:27A>G GGAAGCCTGTAT(A/G)TTCTCAAGGGTG *TT SLY(I/V)LKG p.Ile116Val 0.038 0.962 0.1574 NO 
3 N/A g.53171907C>A c.7:-113C>A GGGTTTGTAGAG(C/A)TCTTCATGCTCT N/A N/A N/A 0.081 0.919   
4 N/A g.53171916C>T c.7:-104C>T AGCTCTTCATG(C/T)TCTTGCAAATGT N/A N/A N/A 0.081 0.919   
11 8 g.53178694G>T c.8:42G>T GGCCTTTGCAGA(G/T)AGGAGTGACCCA GA* AFA(E/D)RSD p.Glu275Asp 0.005 0.995 0.1791 NO 
12 N/A g.53178726G>T c.8:+19G>T AAACCCTGAATCT(G/T)TTCTTTTTCACC N/A N/A N/A 0.005 0.995   
13 N/A g.53178777C>T c.8:+70C>T TTGTCGGCCCCCA(C/T)CCTCCCTCTTCC N/A N/A N/A 0.005 0.995   
14 N/A g.53178781C>T c.8:+74C>T TCGGCCCCCACCCT(C/T)CCTCTTCCCTAA N/A N/A N/A 0.005 0.995   
15 N/A g.53191497A>G c.10:+63A>G TTGCTGCCATGCA(A/G)CCCACACTGTGA N/A N/A N/A 0.113 0.887   
16 N/A g.53191505T>C c.10:+71T>C ATGCAACCCACAC(T/C)GTGAGATTGAGG N/A N/A N/A 0.113 0.887   
17 N/A g.53191506A>G c.10:+72A>G ATGCAACCCACACT(G/A)TGAGATTGAGGC N/A N/A N/A 0.032 0.968   
18 N/A g.53191544G>C c.10:+110G>C GGGAAATGAGCAG(G/C)ACCCTTCATCCT N/A N/A N/A 0.038 0.962   
19 N/A g.53191560C>T c.10:+126C>T CCTTCATCCTGCC(C/T)GAGCTCAGGAAA N/A N/A N/A 0.032 0.968   
20 N/A g.53191581T>A c.10:+147T>A GAAACATGCCAG(T/A)GTGGCCCAATCC N/A N/A N/A 0.113 0.887   
21 N/A g.53192420A>G c.11:-7A>G ATTCTGTCCCTC(G/A)TTGCAGGCTGAC N/A N/A N/A 0.505 0.495   
22 11 g.53192513T>A c.11:87T>A AGGACGTGCTTTC(T/A)GGGAAGATAAAC TC* DVL(S)GKI - 0.124 0.876 0.0967 NO 
23 11 g.53192574G>A c.11:148G>A GATGATGATGAC(G/A)ATGATGATGATG *AT DDD(D/N)DDD p.Asp388Asn 0.124 0.876 0.0967 NO 
24 12 g.53192783C>T c.12.144C>T CCACTCCCTTCT(C/T)ATCAGGAGATGT CT* HSL(L)IRR - 0.124 0.876 0.0967 NO 
Table 5.1: CASQ2 List of variants found in genomic exon regions.  
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Reference and variant allele frequency for each new variant location was used to calculate allelic distributions for the study population. Reference and variant allele 
distribution was tested for normal distribution as defined by HWE. Nonconformity of newly-identified allelic variants to normal HWE distribution was tested for statistical 
significance by two-tailed t-test, with a significance level of P < 0.05. Red data sets highlight variants in protein-coding regions. *Deduced by CLC.
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Nucleotide changes identified in the study were mapped to the gene-coding region with 
corresponding amino acid translation (Figure 5.4). Nucleotide changes that resulted in an amino 
acid change and their predicted tolerance in the translated protein are catalogued in the variant 
Table 5.2. 
 
Figure 5.4: CASQ2 variants mapped to the published reference sequence. 
CASQ2 mapped to build EquCab2.0 reference sequence, CASQ2 gene chromosome location = 5: 
531,318,72–531,929,34. Ensembl gene accession number: ENSECAG00000021854. Long purple bars are 
coding regions; long green bars mark exons. The CASQ2 has one published transcript. Long red bars are 
indicative of 5 and 3 UTR variants are marked with small red boxes. 
Changes in amino acid and their corresponding protein domains are depicted in Figure 5.5. 
Deleterious amino acid changes were only seen in the variants with low allele frequency within this 
population. None of the amino acid-changing variants had a normal Hardy-Weinberg allele 
frequency distribution, suggesting these variants were randomly-occurring as opposed to normal 
genetic variation within a population. 
Of all the variants within protein-coding regions, location 23 would have the most significant 
change. Location 23 (c.11:148G>A, p.Asp388Asn) was characterised by an amino acid change 
from aspartic acid (Asp) to asparagine (Asn) and is predicted not-tolerated by a SIFT score of 0.00. 
Asp is an acidic negatively-charged amino acid. When changed to Asn, a hydrophilic non-charged 
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amino acid, calcium-binding affinity and overall polarity of the protein at that location may be 
affected (Fahie et al. 2002). This may also have downstream effects on the intracellular pH and 
overall calcium regulation. Locations 2 (c.3:27A>G, p.Ile116Val) and 11 (c.8:42G>T, 
p.Glu275Asp), also caused amino acid changes in their respective locations, however both changes 
resulted in substitution with amino acids of similar properties (polarity and binding affinity) and 
were predicted as tolerated with a SIFT score of 1.00, and 0.19 respectively.  
 
Figure 5.5: Approximate locations of variants on CASQ2 protein domain.  
Location 2, 11, and 23 cause amino acid changes at their locations. Domain structures were found using 
publicly-available information at Ensembl (http://asia.ensembl.org 2014).  
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CASQ2 (F621R3)  
BUILD: EquCab2.0, GENE: F621R3-HORSE (CASQ2). 
GENE TRANSCRIPT: ENSECAG00000021854, CHROMOSOME AND GENE REGION: 5:53131872…53192934, STRAND: FORWARD.  
Location 
Anomaly Position; 
Chromosome Position 
Exon: Position Amino Acid Change 
SIFT amino acid predictions. Threshold for intolerance 
0.05 
Seq Rep*  SIFT Score 
Sequences in 
SIFT Alignment 
2 g.53156085A>G c.3:27A>G p.Ile116Val Tolerated 0.98 1.00 53 
11 g.53178694G>T c.8:42G>T p.Glu275Asp Tolerated 0.93 0.19 50 
22 g.53192513T>A c.11:87T>A - - - - - 
23 g.53192574G>A c.11:148G>A p.Asp388Asn Not tolerated, predicted to affect protein function** 0.02 0.0 1 
24 g.53192783C>T c.12.144C>T - - - - - 
Table 5.2: SIFT predicted amino acid-changing variants in the gene CASQ2.  
* Fraction of sequences that contain one of the basic amino acids. A low fraction indicates the position is either severely gapped or unalignable and has little information.  
** SIFT predicted tolerance or intolerance, variant does not appear within SIFT alignments.  
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CHAPTER 6: ANALYSIS OF THE AKT1, PTEN, AND PI3K GENES 
6.1 Introduction 
The Thoroughbred phenotype of interest is characterised by a larger than average ratio of muscle 
mass to body mass. Individuals with this trait also display differences with electrical regulation of 
the heart as seen on ECG reads, but otherwise have completely normal heart regulation and 
function. The AKT1/ PTEN/PI3K pathway is an important regulatory pathway for many biological 
processes. The AKT1/PTEN/PI3K pathway has been found to play a key role in determining cell 
and heart size in laboratory model species through the regulation of PI3K, PTEN, and AKT1 during 
foetal development. All members of the pathway have been shown to play important roles in 
determining size development of the heart.  
AKT1 is a protein kinase, and is a intracellular signalling molecule, which also plays a significant 
role in many cellular developmental and regulatory processes, including cell survival, proliferation, 
growth, and metabolism (Yang et al. 2003; Vandoorne et al. 2013). Cardiac-specific expression of 
activated AKT1 in transgenic mice has been shown to induce an up-regulation of many genes 
including insulin-like growth factor in the heart, whilst simultaneously down-regulating other genes 
(for example: peroxisome proliferator-activated receptor and coactivator–1) resulting in reduced 
cardiomyocyte death and inducement of cardiac hypertrophy. Through regulation of cardiac specific 
genes, AKT1 has been shown to have cardio-protective properties, albeit indirectly (Cook et al. 
2002). AKT1 is also a critical determinant of cell size in many species from Drosophila to 
mammals, and has the ability to regulate many different cardiac specific genes and pathways 
(Morissette et al. 2006). Additionally, AKT1 is also involved indirectly in calcium homeostasis and 
physiological cardiac hypertrophy via interactions with the RYR receptor and CASQ2 (Yamaguchi 
et al. 2011) (see Chapter 5).  
There are many members in the AKT family, and AKT1 plays an essential role in angiogenesis 
through the PI3K–AKT1 signalling pathway (Vandoorne et al. 2013). Whilst very important for 
many tissues during foetal (and supportive structures) development, previous research has also 
identified AKT1 as critical for heart and cardiovascular development (Chang et al. 2010). Chang et 
al. (2010) found that AKT1 is the main isoform of AKT in the heart and that reduced AKT1 caused 
cardiovascular defects, resulting in progressive contractile failure and post-natal infant mortality. 
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Other aspects of the pathway also influence heart size. Studies of transgenic mice by Shioi et al 
(2000) have shown that mice with the constitutively active transgenic version of the PI3K gene 
developed larger hearts, whilst mice with the inactive dominant negative transgenic version of the 
PI3K gene (resulting in individuals with inactive PI3K proteins) developed smaller hearts than age-
matched controls. This organ size difference was also found to be directly related to myocyte size, 
and was not associated with a disease state. Shioi et al. (2000) concluded the PI3K pathway is 
necessary to promote organ growth in mammals. 
PI3K is found in many tissues (for example blood vessels and heart tissue) and mediates many 
cellular responses in both normal and disease state physiology. It acts an intermediate message relay 
protein that, once activated, can recruit and activate other messenger or effector proteins such as 
AKT1 (Oudit et al. 2004). PI3K has been shown to be involved in many different molecular 
pathways in the heart. For example, inactivation of PTEN (phosphatase and tensin homologue) – a 
PI3K antagonist (PI3K down-regulator) – was found to cause an increase in heart size and cardiac 
hypertrophy due to increased PI3K activity. Deletion of PI3K itself has been shown to increase 
contractility and contractile force in the heart, particularly in response to or in conjunction with 
other stimuli (Alloatti et al. 2004). PI3K’s ability to indirectly contribute to cardiac phenotypes 
through involvement in many different molecular pathways is the key reason it has been selected as 
a candidate gene in this study.  
PTEN is a multifunctional phosphatase whose major substrate is PI3K within the PI3K/PTEN/AKT1 
pathway. PTEN activates numerous downstream targets, including the PI3K/AKT1 pathway acting 
to dephosphorylate PI3K and negatively regulate PI3K and PTEN expression. This process is 
particularly important in embryonic cardiovascular development and post-natal neovascularisation, 
as expression levels of PI3K are known to influence heart size (Shioi et al. 2000; Shioi et al. 2002). 
PTEN is important for normal cardiovascular homeostasis, and it has been shown that PTEN is 
needed for normal function of the PI3K–PKB/AKT–PTEN regulatory pathway in the proliferation of 
endothelial cells required for cardiovascular development (Oudit & Penninger 2009).  
PTEN negatively regulates PI3K and AKT1 by dephosphorylation. Loss of PTEN in cardiac tissue 
results in uncontrolled up-regulation of AKT1 and PI3K, causing an increase in cardiomyocytes and 
heart size during development and reduced myocardial contractility and relaxation (Oudit & 
Penninger 2009). 
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In this study, genes from the PI3K/PTEN/AKT1 pathway have been selected for further research 
due to their regulatory role in foetal cardiovascular development and influence on organ size and 
function in the adult. In equines, all three genes have one known transcript: 
 PTEN gene has one transcript in the equine – it features nine exons (five coding) with a 
transcription length of 13,434 bp, which is translated into a protein length of 270 aa. 
 PI3K gene has one transcript in the equine – it features 15 exons (all coding) with a 
transcription length of 12,219 bp, which is translated into a protein length of 724 aa. 
 AKT1 gene has one transcript in the equine; it features 12 exons (all coding) with a 
transcription length of 1445 bp, which is translated into a protein length of 479 aa. 
6.2 Results and discussion – AKT1 
A total of 29 variant locations were found for the gene AKT1 within the study population. Of these, 
all variants were of a novel nature and had not been identified previously. Figure 6.2.1 shows 
graphically the distribution of variants over the entire gene region. It can be seen that the variants 
were evenly spread over the gene region, with the majority of variants located in intronic regions. 
Variants found in the AKT1 gene region on average affect a greater number of individuals in the 
sample population than variants found in other genes. AKT1 has three protein domains (Figure 
6.2.2) that can interact with many other regulatory factors, including PI3K and PTEN.  
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Figure 6.2.1: AKT1 Graphical overview of variant distribution over total gene length.  
Green boxes denote gene exons; intronic regions denoted by black connecting lines. Red boxes denote 3 and 
5 UTR. Each bar on the graph represents the number of individuals different from the published equine 
reference sequence (n = 93).  
 
 
Figure 6.2.2: AKT1 expected protein domains.  
Structural domains were established using publicly-available information from Ensembl 
(http://asia.ensembl.org 2014). 
Of the variants identified, three were found within the protein-coding regions (g.46114436C>T, 
g.46111888C>T, and g.46111442C>T) and one in the 5 UTR (g.46133169–46133167delCGC) 
(Figure 6.2.3). Each sample in the study population was genotyped for each location and allele 
frequencies were calculated. This result was then used to identify any population distribution 
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patterns, which would be an indicator of whether the variant at that location was the product of 
normal genetic variation or a less common random mutation event. Figure 6.2.3 shows the 
population breakdown of genotypes for each variant location in the protein-coding region and 5 
UTR. Table 6.2.1 shows specific variant information as well as confirmation of allelic distribution 
patterns where present. The unknown dominant or recessive nature of each variant has been taken 
into consideration with all frequency distribution calculations, using the Hardy-Weinberg equation. 
P values were used as a measure of conformity to Hardy-Weinberg distributions with a significance 
of 0.05. 
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\ 
Figure 6.2.3: Number of individuals with variants found in the protein-coding region of AKT1 gene.  
Each variant found in the study has been given a location number for ease of analysis. At each variant 
location, samples were identified as heterozygous, homozygous reference or homozygous variant. Absolute 
numbers of individuals’ genotype is graphed (n = 93). Dominant or recessive nature of variants is unknown 
so traditional significance level statistical tests are invalid for this data set. Hardy-Weinberg equilibrium 
distribution analysis of variant distribution was performed in following tables. Location 3 is a 3 bp deletion 
within the 5 UTR of the AKT1 gene; the other locations are SNP events. Location 9 showed HWE 
distribution of allele frequency for this population.  
Of the variants found in 5 UTR or protein-coding regions, location 9 (g.46114436C>T) was the 
only variant displaying a normal HWE of allelic distribution. This variant was an SNP, changing 
the amino acid codon at the nucleotide level, but not translating to an amino acid substitution event. 
The other two variants found in protein-coding regions similarly caused nucleotide substitutions 
that did not produce an amino acid change. 
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AKT1  
BUILD: EquCab2.0, GENE: AKT1, GENE TRANSCRIPT: ENSECAT00000008264.  
CHROMOSOME AND GENE REGION: 24:461,097,51-461,330,97, STRAND: MINUS. 
Location Exon 
Anomaly Position; 
Chromosome 
Position 
Exon: Position Nucleotide Sequence 
Variant 
Codon 
Position 
Amino Acid 
Sequence 
Amino Acid 
Change 
Variant 
Allele 
Frequency 
Reference 
Allele 
Frequency 
P Value 
(two 
tailed) 
HWB Normal 
Distribution 
(P < 0.05) 
1 
BEFORE 
5' UTR 
g.46133251G>A c.1:-154G>A GGTGTGACG(G/A)GCCTCCTGG N/A N/A N/A 0.010 0.990   
2 
BEFORE 
5' UTR 
g.46133235G>A c.1:-138G>A TGGGCTCCT(G/A)TGAGTGGCG N/A N/A N/A 0.010 0.990   
3 1/ 5' UTR 
g.46133169-
46133167delCGC 
c.1:-72-69delCGC TGTGGGCGC(CGC/---)TGGGCTTGG 5' UTR N/A N/A 0.10 0.90 0.1234 NO 
4 N/A g.46133025G>A c.1:+27G>A GGGGCTGGGCCTG(G/A)GGCCAGGGGCCTG N/A N/A N/A 0.05 0.99   
5 N/A g.46133003G>A c.1:+49G>A GCCTGAGGCAGGG(G/A)GCCCAGAGCCGGC N/A N/A N/A 0.05 0.99   
6 N/A g.46132993C>T c.1:+59C>T GGGGGCCCAGAGC(C/T)GGCCTGTGTGCTG N/A N/A N/A 0.52 0.48   
7 N/A g.46118897G>T c.2:-8G>T TCACTGCCCTCGT(G/T)TCCTCAGGAGAGT N/A N/A N/A 0.11 0.89   
8 N/A g.46118740C>T c.2:+21C>T TGCCGCGGCCGCC(C/T)GGCCTGGGAACTG N/A N/A N/A 0.40 0.60   
9 EX5 g.46114436C>T c.5:9C>T CTCAGACCATGAA(C/T)GAGTTTGAGTACC AA* VTM(N)EFE - 0.26 0.74 0.0416 YES 
10 N/A g.46114248T>C c.6:-4T>C TGGGACCTGTCTT(T/C)CAGGACGAGGTGG N/A N/A N/A 0.50 0.50   
11 N/A g.46114122C>T c.6:+57C>T TGGGTGGGTGGCA(C/T)GGGAGTGGGGCAC N/A N/A N/A 0.03 0.97   
12 N/A g.46112857C>T c.7:-82C>T CCCAGTGACCATC(C/T)CTCCAGCAGGGCG N/A N/A N/A 0.31 0.69   
13 N/A g.46112843C>T c.7:-68C>T CTCCAGCAGGGCG(C/T)GTGGGGCAGCCCG N/A N/A N/A 0.13 0.87   
14 N/A g.46112548A>G c.8:-49A>G GGAGGTGGCTGGG(A/G)TGGGGAGGGCACCT N/A N/A N/A 0.79 0.21   
15 N/A g.46112547T>C c.8:-48T>C GGAGGTGGCTGGGA(T/C)GGGGAGGGCACCT N/A N/A N/A 0.80 0.20   
16 N/A g.46111953C>T c.10:-48C>T AGTTCCCCCATGC(C/T)CCCTGTGTCCCGG N/A N/A N/A 0.32 0.68   
17 N/A g.46111943C>T c.10:-38C>T CCCCCTGTGTC(C/T)CGGGCACCCTC N/A N/A N/A 0.01 0.99   
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Table 6.2.1 Continued 
Location Exon 
Anomaly Position; 
Chromosome 
Position 
Exon: Position Nucleotide Sequence 
Variant 
Codon 
Position 
Amino Acid 
Sequence 
Amino 
Acid 
Change 
Variant Allele 
Frequency 
Reference 
Allele 
Frequency 
P Value 
(two 
tailed) 
HWB Normal 
Distribution (P 
< 0.05) 
18 N/A g.46111938C>A c.10:-33C>A TGTCCCGGG(C/A)ACCCTCTGAC N/A N/A N/A 0.18 0.82   
19 N/A g.46111914G>A c.10:-9G>A GTGCCCCTGC(G/A)TCCCCCAGGT N/A N/A N/A 0.20 0.80   
20 10 g.46111888C>T c.10:18C>T GGAGGACAACGA(C/T)TACGGCCGGGCG GA* EDN(D)YGR - 0.23 0.77 0.0534 NO 
21 N/A g.46111678C>T c.10:+13C>T GTGCGCCCCCTG(C/T)CCGGGCCCTGGG N/A N/A N/A 0.01 0.99   
22 N/A g.46111607C>T C.11:-108C>T CTGCAGTGTC(C/T)CCACGGCAC N/A N/A N/A 0.01 0.99   
23 N/A g.46111589C>T c.11:-90C>T ACTGGGCCCC(C/T)ACCCCCCGGGA N/A N/A N/A 0.01 0.99   
24 N/A g.46111589A>G c.11:-89A>G ACTGGGCCCCC(A/G)CCCCCCGGGA N/A N/A N/A 0.08 0.92   
25 11 g.46111442C>T c.11:58C>T TTCTTTGCCAG(C/T)ATCGTGTGGCAG AG* FFA(S)IVW - 0.01 0.99 0.1791 NO 
26 N/A g.46111286C>T c.11:+126C>T CTCGTTCCTCC(C/T)AGGAGGAGCCAC N/A N/A N/A 0.01 0.99   
27 N/A g.46111244C>T c.11:+168C>T GCACCTCCGCCC(T/C)CGTCAGGTTTGA N/A N/A N/A 0.01 0.99   
28 N/A g.46110358G>A c.12:-133G>A GCATCCGTACC(G/A)CCTGGGCACAG N/A N/A N/A 0.17 0.83   
29 
AFTER 3’ 
UTR 
g.46109681C>T c.13:-70C>T TCGATGGATCG(C/T)GAGGACGTCTC N/A N/A N/A 0.19 0.66   
Table 6.2.1: List of variants found in genomic exon regions of AKT1.  
Reference and variant allele frequency for each new variant location was used to calculate allelic distributions for the study population. Reference and variant allele 
distribution was tested for normal distribution as defined by HWE. Nonconformity of newly-identified allelic variants to normal HWE distribution was tested for statistical 
significance by two-tailed t-test, with a significance level of P < 0.05. Variants in 5 UTR and protein-coding regions are highlighted in red. All changes are synonymous. 
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Nucleotide changes identified in the study are mapped to the gene-coding region with 
corresponding amino acid translation (Figure 6.2.4). Nucleotide changes in protein-coding regions 
have been catalogued and highlighted in the variant Table 6.2.1. 
 
Figure 6.2.4: AKT1 variants mapped to the published reference sequence. 
AKT1 mapped to build EquCab2.0. AKT1 gene chromosome location = 24:461,097,51–461,330,97. 
Ensembl gene accession number: ENSECAG00000008264. Long purple bars are coding regions; long 
green bars mark exons. Long red bars are indicative of 5 and 3 UTR; variants are marked with small red 
boxes.  
No deleterious amino acid changes (as determined by CLC, Ch2, 2.8 Sequencing Variation 
Identification and Chromatogram Analysis Method, P. 34) were found in the AKT1 gene during this 
study. Only one of the variants found (g.46114436C>T) displayed a normal allelic distribution 
(expected of a large population with low breeding constraints) with an allelic distribution of 0.26 for 
the newly-identified variant vs. 0.74 for the reference sequence. The other variants, whilst not 
having standard allele distributions, did see a greater number of individuals carrying the non-
reference variant (Figure 6.2.1). The variants in coding regions are mapped to approximate protein 
locations in Figure 6.2.3.  
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Variants g.46114436C>T, g.46111888C>T and g.46111442C>T are located in protein regions were 
amino acid substitutions are generally well tolerated. Whilst the current variants were synonymous, 
an A or G codon change in these positions would cause a non-synonymous amino acid change in 
the resulting protein (for example: g.46114436A>G = Lys, g.46111888A>G = Glu and 
g.46111442A>G = Arg). Amino acid substitution predictions via SIFT analysis showed SIFT scores 
of 0.27, 0.35, and 0.30 respectively, suggesting these changes, should they occur, would not affect 
protein production significantly, but may have some structural or folding change due to the 
difference in amino acid polarity.  
Variant g.46133169–46133167delCGC, in the 5 UTR of the AKT1 gene may cause unknown 
affects in translation and regulation, which could play a significant inhibitory role to the function 
and abundance of the overall protein, potentially also affecting the many processes to which AKT1 
both directly and indirectly contributes (Manning & Cantley 2007). Outside influences on the AKT1 
gene have been extensively documented in the literature, however 5 UTR variations and mutations 
within the AKT1 gene itself (and their immediate effect on protein production and function) has yet 
to be comprehensively investigated in the horse, and should be an area of future research (Dummler 
& Hemmings 2007). 
 
Figure 6.2.5: Approximate location of variants on AKT1 protein domain 
Structural domains were established using publicly-available information from Ensembl 
(http://asia.ensembl.org 2014). 
Whilst no protein changing variants were found in the equine AKT1 gene, the 3bp 5 UTR deletion 
found at location 3 (g.46133169-46133167delCGC) could have unknown effects in translation or 
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regulation of the gene as well as expression levels of the translated protein, and as such may have 
significant downstream consequences. The AKT gene family is involved in many cell-signalling 
processes. AKT acts as a direct and indirect signalling molecule and is its self also regulated and 
acted upon by other signalling molecules. The AKT family of signalling molecules is involved in 
protein synthesis, cell proliferation, survival and apoptosis (problems with this process often result 
in unregulated cell proliferation and tumour formation), cellular glucose metabolism, nuclear 
protein organisation, synaptic signalling, neuroprotection and degradation and cardiovascular 
homeostasis.  
A significant binding and regulatory site for members of the AKT family is the 5 and 3 UTR. 
Alterations in this region may cause disturbances in many of the cellular processes they are 
involved in, as well as on the direct translation of the AKT protein itself. AKT1 as part of the 
PI3K/PTEN/ AKT1 pathway is important in cardiovascular homeostasis including heart size and 
contraction regulation. Previous studies have shown that deletions or other changes to the 5 or 3 
UTR can cause loss or reduction of function of AKT1 leading to disturbances in the 
PI3K/PTEN/AKT1 pathway, which can result in irregular cardiac development as well as increased 
or decreased heart size.  
6.3 Results and discussion – PTEN 
In total, 14 variant locations were found for the gene PTEN in the study population. Of these, all 
variants were of a novel nature and had not been identified previously. Figure 6.3.1 shows 
graphically the distribution of variants over the entire gene region. Variants identified in the PTEN 
gene are distributed across both 5 and 3 UTRs and intronic regions. No variants were found in 
protein-coding regions. Variants found in the PTEN gene region include two insertions (g.-
40577268^-40577267insA and g.-40577220^-40577219insG) and one deletion in the 5 UTR (g.-
40577238delA) as well as two SNP locations, found within the 3 UTR (g.-40517053A>T and g.-
40514341G>A). Of the 14 variants identified, five locations had a greater allelic frequency for the 
non-reference allele than that of the published reference sequence allele, three of these were in the 
5 UTR (g.-40577268^-40577267insA, g.-40577238delA and g.-40577220^-40577219insG) and 
their allelic frequencies were 1.00, 0.99 and 1.00 respectively. Furthermore g.-40577268^-
40577267insA and g.-40577220^-40577219insG saw no individuals with the reference sequence 
(variant allelic frequency was 1.00 for both variants), in this case suggesting the newly identified 
variant as the major allele in this gene location. Consequently the genome sequenced and used as 
the Equus ferus caballus reference sequence, Twilight (Wade et al. 2009), has been demonstrated to 
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naturally carry more minor alleles in the PTEN gene. PTEN is a lipid phosphatase that has two 
protein domains (Figure 6.3.2). PTEN protein expression and posttranscriptional modification is 
controlled largely by external transcription factors. PTEN has large genomic UTR for this reason, 
and is itself a negative pathway regulator for the PI3K/AKT1 pathway in cardiomyocytes and 
endothelial cells.  
 
Figure 6.3.1: Graphical overview of variant distribution over total PTEN gene length.  
Green boxes denote gene exons; red boxes stacked above green boxes denote 3 and 5 UTR. PTEN has 
significantly large UTR. Each bar on the graph represents the number of individuals different from the 
published equine reference sequence (n = 93).  
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Figure 6.3.2: PTEN expected protein domains. 
Structural domains were established using publicly-available information from Ensembl 
(http://asia.ensembl.org 2014). 
Each sample in the study population was genotyped at each location and allele frequencies were 
calculated. This result was then used to identify any population distribution patterns, which would 
be an indicator of whether the variant at that location was the product of normal genetic variation or 
a less common random mutation event. Figure 6.3.3 shows the population breakdown of genotypes 
for each variant location within the PTEN genomic region. Table 6.3.1 shows specific variant 
information as well as confirmation of allelic distribution patterns where present. The unknown 
dominant or recessive nature of each variant has been taken into consideration with all frequency 
distribution calculations, using the Hardy-Weinberg equation. P values were used as a measure of 
conformity to Hardy-Weinberg distributions with a significance of 0.05. 
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Figure 6.3.3: Number of individuals with variants found in 5 and 3 UTR of PTEN gene.  
Each variant found in the study has been given a location number for ease of analysis. At each location, 
samples were identified as heterozygous, homozygous reference or homozygous variant. Absolute numbers 
of individuals’ genotype is graphed (n = 93). Dominant or recessive nature of variants are unknown so 
traditional significance level statistical tests are invalid for this data set. Hardy-Weinberg equilibrium 
distribution analysis of variant distribution is displayed in following tables. Variants found in the UTRs 
included two insertions, one deletion, and two SNPs affecting low numbers of the population. 
Alterations in the 5 or 3 UTR of a gene can have transcriptional and posttranscriptional 
modification effects as well as effects on expression levels of the PTEN protein, by modification or 
ablation of promoter regions. In this way, variants can have an altering effect on protein products 
even if the coding region is unchanged.  
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PTEN  
BUILD: EquCab2.0, GENE: PTEN, GENE TRANSCRIPT: ENSECAG00000017012.  
CHROMOSOME AND GENE REGION: 1:-40599500… -40513515, STRAND: MINUS. 
Location Exon 
Anomaly Position; 
Chromosome Position 
Exon: Position Nucleotide Sequence 
Variant 
Codon 
Position 
Amino Acid 
Sequence 
Amino 
Acid 
Change 
Variant Allele 
Frequency 
Reference 
Allele 
Frequency 
P Value 
(two 
tailed) 
HWB Normal 
Distribution (P 
< 0.05) 
1 N/A g.-40600846C>G c.1:+196C>G GATGGGACTCTTG(G/C)CTGGTTGCAAGT N/A N/A N/A 0.263 0.737     
2 2 
g.-40577268^-
40577267insA 
c.2:12^13insA ATATTTATCCAA(-/A)CATTATTGCTATG 5' UTR N/A N/A 1 0 0.1835 NO 
3 2 g.-40577238delA c.2:42delA TTTCCTGCAGAAA(A/-)GACTTGAAGGCGT 5' UTR N/A N/A 0.989 0.01 0.1791 NO 
4 2 
g.-40577220^-
40577219insG 
c.2:60^61insG AAGGCGTATACAG(-/G)AACAATATCGATG 5' UTR N/A N/A 1 0 0.1835 NO 
5 N/A g.-40551324G>T c.3:+223G>T TCACGTTGCTTGA(G/T)CTGCTTAAATGA N/A N/A N/A 0.575 0.425   
6 N/A g.-40545993A>G c.4:-215A>G CTAATTACATAC(A/G)CTTGACATTTTA N/A N/A N/A 0.038 0.962   
7 N/A g.-40545938T>C c.4:-160T>C AATAATAACAGTA(T/C)AATTCCATAGGA N/A N/A N/A 0.011 0.989   
8 N/A g:-40545931A>C c.4:-153A>C CAGTATAATTCC(A/C)TAGGATTCTTAG N/A N/A N/A 0.059 0.941   
9 N/A g:-40545677A>G c.4:+58A>G TAGACTAAGTCTT(A/G)CTGTCACAGCAG N/A N/A N/A 0.005 0.995   
10 N/A g:-40545436T>C c.4:+299T>C TGGCAAGGAGCG(T/C)GACCTAAAAGGT N/A N/A N/A 0.005 0.995   
11 N/A g.-40520580A>G c.8:+20A>G TAAAAACATTTTG(A/G)GGAGTTGGTGTG N/A N/A N/A 0.065 0.935   
12 9 g.-40517053A>T c.9:491A>T CAGTTTTATAAAA(A/T)GTGGAGACAGAC 3' UTR N/A N/A 0.005 0.994 0.1791 NO 
13 9 g.-40514341G>A c.9:757G>A CCATCTCCAGCT(G/A)TTTACATGCACC 3' UTR N/A N/A 0.048 0.951 0.1453 NO 
14 
AFTER 3' 
UTR 
g.-40513489T>C C.9:+26T>C GCTTTTATCAAGT(T/C)GCTATTGAAAGA N/A N/A N/A 0.591 0.409   
Table 6.3.1: List of variants in PTEN genomic exon region. 
Reference and variant allele frequency for each new variant location was used to calculate allelic distributions for the study population. Reference and variant allele 
distribution was tested for normal distribution as defined by HWE. Nonconformity of newly-identified allelic variants to normal HWE distribution was tested for statistical 
significance by two-tailed t-test, with a significance level of P < 0.05. Variants in 5 or 3 UTR are highlighted in red.  
 80 
Nucleotide changes identified in the study are mapped to the gene-coding region with 
corresponding amino acid translation (Figure 6.3.4). In the case of PTEN no nucleotide changes 
resulted in an amino acid substitution. 
 
Figure 6.3.4: PTEN variants mapped to the published reference sequence.  
PTEN is mapped to build EquCab2.0. PTEN gene chromosome location = 1:-405,995,00–405,135,15. 
Ensembl gene accession number: ENSECAG00000017012. Long purple bars are coding regions; long 
green bars mark exons. Long red bars are indicative of 5 and 3 UTR; variants are marked with small red 
boxes.  
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6.4 Results and discussion – PI3K 
In total 22 variant locations were found for the PI3K gene in the study population. Of these, all were 
of a novel nature and had not been identified previously. Figure 6.4.1 shows the distribution of 
variants over the entire gene region. It can be seen that of all the variants only one affects a large 
proportion of the population (Location 21, g.-5673487A>G). This variant is located in an intronic 
region between exons 14 and 15 and is not involved in protein production. Of all the variants 
identified, nine are located in protein-coding regions, with the rest distributed over non-coding 
intron regions. The PI3K gene codes for a protein of three domain types: the Rho GTPase-activating 
domain, SH3 domain, and two repeated SH2 domains (Figure 6.4.2). Coding variants are located in 
exons 1, 2, 5, and 11. These locations correlate to the Rho GTPase-activating domain and the first 
repeat of the SH2 domain. SH2 domain is usually structurally-conserved, and important in physical 
protein-protein interactions (Liu et al. 2011). This binding domain works in conjunction with Rho 
GTPase-activating domain to enable PI3K’s down-regulating function in the PI3K/ AKT1/ PTEN 
pathway by inactivation of target G proteins.  
 
Figure 6.4.1: Graphical overview of variant distribution over total PI3K gene length.  
Green boxes denote gene exons. Red boxes stacked above green boxes denote 3 UTR. Each bar on the 
graph represents the number of individuals different from the published equine reference sequence (n = 
93).  
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Figure 6.4.2: PI3K expected protein domains. 
Structural domains were established using publicly-available information from Ensembl 
(http://asia.ensembl.org 2014). 
Each sample in the study population was genotyped as heterozygous, homozygous reference, or 
homozygous variant and allele frequencies calculated. This result was then used to identify any 
population distribution patterns, which would be an indicator of whether the variant at any specific 
location was the product of normal genetic variation or a less common random mutation event. 
Figure 6.4.3 shows the population breakdown by genotype for each variant location in a protein-
coding region. Table 6.4.1 shows specific variant information as well as confirmation of allelic 
distribution patterns where present. P values were used as a measure of conformity to Hardy-
Weinberg distributions with a significance of 0.05.  
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Figure 6.4.3: Number of individuals with variants found in the protein-coding region of PI3K gene.  
Each variant found in the study has been given a location number for ease of analysis. At each location, 
samples were identified as heterozygous, homozygous reference, or homozygous variant. Absolute numbers 
of individuals’ genotype is graphed (n = 93). Hardy-Weinberg equilibrium distribution analysis of variant 
distribution is performed in following tables. All variants found in the gene-coding region were SNP 
variants affecting low numbers of the population. 
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PI3K (PIK3R1)  
BUILD: EquCab2.0, GENE: PI3K1, GENE TRANSCRIPT: ENSECAG00000019837.  
CHROMOSOME AND GENE REGION: 21:-5741577… -5673136, STRAND: MINUS. 
Location Exon 
Anomaly Position; 
Chromosome Position 
Exon: Position Nucleotide Sequence 
Variant 
Codon 
Position 
Amino Acid 
Sequence 
Amino Acid 
Change 
Variant 
Allele 
Frequency 
Reference 
Allele 
Frequency 
P 
Value 
(two 
tailed) 
HWB Normal 
Distribution (P 
< 0.05) 
1 1 g.-5741305A>G c.1:272A>G CAAAGCCCCGGCC(A/G)CCTCGACCCCTT CC* KPR(P)PRP - 0.043 0.957 0.1532 NO 
2 2 g.-5698092G>A c.2:53G>A CTGACATCGCTCC(G/A)CCTCTTCTTATC CC* DIA(P)PLL - 0.016 0.984 0.1705 NO 
3 N/A g.-5697946C>T c.2:+106C>T ACCTGTGCTAGA(C/T)GCACAAGCTATT N/A N/A N/A 0.242 0.758   
4 N/A g.-5697945G>A c.2:+107G>A ACCTGTGCTAGAC(G/A)CACAAGCTATTT N/A N/A N/A 0.022 0.978   
5 N/A g.-5692350A>G c.4:-44A>G CCCAACCAACTAA(A/G)TGTCTAAAATGT N/A N/A N/A 0.022 0.978   
6 5 g.-5691357G>A c.5:10G>A GAAGTACAAA(G/A)CTCCGAGGAATA A*C EVQ(S/N)SEE p.Ser215Asn 0.043 0.957 0.1494 NO 
7 5 g.-5691240C>A c.5:127C>A ACTCACTCAAACCT(C/A)CAGCAAAAATCT T*C TQT(S/Y)SKN p.Ser254Tyr 0.011 0.989 0.1791 NO 
8 N/A g.-5677794G>A c.8:-72G>A AAAAATAAAGTCC(G/A)TTAAAAACAGTG N/A N/A N/A 0.511 0.489   
9 N/A g.-5676803^ -5676802insAT c.10:+54insAT ATTAGAACCTAAC(--/^AT)GTGTTATATTCAG N/A N/A N/A 0.011 0.989   
10 N/A g.-5676742G>A c.10:+115G>A TGCACATGAAGTC(G/A)GGGGAGAGATCA N/A N/A N/A 0.022 0.978   
11 N/A g.-5676187C>T c.11:-86C>T AAGTGGTAATACA(C/T)ATCAAATGTCCT N/A N/A N/A 0.005 0.995   
12 N/A g.-5676166C>T c.11:-64C>T CCTGGTAGTGTC(T/C)TGCAATAAGAAA N/A N/A N/A 0.011 0.989   
13 11 g.-5676058C>T c.11:44C>T TTAATGAAA(C/T)TATAAAAA A*T FNE(T/I)IKI p.Thr490Ile 0.011 0.989 0.1791 NO 
14 11 g.-5676028C>T c.11:74C>T AACAGTGCCAAA(C/T)CCAGGAGCGGTA A*C QCQ(T/I)QER p.Thr500Ile 0.011 0.989 0.1791 NO 
15 11 g.-5676026C>T c.11:76C>T CAGTGCCAAACC(C/T)AGGAGCGGTACA *AG CQT(Q/STOP)ERY p.Gin501Stop 0.011 0.989 0.1791 NO 
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Table 6.4.1 continued. 
Location Exon 
Anomaly Position; 
Chromosome 
Position 
Exon: Position Nucleotide Sequence 
Variant 
Codon 
Position 
Amino Acid 
Sequence 
Amino Acid 
Change 
Variant Allele 
Frequency 
Reference 
Allele 
Frequency 
P Value 
(two 
tailed) 
HWB Normal 
Distribution (P 
< 0.05) 
16 11 g.-5675979C>T c.11:123C>T TAAACGCGAAGG(C/T)AACGAGAAAGAA GG* KRE(G)NEK - 0.011 0.989 0.1791 NO 
17 11 g.-5675967A>T c.11:135A>T GCAACGAGAAAGA(A/T)ATACAAAGGTTG GA* NEK(E)IQR - 0.022 0.978 0.1662 NO 
18 N/A g.-5675762G>C c.12:-39G>C AACCCTCATAAT(G/C)CACCCAGGTATT N/A N/A N/A 0.022 0.978   
19 N/A g.-5674423C>T c.14:+107C>T AAAAAGTTCTAAT(C/T)TTGGAGAATCTT N/A N/A N/A 0.005 0.995   
20 N/A g.-5673593A>G c.15:-224A>G CCATTTTAAAGAT(A/G)AAAATACCTAGC N/A N/A N/A 0.468 0.532   
21 N/A g.-5673487A>G c.15:-118A>G TCCCCTTGCGGAG(A/G)CTGGCCTGCATA N/A N/A N/A 0.005 0.995   
22 N/A g.-5673380C>T c.15:-11C>T TTATTTGTTCTCT(C/T)TCTTCTCTAGGG N/A N/A N/A 0.113 0.887   
 
Table 6.4.1: list of variants in PI3K genomic exon region.  
Reference and variant allele frequency for each new variant location was used to calculate allelic distributions for the study population. Reference and variant allele 
distribution was tested for normal distribution as defined by HWE. Nonconformity of newly-identified allelic variants to normal HWE distribution was tested for statistical 
significance by two-tailed t-test, with a significance level of P < 0.05. Variants in protein-coding regions are highlighted in red. *Deduced by CLC.
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Nucleotide changes identified in the study are mapped to the gene-coding region with 
corresponding amino acid translation (Figure 6.4.4). Nucleotide changes that resulted in an amino 
acid change are catalogued in the variant Table 6.4.2. 
 
Figure 6.4.4: PI3K variants mapped to the published reference sequence.  
PI3K variants were mapped to build EquCab2.0. PI3K gene chromosome location = 21:-574,1577–
567,3136. Ensembl gene accession number: ENSECAG00000019837. Long purple bars are coding 
regions; long green bars mark exons. Long red bars are indicative of 3 UTR; variants are marked with 
small red boxes. 
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Changes in amino acid and their corresponding protein domains are depicted in Figure 6.4.5. 
Deleterious amino acid changes as determined by CLC were only seen in the variants with low 
allele frequency within this population. None of the amino acid-changing variants had a normal 
Hardy-Weinberg allele frequency distribution, suggesting these variants were randomly occurring 
as opposed to normal genetic variation within a population. The greatest number of variants (five 
locations) was located in exon 11 corresponding the first SH2 domain. Whilst variants in these 
locations have low allelic frequencies, amino acid-changing variants in the SH2 domain may cause 
structural changes to physical mechanisms normally responsible for protein docking, inhibiting their 
binding with target proteins. The Rho GTPase-activating protein domain is a molecular switch 
responsible for turning on and off signalling for cascading molecular pathways once bound to target 
proteins. Alterations in this part of the PI3K protein can inhibit signalling even if molecular docking 
and protein binding is successful. Of all the variants within protein-coding regions, Location 15 (g.-
5676026C>T) would have the most deleterious change. Location 15 is characterised by an amino 
acid change from glutamine to a STOP codon. A STOP codon at this location would result in a 
truncation of the protein at the first repeat of the SH2 domain (in effect also cutting off the second 
SH2 domain), thus drastically inhibiting the PI3K protein’s binding ability. This change would 
affect many downstream processes, as PI3K is a prolific signalling protein.  
 
 
 
 
 
 
 
 
 
Figure 6.4.5: Approximate location of variants on PI3K protein domain. 
Structural domains were established using publicly-available information from Ensembl 
(http://asia.ensembl.org 2014). 
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PI3K (PIK3R1)  
BUILD: EquCab2.0, GENE: PI3K1, GENE TRANSCRIPT: ENSECAG00000019837.  
CHROMOSOME AND GENE REGION: 21:-5741577… -5673136, STRAND: MINUS. 
Location 
Anomaly Position; Chromosome 
Position 
Exon: Position Amino Acid Change 
SIFT amino acid predictions. Threshold for 
intolerance 0.05 
Seq Rep* SIFT Score 
Sequences in SIFT 
Alignment 
1 g.-5741305A>G c.1:272A>G - - - - - 
2 g.-5698092G>A c.2:53G>A - - - - - 
6 g.-5691357G>A c.5:10G>A p.Ser215Asn Tolerated** 0.42 0.35 27 
7 g.-5691240C>A c.5:127C>A p.Ser254Tyr 
Not tolerated, predicted to affect protein 
function** 
0.42 0.02 27 
13 g.-5676058C>T c.11:44C>T p.Thr490Ile Tolerated 0.95 0.06 61 
14 g.-5676028C>T c.11:74C>T p.Thr500Ile 
Not tolerated, predicted to affect protein 
function** 
0.94 0.00 60 
15 g.-5676026C>T c.11:76C>T p.Gin501Stop Not tolerated - - - 
16 g.-5675979C>T c.11:123C>T - - - - - 
17 g.-5675967A>T c.11:135A>T - - - - - 
Table 6.4.2: SIFT predicted amino acid-changing variants in PI3K.  
* Fraction of sequences that contain one of the basic amino acids. A low fraction indicates the position is either severely gapped or unalignable and has little information.  
** SIFT predicted tolerance or intolerance, variant does not appear within SIFT alignments. P.Gin501Stop results in a truncated protein, predicted to affect protein 
function. 
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CHAPTER 7: ANALYSIS OF PERFORMANCE AND 
CORRELATION WITH GENETIC DATA 
7.1 Introduction 
The influence of the larger than average Thoroughbred heart size phenotype on athletic 
performance is well-documented (Young, Rogers & Wood 2005). Thoroughbreds are raced under 
several different race types and conditions. Each race type may be associated with specific 
phenotypes seen only in the racehorses that excel in those race types, making comparison between 
individuals of differing race types difficult. One key example of this is short sprint races versus 
longer endurance races (Sobczynska 2006). Recently myostatin variants have been identified in 
Thoroughbreds that are strongly correlated with an individual’s ability to perform in races of 
different lengths (Tozaki et al. 2010; Hill et al. 2012). Combining different populations of 
Thoroughbreds without taking into consideration an individual’s strengths (for example, success in 
certain race lengths) can invariably lead to incorrect assumptions of an individual’s overall athletic 
ability (Williamson & Beilharz 1998). This also makes establishment of what it actually means to 
be a successful racehorse subjective, as racing statistics are recorded and interpreted differently by 
different racing bodies.  
To avoid these difficulties, previous research has used lifetime earnings as a measure of success, as 
generally events of a higher competitive nature have a greater monetary prize pool (Thiruvenkadan, 
Kandasamy & Panneerselvam 2009). Racing success and monetary earnings used as a measure of 
athletic performance, and thus inferred genetic desirability of the individual, has both benefits and 
limitations (Gramkow & Evans 2006). Measurement of athletic performance by assessment of 
lifetime earnings is non-invasive, and negates the need for access to other data that would ordinarily 
be used to confirm beneficial or preferred physical traits sought after by breeders and trainers. 
Athletic performance-enhancing traits such as cardiac output and heart size can be tested for via 
ECG or ultrasound and through commercial athletic performance testing (Section 1.4) however, 
these results are not publicly available or performed on all Thoroughbreds due to cost. Whilst 
Thoroughbreds at elite levels of racing are routinely screened for heart defects and other 
abnormalities using these techniques, owners often choose to keep veterinary records confidential. 
As earnings data in Australian is publicly accessible, the need for access to confidential data is 
mitigated, so horses can be used in earnings studies that researchers would not ordinarily have 
access to. 
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Whilst earnings studies provide a good general indication of athletic performance, further 
investigation is often required to distinguish between specific elite racing phenotypes. Additionally, 
generational affects, currency inflation, and often conversion (particularly for historic racing 
records) as well as race type and length must be taken into consideration, resulting in complex 
mathematical models (Sobczynska & Lukaszewicz 2004; Park 2011). 
In this study the panel of Thoroughbreds were selected based solely on lack of pedigree relatedness. 
This was to ensure samples represented the genetic diversity present in the wider Australian 
Thoroughbred population. This step ensured that no single pedigree line or popular breeding 
individual was over-represented in the population, as well as ensuring that the population would not 
be skewed towards more successful racing individuals by over-representing them in the study 
population. Furthermore, to avoid unnecessary bias towards successful or unsuccessful racing 
groups and to avoid skewing the sample population into a group unrepresentative of the general 
Thoroughbred population, animals’ racing history was deliberately unknown at the time of sample 
selection as previously discussed (Sample Selection, Section 2.4). 
This part of the study is focused on looking at the overall athletic performance of the panel and does 
not take into consideration the influence of race length on success. To counteract the limitations 
usually associated with an athletic performance study via lifetime earnings, panel members selected 
were from the same year’s cohort of Thoroughbreds parentage-tested by microsatellite analysis 
(year 2008), and had a mean potential racing career length of 4.68 years +/- 0.19 SD (full range = 
3–12 years, standard deviation of mean = 0.19, predicted as maximal possible racing career between 
two years of age and study). All horses were in Australia for the duration of their career at the time 
of the study, and negligible currency inflation was recorded for this short time period. Extra 
earnings via stud fees were not considered, as this would be highly subjective measurement of 
breeder objectives. The median career length of the panel members was 4 years based on a career 
starting at the age of 2 years (Figure 7.2).  
7.2 Results and discussion 
Overall, the study population of 93 horses showed an earnings distribution typically representative 
of a breeding year’s group of foals. The average age of study participants was 6 ¾ years of age at 
the time of earnings analysis (Figure 7.1). The population was split into earnings groups A–G, for 
further analysis, and earnings categories were then assigned to bins for further analysis (Chen, 
Hardie & Unwin 2007) (Table 7.1). At the time of the study the panel had the potential racing 
career spanning of 4¾ years (with an assumed start at 2 years of age, official retirement age is not 
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recorded in Australian racing data) (Figure 7.2). Age-corrected data showed no disparity from data 
that was not age-corrected (or included in the following analysis).  
 
Figure 7.1: The average age of horses at the time of study.  
Vertical bar shows entire age range, horizontal bar is average age at time of the study. Very few horses 
were on the higher end of the age-range spectrum, and this had a negligible effect to the population’s 
racing statistics analysis. Mean potential racing career length: 4.68 years +/- 0.19 SD (full range = 3–12 
years. 
 
Figure 7.2: Length of racing career – population distribution. 
Mean racing career length = 4.68 years +/- 0.19 SD (full range = 3–12 years, standard deviation of mean 
= 0.19).  
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Table 7.1 Earnings categories and bin selection. 
The earnings data was attained for each individual and the overall distribution of population 
earnings was analysed. Overall prizemoney earned was not evenly distributed amongst the 
population. There was great disparity between earnings categories with most of the prizemoney 
concentrated in the top two categories, containing only five successful individuals (Figure 7.3).  
 
Figure 7.3: Distribution of individuals within the study lifetime earnings brackets.  
The greater share of prizemoney was concentrated to the few successful racehorses in the top categories 
(>$200,000).  
$0  
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The number of individuals in each earnings category as a percentage of the whole population is 
depicted in Figure 7.4. The vast majority (80%) of individuals in this population earned under 
$50,000 over their entire racing career; in actual numbers only 10 (~10%) individuals earned over 
this amount.  
 
Figure 7.4: Lifetime earnings of the sample population.  
Each earning category is represented as a percentage of the total population (n = 93). Earnings categories 
include: A) unraced individuals, B) individuals that raced but did not place or win any prizemoney, C) 
individuals that earned under $1000, D) individuals that earned between $1001 and $10,000, E) individuals 
that earned between $10,001 and $50,000, F) individuals that earned between $50,001 and $100,000, G) 
individuals that earned between $100,001 and $200,000, and H) individuals that earned more than 
$200,001.   
The type and frequency of 5’ and 3’ UTR and protein-coding regions variants found in the study 
population was sorted by earnings category to assess general genetic variability within each 
earnings group. In this way, correlations between genetic diversity and earnings groups can be 
made, as well as identification of specific variants seen only in specific earnings groups (Figure 
7.5).  
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Figure 7.5: The type and number of variants found within the study population.  
The data from all five candidate genes were pooled for this analysis. Earnings groups deemed to be at a 
similar level of racing success were combined for analysis. For example, horses that earned under $1000 
in prizemoney over their 4-¾ year career were deemed to be at a similar level of racing success to those 
that had earned nothing or had failed to race at all. The total number of variants by type is the total number 
of unique variant events occurring within the group, not the amount or total number of times a variant 
appeared in the population. Log-linear regression (Poisson regression) analysis used for trend lines, R-
values displayed on left hand side of each line. 
 
All variant data for the five candidate genes was pooled and the data analysed as a whole. Overall, it 
can be seen that of all the earnings groups, groups that earned a greater amount of prizemoney over 
the mean 4.68-year racing career had fewer total variants (R2 = 0.88), and no amino acid-changing 
variants, when compared with low-earning groups (groups ABC) (population size normalised data 
was assessed and showed the same relationship, data not shown). Overall, high genetic variation in 
the candidate genes analysed did not correlate to high-performing animals in this study’s 
population, Figure 7.5. This suggests that the level of general genetic variation within a population 
alone is not enough to predict the performance outcome of a population or any individual within it.  
This finding however does not discount the possibility of specific gene variants playing a role in 
elite athletic performance, or that high genetic variation within a population may help increase the 
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likelihood of an athletic performance-enhancing gene variant appearing in greater frequency within 
a genetically-diverse population.  
To analyse the potential influence of any one gene on racing success (as measured by earnings) 
variant data for each individual gene was analysed for each earnings group (Figure 7.6). 
 
Figure 7.6: Total number of amino acid-changing and UTR variant locations, by gene.  
Each variant was counted as present in the group or not to graph absolute numbers of variants present in 
that population. All variants in 5’ or 3’ UTR and protein-coding regions were included in this graph. The 
MYH7 gene shows the most genetic diversity of all the genes for all earnings categories. The total number 
of variants by type is the total number of unique variant events occurring within the group, not the amount 
or total number of times a variant appeared in the population. Log-linear regression (Poisson regression) 
analysis used for trend lines, R-values displayed on left hand side of each line. 
Figure 7.6 shows the large difference in genetic variation between the MYH7 gene and the other 
candidate genes. Of interest is the decrease of diversity in the MYH7 gene as the average lifetime 
earnings increases over the earnings groups. Earnings group ABC had by far the most genetic 
variants. In this earnings group, variants from all candidate genes were present. CASQ2 was the 
only gene to have variants located solely in the ABC earnings group. PTEN variants were found in 
all earnings groups. This correlates to locations 2, 3, and 4 (g.-40577268^–40577267insA, g.-
40577238delA and g.-40577220^–40577219insG respectively), and all INDEL events in the UTRs 
of PTEN not previously seen in the published reference sequence (Table 6.3.1 and Figure 6.3.4). To 
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identify variants that may be involved in the Thoroughbred phenotype of interest, variant locations 
present in each group were compared (Table 7.2). It can be seen that some variants appear only in 
the higher-earnings groups (MYH7), and similarly other variants (AKT1 and CASQ2) are only seen 
in lower-earnings groups.  
The one variant in the AKT1 gene that did not occur elsewhere in the population was location 25 
(g.46111286C>T). This location had an allele frequency of 0.01, and occurred only once in a 
heterozygous individual within earnings group A (unraced). This variant did not cause an amino 
acid substitution and, with such a low population frequency, would be difficult to definitively link 
to any specific racing phenotype without significant further studies. The MYH7 gene had three 
variants in the high-earnings group, and not seen elsewhere. Two of these variants, locations 68 and 
121 (g.161510989C>T and g.161506608C>T), were identified in the same top-earning individual 
(>$200,000) and, like the AKT1 variant, both variants had low allele frequencies at 0.01 each. 
Neither variant results in a non-conserved amino acid change. Both variants occur in the same 
individual, which is heterozygous at both locations. A third variant location for MYH7 is also 
identified in the high-earnings group. Location 39, g.161511409C>T, is an amino acid-changing 
variant found in exon 31 of the MHY7 gene. This variant occurs at the 2nd position of the codon and 
causes a nonsynonymous amino acid substitution in the protein from alanine to valine. This area of 
the genomic coding corresponds to the myosin tail coiled coil domain of the protein (Chapter 4). 
Amino acid substitution in this region with valine, a low helix-forming propensity amino acid, 
would result in an altered secondary structure due to changed hydrogen bond angles between 
neighbouring amino acids, and the lower affinity valine has for forming alpha helix coiled 
structures. The individual with this variant is heterozygous at this location and has survived to 
maturity, suggesting that its’ heterozygosity may have mitigated the potential life threatening 
effects of such a change. That is, a homozygous variant horse would likely not have survived 
infancy should the predicted protein affects be correct, due to the critical nature of MYH7 gene 
proteins for cardiac tissue. However, this does not exclude the possibility of some associated 
phenotype as the production of non-functional protein may affect downstream processes requiring 
threshold amounts of functional protein in a “dose response” manner. Whilst each variant is in itself 
unlikely to be the sole underlying genetic cause of such a complicated phenotype, results from this 
study do highlight the highly likely possibility that it is a combination of the inclusion or absence of 
several genetic variants that lead to the characteristic phenotype and the associated increase in 
athletic performance.  
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Earnings Group MYH7 PTEN PI3K AKT1 CASQ2 
ABC 
N= 44 
1, 7, 37, 41, 42, 43, 44, 45, 46, 47, 60, 
61, 62, 64, 65, 67, 70, 71, 74, 75, 76, 86, 
87, 89, 91, 92, 98, 101, 102, 108, 109, 
122, 123. 
2, 3, 4, 12, 13. 1, 2, 6, 13, 15, 
16, 17. 
3, 9, 20, 26 
(1/88 freq). 
2, 22, 23, 24. 
D 
N= 18 
1, 7, 37, 41, 42, 43, 44, 45, 46, 48, 66, 
69, 70, 73, 86, 87, 89, 94, 97, 109, 108, 
122, 124, 125.  
2, 3, 4. 1, 2, 6. 3, 9, 20. 2, 11, 22, 23, 
24. 
E 
N=22 
1, 7, 11, 40, 14, 42, 43, 44, 45, 46, 63, 
69, 72, 86, 87, 89, 96, 99, 100, 108, 109. 
2, 3, 4, 13. 1, 7, 17. 3, 9, 20. 22, 23, 24. 
F 
N= 5 
1, 7, 37, 42, 43, 45, 86, 87, 89, 93, 95, 
99, 108, 109. 
2, 3, 4, 13. 14. 3, 9, 20. 22, 23, 24. 
GH 
N= 5 
1, 7, 37, 39 (1/10 freq), 42, 46, 61, 62, 68 
(1/10 freq), 86, 87, 89, 101, 108, 109, 
121 (1/10 freq). 
2, 3, 4, 13. 6. 9, 20. 22, 23, 24. 
Table 7.2: Variants in coding regions for each gene present in each earnings group.  
Location numbers listed show that the variant allele was present in any form (heterozygous or homozygous) 
at that location within the population of that earning group. Red highlighted locations for gene MYH7 do 
not appear in other earning groups. Location 25 for gene AKT1 is also highlighted in red, as this variant 
does not appear in any other earnings group.  Variants not appearing in any other group have allelic 
frequency displayed as fraction of all possible alleles in the group. Variants with skewed distributions, not 
conforming to HWE due to low variant allele frequencies have been highlighted in blue. Variants with 
skewed distributions, not conforming to HWE due to high variant allele frequencies have been highlighted 
in green. Location numbers with normal HWE distribution (variant as minor allele) are in black.  
It is interesting to note that on comparison with the sample population in this study, the published 
reference sequence of the equine (horse genome project (Wade et al. 2009)) was genotyped as the 
less common allelic variant at many positions of genetic variation that were found in this study, 
particularly in the PTEN gene. 
This is of interest as the published equine reference sequence is based on one female Thoroughbred. 
The publically available raw sequencing data for this individual (sequencing chromatograms) was 
analysed in comparison to the sample populations raw sequencing data, and the call quality and 
accuracy of these records assessed.  It was found that the reference sequence attained from the one 
female Thoroughbred was of good sequencing quality and had a call accuracy rate of 100% (for the 
5 genes analysed).   This suggests that the reference sequence individual carries the minor allele for 
many of the variant locations found during this current work.  This observation, whilst not part of 
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the original study, is of interest and should be investigated further, as recessive homozygous traits 
can be indicative of a founder effect in small isolated populations, or as a product of intensive 
selective inbreeding over time, both of which would be important areas of study and provide crucial 
information for the future management of the wider Thoroughbred population. 
Throughout the study it was noticed that certain groups of variants occurred more frequently 
together.  To investigate this further, variants were analysed for frequency of co-occurrence and 
significance of co-occurrence distribution over the entire population (Table 7.3).  
Variant* Variant 
Allele 
frequency 
x/186 
Co-occurring variants* Frequency of co-
occurrence** 
Significance 
(Chi squared 
test)*** 
AKT1 Loc 3 17 A3, A9, A20, C22, C23, C34, 
PK1, PK6, PK17, PT2, PT3, PT4, 
PT13, M1, M94, M97, M122, 
M124 
17, 4, 5, 1, 1, 1, 4, 1, 1, 
28, 26, 28, 26, 7, 1, 1, 1, 
1, 
0 
AKT1 Loc 9 49 A3, A9, A20, A25, C2, C22, C23, 
C24, PK1, PK2, PK6, PK15, 
PK17, PT2, PT3, PT4, PT12, 
PT13, M1, M40, M61, M63, M64, 
M65, M67, M92, M101, M121, 
M123 
3, 49, 15, 1, 2, 8, 8, 8, 2, 
3, 3, 1, 1, 86, 86, 86, 1, 
84, 20, 1, 1, 1, 1, 1, 1, 2, 
1, 1, 1 
0 
AKT1 Loc 20 43 A3, A9, A20, C2, C22, C23, C24, 
PK1, PK6, PK2, PK4, PK17, PT2, 
PT3, PT4, PT13, M1, M40, M61, 
M64, M65, M66, M71, M73, 
M93, M94, M95, M96, M97, 
M101, M122, M124 
7, 13, 42, 1, 10, 10, 10, 3, 
1, 8, 1, 1, 68, 68, 68, 63, 
15, 1, 1, 1, 1, 1, 1, 1, 1, 2, 
2, 1, 1, 1, 2, 1, 
0 
AKT1 Loc 25 1 A9, A25, PT2, PT3, PT4, PT13, 
M1, M123 
1, 1, 1, 2, 2, 2, 2, 1, 1, 1 
CASQ2 Loc 2 7 A9, C2, C22, C23, C24, PK1, 
PT2, PT3, PT4, PT13, M1 
2, 1, 7, 7, 7, 7, 1, 12, 12, 
12, 11, 3 
0.094 
CASQ2 Loc 11 1 C11, PT2, PT3, PT4, PT13 1, 2, 2, 2, 2, 1 
CASQ2 Loc 22 23 A3, A9, A20, C2, C22, C23, C24, 
PK1, PK2, PK6, PT2, PT3, PT4, 
PT13, M1, M39, M61, M63, M66, 
M73, M93, M122, M124 
2, 10, 14, 7, 23, 23, 23, 1, 
1, 3, 44, 44, 44, 41, 14, 1, 
1, 1, 1, 1, 1, 1, 1, 
0 
CASQ2 Loc 23 25 A3, A9, A20, C2, C22, C23, C24, 
PK1, PK2, PK6, PT2, PT3, PT4, 
PT13, M1, M39, M61, M63, M66, 
M73, M93, M122, M124 
2, 10, 14, 7, 23, 23, 23, 1, 
1, 3, 44, 44, 44, 41, 14, 1, 
1, 1, 1, 1, 1, 1, 1, 
0 
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Table 7.3 continued. 
Variant* Variant 
Allele 
frequency 
x/186 
Co-occurring variants* Frequency of co-
occurrence** 
Significance 
(Chi squared 
test)*** 
CASQ2 Loc 24 23 A3, A9, A20, C2, C22, C23, 
C24, PK1, PK2, PK6, PT2, PT3, 
PT4, PT13, M1, M39, M61, 
M63, M66, M73, M93, M122, 
M124 
2, 10, 14, 7, 23, 23, 23, 1, 
1, 3, 44, 44, 44, 41, 14, 1, 
1, 1, 1, 1, 1, 1, 1, 
0 
PI3K Loc 1 8 A3, A9, A20, C2, C22, C23, 
C24, PK1, PK17, PT2, PT3, 
PT4, PT13, M1 
4, 3, 3, 1, 1, 1, 1, 8, 1, 14, 
14, 14, 12, 6 
0 
PI3K Loc 2 3 A9, A20, C22, C23, C24, PK2, 
PK6, PT2, PT3, PT4, PT13, M1 
4, 1, 1, 1, 1, 3, 1, 6, 6, 6, 
6, 1 
1 
PI3K Loc 6 8 A3, A9, A20, C22, C23, C24, 
PK2, PK6, PT2, PT3, PT4, 
PT13, M1, M61, M64, M94, 
M97 
2, 3, 10, 3, 3, 3, 1, 8, 16, 
16, 16, 16, 2, 1, 1, 1, 1 
0 
PI3K Loc 7 2 PK7, PT2, PT3, PT4, PT13, 
M11 
2, 2, 2, 2, 2, 2, 1 
PI3K Loc 13 1 PK13, PT2, PT3, PT4, PT13, 
M1, M61 
1, 2, 2, 2, 2, 1, 1, 1 
PI3K Loc 14 1 A20, PK14, PT2, PT3, PT4, 
PT13, M1, M95 
1, 2, 2, 2, 2, 1, 2 1 
PI3K Loc 15 1 A9, A25, PK15, PT2, PT3, PT4, 
PT13, M1 
1, 1, 1, 2, 2, 2, 2, 1 1 
PI3K Loc 16 1 PK16, PT2, PT3, PT4, PT13 1, 2, 2, 2, 2, 1 
PI3K Loc 17 4 A3, A9, A20, PK1, PK17, PT2, 
PT3, PT4, PT13, M1 
1, 1, 1, 1, 4, 8, 8, 8, 7, 6 0.799 
PTEN Loc 2 186 ALL VARIANTS 17, 49, 42, 1, 7, 1, 23, 23, 
23, 8, 3, 8, 2, 1, 1, 1, 1, 4, 
188, 186, 188, 1, 179, 44, 
2, 1, 1, 3, 1, 1, 1, 1, 1, 1, 
1, 2, 2, 2, 2, 1, 1, 3, 1, 2, 
1, 1, 1 
0 
PTEN Loc 3 184 ALL VARIANTS 16, 49, 42, 1, 7, 1, 23, 23, 
23, 8, 3, 8, 2, 1, 1, 1, 1, 4, 
188, 186, 188, 1, 179, 44, 
2, 1, 1, 3, 1, 1, 1, 1, 1, 1, 
1, 2, 2, 2, 2, 1, 1, 3, 1, 2, 
1, 1, 1 
0 
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 Table 7.3 continued. 
Variant* Variant Allele 
frequency 
x/186 
Co-occurring variants* Frequency of co-
occurrence** 
Significance 
(Chi squared 
test)*** 
PTEN Loc 4 186 ALL VARIANTS 17, 49, 42, 1, 7, 1, 23, 23, 
23, 8, 3, 8, 2, 1, 1, 1, 1, 4, 
188, 186, 188, 1, 179, 44, 
2, 1, 1, 3, 1, 1, 1, 1, 1, 1, 
1, 2, 2, 2, 2, 1, 1, 3, 1, 2, 
1, 1, 1 
0 
PTEN Loc 12 1 A9, PK17, PT2, PT3, PT4, 
PT12, PT13, M1, M67 
1, 1, 2, 2, 2, 1, 2, 1, 1, 
1 
PTEN Loc 13 179 ALL VARIANTS 17, 49, 42, 1, 7, 1, 23, 23, 
23, 8, 3, 8, 2, 1, 1, 1, 1, 4, 
188, 186, 188, 1, 179, 44, 
2, 1, 1, 3, 1, 1, 1, 1, 1, 1, 
1, 2, 2, 2, 2, 1, 1, 3, 1, 2, 
1, 1, 1 
0 
MYH7 Loc 1 44 A3, A9, A20, A25, C2, C22, 
C23, C24, PK1, PK2, PK6, 
PK13, PK14, PK15, PK17, 
PT2, PT3, PT4, PT12, PT13, 
M1, M39, M61, M63, M65, 
M66, M67, M73, M92, M95, 
M121, M122, M123, M124, 
M125 
8, 22, 17, 1, 3, 12, 12, 12, 
6, 1, 2, 1, 1, 1, 4, 78, 78, 
78, 1, 74, 44, 1, 2, 1, 1, 1, 
1, 1, 2, 2, 1, 2, 1, 1, 1 
0 
MYH7 Loc 11 2 PK7, PT2, PT3, PT4, PT13, 
M11 
2, 2, 2, 2, 2, 2 
1 
MYH7 Loc 39 1 C22, C23, C24, PT2, PT3, 
PT4, PT13, M1, M39, M61 
1, 1, 1, 2, 2, 2, 1, 2, 1, 1, 
1 
MYH7 Loc 40 1 A9, A20,PT2, PT3, PT4, 
PT13, M40 
1, 1, 2, 2, 2, 2, 1 
1 
MYH7 Loc 61 3 A9, A20, C22, C23, C24, 
PK6, PT2, PT3, PT4, PT13, 
M1, M39,M61, M64 
1, 1, 1, 1, 1, 1, 1, 6, 6, 6, 
5, 3, 1 
0.658 
MYH7 Loc 63 1 A9, C22, C23, C24, PT2, 
PT3, PT4, PT13, M1, M63 
2, 1, 1, 2, 2, 2, 2, 1, 1, 
1 
MYH7 Loc 64 1 A9, A20, PT2, PT3, PT4, 
PT13, M61, M64 
1, 1, 1, 2, 2, 2, 2, 1, 1, 
1 
MYH7 Loc 65 1 A9, A20, PT2, PT3, PT4, 
PT13, M1,M65 
1, 1, 2, 2, 2, 2, 1, 1 
1 
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Table 7.3 continued. 
Variant* Variant Allele 
frequency 
x/186 
Co-occurring variants* Frequency of co-
occurrence** 
Significance 
(Chi squared 
test)*** 
MYH7 Loc 66 1 A20, C22, C23, C24, PT2, PT3, 
PT4, PT13, M1, M66, M73 
1, 1, 1, 1, 2, 2, 2, 2, 1, 
1, 1, 
1 
MYH7 Loc 67 1 A9, PK17, PT2, PT3, PT4, 
PT12, PT13, M1, M67 
1, 1, 2, 2, 2, 1, 2, 1, 1, 
1 
MYH7 Loc 71 1 A20, PT2, PT3, PT4, PT13, 
M71 
2, 2, 2, 2, 1, 1, 
1 
MYH7 Loc 73 1 A20, C22, C23, C24, PT2, PT3, 
PT4, PT13, M1, M73 
1, 1, 1, 1, 2, 2, 2, 2, 1, 
1, 
1 
MYH7 Loc 92 2 A9, PT2, PT3, PT4, PT13, M1, 
M92, 
1, 2, 2, 2, 2, 1, 2, 1 
MYH7 Loc 93 2 A20, C22, C23, C24, PT2, PT3, 
PT4, PT13, M93 
1, 1, 1, 1, 4, 4, 4, 4, 2, 1 
MYH7 Loc 94 2 A3, A20, PK6, PT2, PT3, PT4, 
PT13, M94, M97 
2, 2, 1, 4, 4, 4, 4, 2, 1 1 
MYH7 Loc 95 2 A20, PK14, PT2, PT3, PT4, 
PT13, M1, M96 
1, 1, 2, 2, 2, 1, 2 1 
MYH7 Loc 96 1 A20, PT2, PT3, PT4, PT13, 
M96 
1, 2, 2, 2, 1, 1, 1 
MYH7 Loc 97 1 A3, A20, PK6, PT2, PT3, PT4, 
PT13, M94, M97 
2, 1, 1, 2, 2, 2, 2, 1, 1, 1 
MYH7 Loc 101 3 A9, A20, PT2, PT3, PT4, PT13, 
M101 
1, 2, 4, 4, 4, 4, 3, 1 
MYH7 Loc 121 1 A9, PT2, PT3, PT4, PT13, M1, 
M121 
1, 2, 2, 2, 2, 1, 1, 1 
MYH7 Loc 122 2 A3, A20, C22, C23, C24, PT2, 
PT3, PT4, PT13, M1 
1, 2, 1, 1, 1, 4, 4, 4, 4, 
2, 2, 1 
1 
MYH7 Loc 123 1 A9, A25, PK15, PT2, PT3, PT4, 
PT13, M1, M123 
1, 1, 1, 2, 2, 2, 2, 1, 1, 1 
MYH7 Loc 124 1 A20, C22, C23, C24, PT2, PT3, 
PT4, PT13, M1, M122, M124 
1, 1, 1, 1, 2, 2, 2, 2, 1, 
1, 1, 
1 
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Table 7.3 continued. 
Variant* Variant Allele 
frequency 
x/186 
Co-occurring variants* Frequency of co-
occurrence** 
Significance 
(Chi squared 
test)*** 
MYH7 Loc 125 1 A3, PT2, PT3, PT4, PT13, M1 1, 2, 2, 2, 2, 1, 1 1 
 
Table 7.3: Co-occurrence of variants for the entire population (N= 93). 
*Location numbers were used for ease of analysis, location number abbreviations are: M= MYH7 variant, 
PT= PTEN gene variant, PK= PI3K gene variant, A= AKT1 gene variant, C= CASQ2 gene variant. 
**Frequency of all other variant alleles co-occurring with the variant in column one. 
***Chi-squared test to see if this distribution fits expected random distribution, with a significance level of 
P=0.5. Chi-squared corrected for multiple testing by Bonferroni. Variants highlighted in red are non-
randomly distributed as found by Chi-squared analysis. 
 
As is shown in Table 7.3, variants with the highest allelic frequencies invariably showed less 
randomness in population distribution, and were also more likely to show co-occurrences with other 
high frequency variants. Of particular interest is variants PTEN locations 2, 3, 4 and 13, as well as 
variants at locations CASQ2 locations 22, 23 and 24.  These Variants occur together frequently, and 
are within close physical range to each other. PTEN locations 2, 3 and 4 are within 48bp of each 
other, and also within 60,500bp of variant location PTEN 13.  The close approximation of these 
variants to each other on the chromatid combined with the co-occurrence of these variants together 
in the same individual, in high population frequencies suggests that these variants may be linked or 
within the same haplotype. Similarly variant locations CASQ2 22, 23 and 24 show a very similar 
pattern of distribution over the study population. These three variants regularly occur together, and 
have their chromosomal distance less than 300bp apart. The low approximation of these variants to 
each other significantly reduces the chances of a chromosomal cross over event suggesting that 
these variants are in fact linked, as opposed to a random mutation or cross over event. Figure 7.7 
shows the allelic frequency from Table 7.3 by gene. It can be seen that the high frequency of the 
variant at PTEN location 2, 3, 4 and 13 make up the majority of variant frequency in all the earning 
groups.  
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Figure 7.7: Allelic frequency of amino acid changing and UTR variant locations; by gene. 
The allelic frequency of the variant was counted at each variant location.  All variants in the 5 and 3 UTR 
were included.  PTEN gene variants had the greatest allelic frequency of a non-reference sequence variant. 
Log-linear regression (Poisson regression) analysis used for trend lines, R-values are displayed in the 
corresponding colour to the data set.    
The possibility that certain groups of variants found within the study population may be linked or 
make up a part of some greater haplotype (athletic performance enhancing or not) is of interest and 
should be further investigated. The possibility that certain groups of co-occurrences may be 
connected to earnings group and thus athletic performance variant co-occurrences within high and 
low earnings groups were also analysed. Preliminary analysis of study variant co-occurrences in 
relation to earnings group is performed in Tables 7.4 and 7.5. 
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Variant* 
Variant 
Allele 
frequency 
x/10 
Co-occurring variants 
Frequency of co-
occurrence** 
Significance 
(Chi squared 
test)*** 
AKT1 Loc 9 3 
A20, PK6, PT2, PT3, PT4, PT13, M1, 
M101, M121 
3, 1, 6, 6, 6, 6, 1, 1, 1 
1 
AKT1 Loc 20 3 
A9, PK6, PT2, PT3, PT4, PT13, M39, 
M101 
2, 1, 4, 4, 4, 4, 1 
1 
CASQ2 Loc 22 2 
A20, C23, C24, PT2, PT3, PT4, PT13, 
M1, M39, M61 
2, 2, 2, 2, 2, 2, 3, 2, 1, 
1 1 
CASQ2 Loc 23 2 
A20, C22, C24, PK6, PT2, PT3, PT4, 
PT13, M1, M39, M61 
2, 2, 2, 2, 2, 2, 3, 2, 1, 
1 1 
CASQ2 Loc 24 2 
A20, C22, C23, C24, PK6, PT2, PT3, 
PT4, PT13, M1, M39, M61 
2, 2, 2, 2, 2, 2, 3, 2, 1, 
1 1 
PI3K Loc 6 1 A9, A20, PT2, PT3, PT4, PT13 1, 1, 2, 2, 2, 2 0 
PTEN Loc 2 10 A9, A20, C22, C23, C24, PK6, PT13,  
3, 5, 2, 2, 2, 1, 9, 3, 1, 
1, 1, 1 0.176 
PTEN Loc 3 10 
A9, A20, C22, C23, C24, PK6, PT13, 
M1, M39, M61, M101, M121 
3, 5, 2, 2, 2, 1, 9, 3, 1, 
1, 1, 1 0.176 
PTEN Loc 4 10 
A9, A20, C22, C23, C24, PK6, PT13, 
M1, M39, M61, M101, M121 
3, 5, 2, 2, 2, 1, 9, 3, 1, 
1, 1, 1 0.176 
PTEN Loc 13 9 
A9, A20, C22, C23, C24, PK6, M1, 
M39, M61, M101, M121 
3, 5, 2, 2, 2, 1, 3, 1, 1, 
1, 1 1 
MYH7 Loc 1 3 
A9, A20, C22, C23, C24, PK6, PT2, 
PT3, PT4, PT13, M1, M39, M61 
1, 1, 1, 1, 4, 4, 4, 3, 1, 
1 1 
MYH7 Loc 39 1 
C22, C23, C24, PT2, PT3, PT4, PT13, 
M1,M61 
1, 1, 1, 1, 4, 4, 4, 3, 1, 
1 1 
MYH7 Loc 61 1 
A20, C22, C23, C24, PT2, PT3, PT4, 
PT13, M1, M39  
1, 1, 1, 2, 2, 2, 1, 2, 1 
1 
MYH7 Loc 101 1 A9, A20, PT2, PT3, PT4, PT13 1, 2, 2, 2, 2, 2 1 
MYH7 Loc 121 1 A9, PT2, PT3, PT4, PT13 1, 2, 2, 2, 2 1 
 
Table 7.4: Co-occurrence of variants for the High Earners group (GH, N= 5). 
*Location numbers were used for ease of analysis, location number abbreviations are: M= MYH7 variant, 
PT= PTEN gene variant, PK= PI3K gene variant, A= AKT1 gene variant, C= CASQ2 gene variant. 
**Frequency of all other variant alleles co-occurring with the variant in column one. 
***Chi-squared test to see if this distribution fits expected random distribution, with a significance level of 
P=0.05. Chi-squared corrected for multiple testing by Bonferroni. All variants were randomly distributed as 
found by Chi-squared analysis. 
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High earners had much fewer variant locations present in the group, with no variant co-occurrences 
presenting as a non-randomised distribution (Table 7.4).  This may be a result of a low sample 
population as this group has significantly lower numbers than other groups. This analysis could be 
confirmed with the screening of a larger panel of high earnings Thoroughbreds.  
 
The low earnings group was also analysed (Table 7.5). This group had many co-occurring variants 
displaying non-randomised variant distributions. These included all non-randomised variant co-
occurrences seen in the combined group analysis with the addition of PI3K location 1.  This may 
indicate that in fact these variant co-occurrences are linked to a low earnings haplotype that is 
currently over represented in the current study population (although would also be high in a regular 
population).  This could however, be tested for by increasing the number of high earning 
individuals within the study group to see if the variant co-occurrence distribution becomes 
randomised with a greater number of high earnings individuals.     
Variant* 
Variant Allele 
frequency x/44 
Co-occurring variants 
Frequency of co-
occurrence** 
Significance 
(Chi squared 
test)*** 
AKT1 Loc 3 7         
A9, A20, A25, C2, C22, C23, C24, 
PK1, PK2, PK6, PK13, PK15, PK16, 
PK17, PT2, PT3, PT4, PT1, PT13, 
M1, M61, M64, M65, M67, M71, 
M92, M101, M122 
1, 1, 2, 1, 12, 10, 12, 
12, 3, 1 
0 
AKT1 Loc 9 22         
A3, A20, A25, C22, C23, C24, PK2, 
PK6, PK15, PK17, PT2, PT3, PT4, 
PT12, PT13, M1, M61, M64, M65, 
M67, M92, M123 
1, 4, 1, 1, 1, 1, 2, 2, 1, 
1, 38, 38, 38, 1, 44, 9, 
1, 1, 1, 1, 2 
0 
AKT1 Loc 
20 
17         
A3, A9, C2, C22, C23, C24, PK1, 
PK2, PK6, PT2, PT3, PT4, PT12, 
M1, M61, M64, M65, M71, M101, 
M122 
1,4,1, 5, 5, 5, 1, 1, 6, 
34, 34, 34, 32, 8, 1, 1, 
1, 1, 1 
0 
AKT1 Loc 
25 
1         
A9, PK15, PT2, PT3, PT4, PT13, 
M1, M123 
1, 1, 2, 2, 2, 2, 1, 1 
1 
CASQ2 Loc 
2 
3         
A20, C22, C23, C24, PK1, PT2, PT3, 
PT4, PT13, M1 
1, 3, 3, 3, 1, 4, 4, 4, 4, 
1, 1 
CASQ2 Loc 
22 
11         
A9, A20, C2, PK1, PK2, PK6, PT2, 
PT3, PT4, PT13, M1 
4, 7, 4, 1, 1, 3, 20, 20, 
20, 18, 5 0 
CASQ2 Loc 
23 
11         
A9, A20, C2, PK1, PK2, PK6, PT2, 
PT3, PT4, PT13, M1 
4, 7, 4, 1, 1, 3, 20, 20, 
20, 18, 5 0 
CASQ2 Loc 
24 
11         
A9, A20, C2, PK1, PK2, PK6, PT2, 
PT3, PT4, PK13, M1 
4, 7, 4, 1, 1, 3, 20, 20, 
20, 18, 5 0 
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Table 7.5 continued. 
Variant* 
Variant Allele 
frequency x/44 
Co-occurring variants 
Frequency of co-
occurrence** 
Significance 
(Chi squared 
test)*** 
PI3K Loc 1 3         
A9, PK17, PT2, PT3, PT4, PT13, 
M1 
2, 1, 4, 4, 4, 3, 3 
1 
PI3K Loc 2 1         
A9, A20, C2, C22, C23, C24, PK6, 
PT2, PT3, PT4, PT13 
1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 
1 
PI3K Loc 6 6         
A9, A20, C22, C23, C24, PK2, PT2, 
PT3, PT4, PT13 
2, 8, 3, 3, 3, 1, 12, 12, 
12, 12, 2, 1, 1  0 
PI3K Loc 13 1         PT2, PT3, PT4, PT13, M1, M61 2, 2, 2, 2, 1, 1,  1 
PI3K Loc 15 1         
A9, A25, PT2, PT3, PT4, PT13, M1, 
M123 
1, 1, 2, 2, 2, 2, 1, 1,  
1 
PI3K Loc 16 1         PT2, PT3, PT4, PT13 2, 2, 2, 2,  1 
PI3K Loc 17 3         
A3, A9, PK1, PT2, PT3, PT4, PT13, 
M1, M67 
1, 1, 1, 6, 6, 6, 5, 4, 1,  
1 
PTEN Loc 2 88         A3, A9, A20, A25, C2, C22, C23, 
C24, PK1, PK2, PK6, PK13, PK15, 
PK16, PK17, PT3, PT4, PT12, 
PT13, M1, M61, M64, M65, M67, 
M71, M92, M101, M122, M123 
7, 22, 17, 1, 3, 11, 11, 
11, 3, 1, 6, 1, 1, 1, 3, 86, 
88, 1, 84, 20, 2, 1, 1, 1, 
1, 2, 2, 1, 1,  
0 
PTEN Loc 3 86         A3, A9, A20, A25, C2, C22, C23, 
C24, PK1, PK2, PK6, PK13, PK15, 
PK16, PK17, PT2, PT4, PT12, 
PT13, M1, M61, M64, M65, M67, 
M71, M92, M101, M122, M123 
7, 22, 17, 1, 3, 11, 11, 
11, 3, 1, 6, 1, 1, 1, 3, 88, 
88, 1, 84, 20, 2, 1, 1, 1, 
1, 2, 2, 1, 1,  
0 
PTEN Loc 4 88         A3, A9, A20, A25, C2, C22, C23, 
C24, PK1, PK2, PK6, PK13, PK15, 
PK16, PK17, PT2, PT3, PT12, 
PT13, M1, M61, M64, M65, M67, 
M71, M92, M101, M122, M123 
7, 22, 17, 1, 3, 11, 11, 
11, 3, 1, 6, 1, 1, 1, 3, 88, 
86, 1, 84, 20, 2, 1, 1, 1, 
1, 2, 2, 1, 1,  
0 
PTEN Loc 
12 
1         A9, PK17, PT2, PT3, PT4, PT13, 
M1, M67 
1, 1, 2, 2, 2, 2, 1, 1,  1 
PTEN Loc 
13 
84         A3, A9, A20, A25, C2, C22, C23, 
C24, PK1, PK2, PK6, PK15, PK16, 
PK17, PT2, PT3, PT4, PT12, M1, 
M61, M64, M65, M67, M71, M92, 
M101, M122, M123 
7, 22, 17, 1, 3, 11, 11, 
11, 3, 1, 6, 1, 1, 1, 3, 88, 
86, 88, 1, 84, 20, 2, 1, 1, 
1, 1, 2, 2, 1, 1,  
0 
MYH7 Loc 
1 
20         
A3, A9, A20, A25, C2, C22, C23, 
C24, PK1, PK2, PK6, PK13, PK15, 
PK16, PK17, PT2, PT3, PT12, PT13, 
M1, M61, M64, M65, M67, M71, 
M92, M101, M122, M123 
4, 9, 11, 1, 1, 5, 5, 5, 4, 
2, 1, 1, 3, 36, 36, 36, 34, 
1, 1, 2, 1, 1 
0 
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Table 7.5 continued. 
Variant* 
Variant 
Allele 
frequency 
x/44 
Co-occurring variants 
Frequency of co-
occurrence** 
Significance 
(Chi squared 
test)*** 
MYH7 Loc 1 20         
A3, A9, A20, A25, C2, C22, C23, C24, 
PK1, PK2, PK6, PK13, PK15, PK16, 
PK17, PT2, PT3, PT12, PT13, M1, M61, 
M64, M65, M67, M71, M92, M101, M122, 
M123 
4, 9, 11, 1, 1, 5, 5, 
5, 4, 2, 1, 1, 3, 36, 
36, 36, 34, 1, 1, 2, 
1, 1 
0 
MYH7 Loc 61 2         
A9, A20, PK6, PK13, PT2, PT3, PT4, 
PT13, M64  
1, 1, 1, 1, 4, 4, 4, 4, 
1,  1 
MYH7 Loc 64 1         A9, A20, PK6, PT2, PT3, PT4, PT13, M1 1, 1, 1, 2, 2, 2, 2,1,  1 
MYH7 Loc 65 1         A9, A20, PT2, PT3, PT4, PT13, M1 1, 1, 2, 2, 2, 2, 1,  1 
MYH7 Loc 67 1         
A9, PK17, PT2, PT3, PT4, PT12, PT13, 
M1 
1, 1, 2, 2, 2, 1, 2, 1 
1 
MYH7 Loc 71 1         A20, PT2, PT3, PT4, PT13 2, 2, 2, 2, 1,  1 
MYH7 Loc 92 2         A9, PT2, PT3, PT4, PT13, M1 1, 2, 2, 2, 2, 1 1 
MYH7 Loc 
101 
2          PT2, PT3, PT4, PT13 2, 2, 2, 2 
1 
MYH7 Loc 
122 
1         A3, A20, PT2, PT3, PT4, PT13, M1 1, 1, 2, 2, 2, 2, 1 
1 
MYH7 Loc 
123 
1         A9, A25, PT2, PT3, PT4, PT13, M1 1, 1, 1, 2, 2, 2, 2, 1 
1 
Table 7.5: Co-occurrence of variants for the Low Earners group. 
*Location numbers were used for ease of analysis, location number abbreviations are: M= MYH7 variant, 
PT= PTEN gene variant, PK= PI3K gene variant, A= AKT1 gene variant, C= CASQ2 gene variant. 
**Frequency of all other variant alleles co-occurring with the variant in column one. 
***Chi-squared test to see if this distribution fits expected random distribution, with a significance level of 
P=0.5. Chi-squared corrected for multiple testing by Bonferroni. Variants highlighted in red are non-
randomly distributed as found by Chi-squared analysis. 
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CHAPTER 8: DISCUSSION, CONCLUSION AND FURTHER 
RESEARCH RECOMMENDATIONS 
The results obtained from this study give an insight into the nature of genetic diversity, cardiac-
specific genes, and their possible association with racing performance in the Australian 
Thoroughbred. This study identified a total of 214 sequence variants over the five candidate genes 
screened. Of these, 84 were in coding or UTR regions and 130 were found in non-coding, non-UTR 
regions.  
In conclusion the following was found in each gene: 
 125 novel variants were identified in the MYH7 gene in the study population. Of these, 61 
were found in protein-coding regions or UTRs. Of these variants, 18 were amino acid-
changing, with 10 of these predicted to cause deleterious protein changes.  
 24 novel variants were identified in the CASQ2 gene in the study population. Of these, five 
were found in protein-coding regions. Three of these variants were amino acid-changing, 
with one of these predicted to cause deleterious protein changes.  
 29 novel variants were identified in the AKT1 gene in the study population. Of these, four 
were found in protein-coding regions. All variants were synonymous.  
 14 novel variants were identified in the PTEN gene in the study population. Of these three 
were found in the 5 UTR and two found in the 3 UTR.   
 22 novel variants were identified in the PI3K gene in the study population. Of these, nine 
were found in protein-coding regions. Four of the variants were synonymous. Five of these 
variants were predicted to be amino acid-changing, with three of these predicted to cause 
deleterious protein changes.  
This provides a significant step in identifying cardiac gene-specific variants that may influence 
athletic performance as indicated by earning potential. The candidate gene method used in this 
study provides an excellent tool to produce reliable and useful research without the need for a much 
larger GWAS. Targeted genetic screening using the candidate gene approach has, in this case, 
allowed a detailed preliminary investigation, which despite of its smaller sample size (n = 93), has 
produced an excellent result on which to build further research.  
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Preliminary analysis of the general distribution of variants over the test population shown in the 
results of this study did predict whether variant distribution conforms to known patterns of genetic 
diversity or Mendelian inheritance. This information would be of particular importance as a solid 
base to build upon for further studies in genetic diversity and athletic performance-enhancing traits.  
This has been achieved by performing a two-way Hardy-Weinberg equilibrium (HWE) analysis on 
allele frequencies (to also take into account the unknown dominant phenotype for each novel 
variant location). The HWE distribution of variants in this case can be used as an indicator of 
whether the novel variant identified is the product of the natural genetic variation expected within a 
population, or the result of random spontaneous mutation. Very few of the variant locations 
identified in this study had normal distribution. As stated previously, Thoroughbred horses have 
breed-specific differences making them well-suited for activities involving high athletic 
performance. Thoroughbred horses as a breed are documented to have a slightly larger heart (ratio 
of cardiac muscle to body weight) than other equine breeds normally. This is a characteristic of the 
breed, and has been selected via breeding in the same way as long legs and large lung capacity have 
been selected, because horses with these traits are better suited to racing (see Chapter 1, literature 
review). As Thoroughbreds generally have the breed-specific phenotype of a slightly larger ration 
of heart mass to body mass than other equine breeds, one would expect general breed-specific 
differences such as these to be of high allelic frequency and distribution in the Thoroughbred 
population. 
Within Thoroughbreds as a group there is also a subgroup of horses that have a significantly larger 
heart than the average Thoroughbred heart, and this condition has been associated with elite racing 
success. The Thoroughbred phenotype of a much greater ratio of heart weight to body mass is seen 
in a very small percentage of the Thoroughbred population, so it would be expected that any variant 
contributing to this condition would have a low allelic frequency (Stewart 1981). This study has 
identified three novel variants that were confined to the successful racing group. These three 
variants were found in the MYH7 gene and were not seen in any other racing group. The absence of 
amino acid-changing variants in the CASQ2 gene for mid-range to high-range earning horses 
(groups D to H) was also of interest, and should be investigated further. It would, therefore, be 
prudent to screen a multiple breed panel to confirm any of the widely distributed variants found in 
this study as contributing factors to Thoroughbred heart size. Such activities would also have the 
added benefit of providing breed-specific characterisation of these genes for other equine breeds, 
which is currently lacking. Further screening of a larger panel of Thoroughbreds would increase the 
likelihood of identifying variants responsible for the much larger heart phenotype, and help 
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distinguish these individuals from an already athletically-gifted populous with above-average heart 
size.  
Genetic differences between breeds will account for the breed-specific differences in heart size 
previously documented. This study has shown the great degree of genetic variation seen within 
Thoroughbreds that could be contributing factors to the differences seen between breeds, and also 
for the special case seen in some Thoroughbreds with greater athletic performance.  
In this study it was found that, unlike previous expectations, a greater level of genetic variability did 
not positively correlate to successful racing performance. It was found that less successful racers 
had on average more variants than those with a greater racing success. This suggests that the 
candidate genes within this study are important for cardiac health and athletic performance, and as 
such may be more conserved in highly-performing animals.  
The preliminary co-occurrence analysis performed in Chapter 7 found a significant deviation from a 
randomised or normal allelic distribution for some variant groups suggesting a linkage between 
certain variants and the possibility of a low earnings haplotype. The possibility that certain groups 
of variants found within the study population may be linked, or make up a part of some greater 
haplotype (athletic performance enhancing or not) is of interest and should be further investigated. 
This candidate gene study provides important preliminary research into the genetic influences on 
the Thoroughbred heart. Future research should include the genome-wide screening of a much 
larger equine population for the confirmation of gene variants identified in this study, as well as for 
the identification of potential new variants not seen within this population. Groups of successful and 
unsuccessful Thoroughbred racehorses should also be screened and full haplotype structure analysis 
performed on these groups to identify common (or uncommon) haplotypes in all gene regions, and 
to ascertain haplotype divergence (if any) between them. In this way, further haplotype associations 
to racing performance could also be achieved. Further research recommendations include the 
undertaking of a greater association study to establish links between race performance and 
genotype, as well as the characterisation of the normal gene expression and protein function in 
equine heart tissue for these candidate genes. Individual animals with a genotype predicted to 
produce non-disease state cardiac hypertrophy should be further tested by conducting a range of 
physiological tests, including Doppler sonography, echocardiogram, and ECG, to confirm the heart 
size phenotype to genotype link. Establishment of a link between the genetic control of heart size 
and athletic performance would make way for the development of a screening test to identify 
mutations in, and inheritance patterns of, affected genes. Identification and classification of heart-
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specific developmental or functional genes and their expression in Equus ferus caballus would 
greatly contribute to trait awareness, which in turn would lead to advancements in equine science 
and better equine management and breeding practise.
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APPENDICES 
10.1: Experimental Oligonucleotides 
CASQ2 PCR 
EXON PRIMER NAME PRIMER  TM ANNEALING 
(Celsius) 
BP PRODUCT 
5 CASQ2-EX5F AATTGGCTTCCCACTCTC 51.1 52.3 376 
 CASQ2-EX5R CAGAAATACCCTCCATCCTC 51.3   
6 CASQ2-EX6F TCTGTTGCCGTTTGCTTCCT 57.1 56.7 588 
 CASQ2-EX6R GGCCTAACCCTGCTTACAAGT 56.5   
7 CASQ2-EX7F CCCTCTGACCCATTGTTTGT 54.3 55.6 632 
 CASQ2-EX7R ATGGCAGATTCTGGGCTTGA 55.9   
8 CASQ2-EX8F TGAGGCCCATTCAGTGCTAA 55.6 57.4 489 
 CASQ2-EX8R TTCTCCCAGCTACGTGCATA 55.2   
9 CASQ2-EX9F GCCTAAGAAACCCTCATGGA 53.5 55.6 270 
 CASQ2-EX9R AGGATCTCACGCCAAACCTA 55   
10 CASQ2-EX10F CCACAGCTGTTTTGGAAACC 54.5 56.3 363 
 CASQ2-EX10R CACACTGGCATGTTTCCTGA 55.1   
11 & 12 CASQ2-EX11+12 CTGCAGGTAGGGATTTCCTT 53.5 55.5 801 
 CASQ2-EX11+12 GTCTTCCCTGGGCTCTGATTA 55.3   
 
CASQ2 SEQUENCING 
EXON DIRECTIO
N 
NAME SEQUENCE ANNEALING  
(Celsius) 
5 F CASQ2-EX5F-SEQ GGGAAATTTCTGCAGTGTG 51.5 
5 R CASQ2-EX5R-SEQ GGAGGATGGTTAATGTTGC 50.6 
6 F CASQ2-EX6F-SEQ TGCGTCGAGCATGCACTTT 57.8 
6 R CASQ2-EX6R-SEQ ATCCCTGCCACTGATCAA 52.3 
7 F CASQ2-EX7F-SEQ ACGGTTGGATTCAATGGG 51.8 
7 R CASQ2-EX7R-SEQ TGTGTAGGCCAAAGAGGT 52.2 
8 F CASQ2-EX8F-SEQ TCAAACTCCACGCATGCCT 56.7 
8 R CASQ2-EX8R-SEQ ATGGATGCGTGCCTCACA 56.3 
9 F CASQ2-EX9F-SEQ CTCCACGTTAGAAGCTGT 50.8 
9 R CASQ2-EX9R-SEQ CTCACGCCAAACCTAAAC 51 
10 F CASQ2-EX10F-SEQ TACTCTGATGGGATGGCA 51.3 
10 R CASQ2-EX10R-SEQ TGAAGGGTCCTGCTCATT 52.2 
11 F CASQ2-EX11F-SEQ TCAGCACAGCTACTCAGCA 55.4 
11 R CASQ2-EX11R-SEQ AAGGTAGTGGGTAGCTGT 51.1 
12 F CASQ2-EX12F-SEQ CGTGCTTTCTGGGAAGAT 51.6 
12 R CASQ2-EX12R-SEQ CGGTCATGGTCAAAGACA 51.6 
 
 127 
CASQ2 PCR 
Acknowledgment: These oligonucleotides designed by AT. 
EXON PRIMER NAME PRIMER  TM ANNEALING 
(Celsius) 
BP 
PRODUCT 
1 CASQ2-EX1F7p-AT GGCCAAGCTATGTGAGGTATCT 55 57 444 
 CASQ2-EX1R2p-AT GAAATGCAGGGAGTCTTCAGG 54   
2 CASQ2-EX2F1p-AT AGGGTGTGTGACAGTGGATA 52 55 567 
 CASQ2-EX2R1p-AT ACCTGGGAGCTGAAAACTGA 52   
3 CASQ2-EX3F3-AT CCAGGTAGAATTGTTGGTTCTTG 53 54 502 
 CASQ2-EX3R3-AT CTCTGGGGATGTTGGTGTATAG  55   
4 CASQ2-EX4F4-AT GTCATTGGTCAGCATTGGGT 52 55 480 
 CASQ2-EX4R4-AT TGCCAACATCAGGCAGAAAG 52   
CASQ2 SEQ 
Acknowledgment: These oligonucleotides designed by AT. 
EXON DIRECTION NAME  SEQUENCE ANNEALING 
(Celsius) 
1 F CASQ2-EX1F1s-AT GGAGGGGAAGAGTCGGTT 52 
1 R CASQ2-EX1RAs-AT CCCTCCTTCCCACGTCC 54 
2 F CASQ2-EX2F1s-AT AGGTCTGATCCTCACAGT  48 
2 R CASQ2-EX2R2s-AT AGTGTCAGTTTCTGCAGG 48 
3 F CASQ2-EX3F1s-AT GAAGCCCTTCAGAAGTGT 48 
3 R CASQ2-EX3R1s-AT AGTCCTGATTTGTGACCC 48 
4 F CASQ2-EX4F2s-AT TCCTCAAAAGGCACTGCT  48 
4 R CASQ2-EX4R2s-AT TTCAGCTCCTCTGCCTAT 48 
 
MYH7 PCR 
EXON PRIMER NAME SEQUENCE TM ANNEALING  
(Celsius) 
BP 
PRODUCT 
1+UTR MYH7-1AF ACCTGCAGGCTTGAGCTTCTTT 55 55.3 135 
 MYH7-1AR CCAAGACATTCTCCCCAAGGCAA 57   
1 MYH7-1BF AAAGAGGGACTCGCCAGTGA 54 59.5 474 
 MYH7-1BR ACCCAAAGGAAGGGGAAATCGGA 57   
1 MYH7-1F-P GGATTAAGACTCAGAGTTGGGT 53.5 55.9 339 
1 MYH7-1R-P CTCCCCAAGGCAAGATAGAAAC 55.1   
2 MYH7-2F CTCTCCTGAACATGGTTGTCCT 55 57.5 339 
 MYH7-2R GGCGCAAAGAACAAACTCTTGG 55   
3,4 MYH7-3.4F  TCCCTGGCAACTCACTCCTTTT 55 59 525 
 MYH7-3.4R TGGCATGAAGGTGGAGGGAAAGA 57   
5,6,7 MYH7-5.6.7F AGCTGTGTGTTTGGGATGCGTA 55 58.7 681 
 128 
 MYH7-5.6.7R  AGAGAGCGAGAGGTTGAGCTTGA 57   
8 MYH7-8F  TCCGTGTGTCTGTGTCTGAGTCT 57 55.9 274 
 MYH7-8R  TTGGTCTCGGTTGGTAGCTCTGA 57   
9 MYH7-9F GTTTGTGCCCACATCCTAACCA 55 57.2 269 
 MYH7-9R ACAGGGCCATACCACTTTGAAC 55   
10,11,12 MYH7-10.11.12F  ACCCATAGGGAGTCAGGAGACAA 57 58.9 861 
 MYH7-10.11.12R  AATGACTGCCTCCATCACTGCT 55   
11 MYH7-EX11F-
NEW 
TACCCACTTCGCTACCTTCCCTTT 59.4 57.4 144 
 MYH7-EX11R-
NEW 
ACATTCTGCCCCTTGGTGACAT 58.5   
13 MYH7-13F  AGCAGTGATGGAGGCAGTCATT 55 59.2 503 
 MYH7-13R TACTCTGTCTTGGGTGGCCAGAA 57   
14,15 MYH7-14.15F  GGATCCATCTCCATCTGCATGA 55 58.1 853 
 MYH7-14.15R  AATGGAGAGGACGAGAAGCTCA 55   
14-15 MYH7-EX14-
15F-NEW 
AGGCCAAGCTGTTTGACAACCA 59.5 57.5 246 
 MYH7-EX14-
15R-NEW 
TACGTGCATCAGCCCCAAGATAGT 59.5   
16 MYH7-16F  CCCAGCATTCCTTCACTCTCTT 55 56.3 372 
 MYH7-16R  AGGGAGGCATAATCTCTGAGAC 55   
17,18 MYH7- 17.18F AGCCAAGAGCAGAACCCAGAAA 55 59.3 593 
 MYH7- 17.18R AGGGGTAGCATGTGGTTCAGAGA 57   
19 MYH7- 19F TGCCATTGACCTTCTCCCCATA 55 58.2 288 
 MYH7-19R AGATGGCTGGGAAGCTCCTTTT 55   
20 MYH7-20F TGGATGAAGGAAGGGGCCGTAA 57 60.1 444 
 MYH7-20R AAGATGGTGAGCCCCTGGGTT 56   
21,22 MYH7-21.22F CTAGCTGAGGATATCCTGGAGA 55 59 783 
 MYH7-21.22R CCCAAACACACAGACACACA 52   
23 MYH7-23F  ACTGGTAATGTGTGGCCCACTT 55 58.7 433 
 MYH7- 23R TTGCAGGCCTTTGCCCACTTAT 55   
24 MYH7- 24F TACCTTTAGGGACCCTACGTCA 55 57.4 344 
 MYH7- 24R AGCAAGTGCCTGTAATGCTG 52   
25 MYH7-25F  TCCACCGGGAGAACTAAACTGA 55 59.3 654 
 MYH7-25R AAGAGACAGGAAGAGGGAAGGCA 57   
26 MYH7-26F  TCAATGGCACCCCTTTCAGTGT 55 58 335 
 MYH7-26R CCCACTCAACTCTTCAAGGTCA 55   
28 MYH7-EX28B-F-
NEW 
AAGTATGAGACAGACGCCATCCAG 58.4 58.8 348 
 MYH7-EX28B-R-
NEW 
TTCTTGTGGCGTCCCTTTGA 56.4   
27 MYH7-27F  AAGAGTTGAGTGGGCCTTGGT 54 58.5 245 
 MYH7-27R  ACAGCAAGCCTCATTCTTGGGA 55   
28 MYH7-28F AGGAAACTCTTCCAGGTCCACT 55 59.5 412 
 MYH7-28R  TGCTGTCAAAACCTCGCTGAAC 55   
29-30-31 MYH7-EX29-30-
31NEW 
TGCAGAATGAGATCGAGGACCTGA 59.3 61 627 
 MYH7-EX29-30-
31R-NEW 
TTCTCCAGCTCGTGGATGGTCTTT 60   
29,30,31 MYH7-29.30.31F  TGTCCAAATCTGCACCCTCCAT 55 60.9 927 
 129 
 MYH7-29.30.31R  TGTTCTAGGCCCTGAGAATGCCA 57   
32 MYH7-32F ACCACTCTTGAACTCGCTTTGT 53 59.2 554 
 MYH7-32R TCCAGTGGGTTGTCTCTGCAAT 55   
34 MYH7-EX34F-
NEW 
TGCTCAGCGCTTTTCATGCTCT 59.8 56.7 103 
 MYH7-EX34R-
NEW 
TTCAGTCTGAAGCTGGGACAGGT 59.6   
33,34,35 MYH7-33.34.35F ATTGCAGAGACAACCCACTGGA 55 60.2 1087 
 MYH7-33.34.35R  TGGAAGAGGCTGAGGGAAAACA 55   
33-34 MYH7-EX33-
34F-NEW 
CCACTAGCATCCAGTTTGGCGTTA 59.3 59.9 474 
 MYH7-EX33-
34R-NEW 
TTCAGTCTGAAGCTGGGACAGGT 59.6   
34-35 MYH7-EX34-
35F-NEW 
AGTGAGTGCGTGAGGACTTA 55 59.1 506 
 MYH7-EX34-
35R-NEW 
ACTCAAGGTAGAACAGGGTTAGGC 57.9   
36 MYH7-36F CAAGTGTTTGGTGAGGGTCAGA 55 59.1 369 
 MYH7-36R CGCTCACCAACATTCATGCAGA 55   
37 MYH7-37F TGAATGTTGGTGAGCGGTGAGA 55 60 401 
 MYH7-37R TGGGGCTTTGCAGTCAGTTCTA 55   
38 MYH7-38F AGCATCCTTCCACCCATCAGGTT 57 58.6 209 
 MYH7-38R CAAAGGGGCTGCAATTTGCGTT 55   
40 MYH7-40F-P CTCCGGAACTTTCCCTCTACA 55.3 57.9 582 
40 MYH7-40R-P TTCCTTCAACCCAGAGTGTC 53.7   
 
MYH7 SEQUENCING 
EXON DIRECTION NAME SEQUENCE ANNEALING 
(Celsius)  
1 F MYH7-1F-S ACCACTTCCCACCCATTT 52.7 
1 R MYH7-1R-S TTCCCAGAATCCCTCACA 51.4. 
8 R MYH7-8R-S AGCAGTGCCATAAACCCA 53.3 
9 F MYH7-9F-S AGGACCCCATTAAGTTCTG 50.5 
11 F MYH7-11F-S CCTGCCACACTTCCTTT 51.2 
11 R MYH7-11R-S GGTAGCGAAGTGGGTAAA 50.9 
12 F MYH7-12F-S TAGGGGTCTTGGATGCTG 52.5 
12 R MYH7-12R-S AAGCTCCTACTGCACCAT 52.4 
13 F MYH7-13F-S TGGTGCAGTAGGAGCTTT 52.6 
13 R MYH7-13R-S AGCTGGCTCTACAAACAGT 53 
14 R MYH7-14R-S GGGGCTTCCATTTTGTCT 51.7 
14.15 R MYH7-14.15R-S1 ACGAGCAAGGCAGGGAAGA 58 
14.15 R MYH7-14.15R-S2 GCAGGGTGAAGAATCACA 51.5 
14.15 R MYH7-14.15R-S3 TTGGGGCACAACCTGACA 55.9 
20 F MYH7-20F-S GAAGGAAGGGGCCGTAA 52.8 
20 R MYH7-20R-S ATGGTGAGCCCCTGGGTT 57.4 
20 F MYH7-20F-S2 GCCGTAACCTAGGAGTCA 52.3 
20 R MYH7-20R-S2 TTGGAGGCGCAGGGTGTGT 61.1 
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21 - 22 F MYH7-21.22F-S TGCCAGGGCAAGTACCTC 55.9 
22 - 22 R MYH7-21.22R-S CACACAAGCACAGATGGA 51.9 
26 F pre/myh7-ex26F TTCAATGGCACCCCTTTCAGTGTC 57 
26 R pre/myh7-ex26R AAACTGAGGTGGGGCTTACCATTC 57 
26-27 F myh7-ex26-27F TTCAATGGCACCCCTTTCAGTGTC 57 
26-27 R myh7-ex26-27R CAGCAAGCCTCATTCTTGGGAAGT 57 
29 F MYH7-29F-S AAATCTGCACCCTCCATC 51.2 
29 R MYH7-29R-S ACAGAATGTCCTCCTTGA 49.1 
30 F MYH7-30F-S GGCCTGGTGTCCTCAAG 53.9 
30 R MYH7-30R-S ACCATATGTGGACACTACC 50.3 
31 F MYH7-31F-S CCACATATGGTGCCACCTA 53.3 
31 R MYH7-31R-S CCCTGAGAATGCCACAGT 53.5 
34 F MYH7-34F-S AGGTTTGGGAGCTACTCA 51.5 
34 R MYH7-34R-S TAAGTCCTCACGCACTCA 52.1 
40 F MYH7-40F-S ACAGCATCCTTCCACCCAT 55.3 
40 R MYH7-40R-S GTCTGGCCTGTGAAGCTGT 56.3 
34-35 F MYH7-34-35seqF CTTAGCCCGCCGGTGCA 57 
 
PTEN PCR 
EXON PRIMER NAME SEQUENCE TM ANNEALING 
(Celsius) 
BP 
PRODUCT 
1 PTEN-ex1F TCAGGCGAGGGAGATGAGAGAC 58 61.5 867 
 PTEN-ex1R AGCCGCAGAAATGGATACAGGT 55   
1 PTEN-EX1F CGGCCTCAGCTTTTCCTTCATT 57.8 60.3 1536 
 PTEN-EX1R AGAAACTCGACCAGGGTTAACG 56.7   
1 PTEN-EX1F-
NEW 
TTCTCCTGAAAGGGAAGGTGGAAG 58.1 59.3 1125 
 PTEN-EX1R-
NEW 
GATGCAACATGCGTACGTGCAA 59.3   
2 PTEN-ex2F  GCACACTTTGACACCCTT 48 52 488 
 PTEN-ex2R  CCAGACACTAACTTGGTGAGAG 55   
3 PTEN-ex3F  CTCACAACTCTGTGTGAGCTAGGT 57 53.7 683 
 PTEN-ex3R  GCTCAAAGATGGGCTAGATGCCAA 57   
4 PTEN-EX4F-
NEW 
CGCCAAATTTAACTGCAGAGGT 56.2 51.8 299 
 PTEN-EX4R-
NEW 
GTCGTTCTGCTTTCTCCATGCAA 58.2   
4 PTEN-ex4F  TGTGTATGCTCAACTGTGGGGTAA 56 54.1 995 
 PTEN-ex4R  ATAACTCGTGGCACCCACTTTCTC 57   
5 PTEN-ex5F  TTGGCTTCCCTGTCTAATGG 52 52.1 455 
 PTEN-ex5R  TCTCTGGTCCTTACTTCTCC 52   
5 PTEN-EX5F-P CGCAGCATTCCTAAAGTTAACC 54.5 52.7 483 
 PTEN-EX5R-P CGAATCAGTCATTTGCTCACA 53.5   
5 PTEN-5F-P2 TACTTGGCTTCCCTGTCTAA 52.1 51.7 705 
5 PTEN-5R-P2 TGAGACCAAACATGAAACAC 50.8   
6 PTEN-ex6F  CCTTTGTTTTGGTGTTGCTCCGAT 56 53.4 519 
 PTEN-ex6R  TCGCTCTTGTCTTCCTTAGCTC 55   
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7 PTEN-ex7F  GACAGTTTGGCAGTTAAAGGCA 53 53.7 641 
 PTEN-ex7R  TTCCAACTCTTGGTCCCATGCT 55   
8 PTEN-ex8F  GCAGGTAACCTACAGATTGCCA 55 53.3 626 
 PTEN-ex8R  GCCCCAGATTTCACCAAACACT 55   
9 PTEN-ex9F  TCTCTGAGTAGCCATGCGGATGTT 57 54.9 3574 
 PTEN-ex9R GCTGCACAGCACAAGAGTATCTGA 57   
9 PTEN-EX9F-
NEW 
AGGAGCCATCAAATCCAGAGGCTA 59.3 54.7 588 
 PTEN-EX9R-
NEW 
CTGTTGCCACAAGTGCAAAGG 58.5   
 
PTEN SEQUENCING 
EXON DIRECTION PRIMER NAME SEQUENCE TM ANNEALING 
1 F PTEN-1F-S3 CTTCATTTCTCCCCACACT 19 51.1 
1 F PTEN-EX1F-S1 GGCCGGTTTTAAACCTC 17 50.2 
1 F PTEN-EX1F-S2 GCCTCAGCTTTTCCTTCA 18 51.8 
1 R PTEN-EX1R-S1 TTTCGCATCCGTCTACTCC 19 53.8 
1 R PTEN-EX1R-S2 GAGGGGAGGTTTAAAACCG 19 52.3 
1 R PTEN-EX1R-S3 AAGAGGCTGCACGGTTA 17 52.7 
1 F PTEN-1seqF GCTGCAGTCATGATGGAA 18 52 
1 R PTEN-1seqR AGCCGCAGAAATGGATACAG 20 54.7 
4 F PTEN-4F-S2 TGGTTGTTTACACATGTGA 19 49.1 
4 R PTEN-4R-S2 AGCAACTGCCAAGCTTC 17 52.5 
4 F PTEN-EX4F-S ACTGCTGTGACAGTAAGAC 19 51.3 
4 R PTEN-EX4R-S AACATGATGCCTGGTACA 18 50.3 
5 F PTEN-5F-S2 ATGCTAGCATGAACGGA 17 50 
5 R PTEN-5R-S2 CTCTGGAGTTCAGTTTT 17 45.1 
5 F PTEN-EX5F-S GCAGCATTCCTAAAGTT 17 50.9 
5 R PTEN-EX5R-S CAGTCATTTGCTCACATGAA 20 46.4 
5 F PTEN-EX5F-S GCAGCATTCCTAAAGTT 17 50.9 
5 R PTEN-EX5R-S CAGTCATTTGCTCACATGAA 20 46.4 
8 F PTEN-8seqF CTTTATACCAGGACCAGA 18 50 
9 F PTEN-9F-S1 GGTGAATCTTCCTCAGCA 18 50.8 
9 F PTEN-9F-S2 CACAGGGTTTTGACACTTG 19 51.3 
9 F PTEN-9F-S3 TTGGCCGCTGTCACTGCTT 19 59.6 
9 F PTEN-9F-S4 ATCAAGGCCAGTGCTAAA 18 50.6 
9 F PTEN-9F-S5 TGCCCAGACTGCATATGA 18 52.5 
9 F PTEN-9F-S6 ATGGGCTTTTGCACTGT 17 51.5 
9 R PTEN-9R-S1  CACATCAGTCTGTCTCCA 18 50.1 
9 R PTEN-9R-S2 TCATTGTTGCTGTGTTTCC 19 51 
9 R PTEN-9R-S3 TGGAACGGCTGACAGCTAT 19 55.3 
9 R PTEN-9R-S4 TGCAGTCTGGGCATATC 17 50.5 
9 R PTEN-9R-S5 AGACCACAGCTAGTGAAC 18 50.5 
9 R PTEN-9R-S6 CAGTGCAAAAGCCCATT 17 50.3 
9 R PTEN-9R-S7 GCTGAATCAGAGTAAGGCT 19 51.1 
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PI3K PCR 
EXON PRIMER NAME SEQUENCE TM ANNEALING 
(Celsius) 
BP 
PRODUCT 
1 Pi3k-ex1F CCAGTGGAGTGCAACAGCAAAATC 57 57.8 803 
1 Pi3k-ex1R TGACTTCTGCCCAAGCATTACAGC 57   
2a Pi3k-ex2aF TGTTTGCAGCTTTGACGCTTCC 55 56.8 126 
2a Pi3k-ex2aR TGGGTCCCTCTTCCAGCTGATT 57   
2b Pi3k-ex2bF GGGCCTGAGATTGCTTCTGTTTGA 57 56.6 354 
2b Pi3k-ex2bR TTCCCCAGGACACAGCTCCAAATA 57   
3 Pi3k-ex3F AGACACTGGATGGAGACTGGAACA 57 57 346 
3 Pi3k-ex3R AGCATCAAAGGTCGGCATGGTT 55   
4 Pi3k-ex4F CAGCAAATTGCCCCAACCAACT 55 55.8 369 
4 Pi3k-ex4R GATGCCATGGTGTGGGAATTTGTG 57   
5 Pi3k-ex5F AACGCATGTCCTGTCTGCTTCT 55 55.3 453 
5 Pi3k-ex5R GTGCACCTGCGAACTGGTATCTTT 57   
6 Pi3k-ex6F AGTTCGCAGGTGCACGTACAT 54 55.1 452 
6 Pi3k-ex6R AGCATAAAAGTTGAGGGGAACGGA 56   
7 Pi3k-ex7F AATCTACAGCACTGCCTCCCAAAC 57 56.1 541 
7 Pi3k-ex7R GCACAGACAGCTGTGATCTCAAG 57   
8 Pi3k-ex8F GAGATACAGCCGATGGGACCTTTT 57 55 429 
8 Pi3k-ex8R TGCAGGTCCTTCTAGTTGTGGGAT 57   
8 PI3K-EX8F GCCCTGTGGACTTTCTGTT 54.4 53.4 390 
8 PI3K-EX8R CCATATTTCCCATCTCGGTG 52.4   
9 Pi3k-ex9F CATGGCGATTACACTCTGAC 52 51.7 673 
9 Pi3k-ex9R CTGATCCTAGAAGGATGACG 52   
10 PI3K-10F-P2 TCAGTGCTTGGTAATGAAGT 51.2 51.1 614 
10 PI3K-10R-P2 CTTGTTAGCTTCCAATCCG 50.7   
10 Pi3k-ex10F TACTCGCACTTCCCAGGTGAGTT 57 54.9 461 
10 Pi3k-ex10R GTCCCAGATACATGACGGCCTAGA 59   
10 PI3K-EX10F TTCCACGTCAGCTATTTTGT 52 51.1 537 
10 PI3K-EX10R TTGTGGAACTTCCAGTTCT 50.6   
11 Pi3k-ex11F ACGCGAAGGCAACGAGAAAGAA 55 55.4 383 
11 Pi3k-ex11R GCGTTTGTCAATCTCGCGATAC 55   
12 PI3K-EX12F AACTGCTGGGCATCCATA 52.7 53.2 417 
12 PI3K-EX12R CAACCACTCGTTCAACTTC 51.2   
12-13a Pi3k-ex12+13aF GCCGAGTATCGCGAGATTGACAAA 57 55.9 695 
12 Pi3k-ex12+13aR TCAAGTCAGCAACTAGGCTCAGGT 57   
12-13b Pi3k-ex12+13bF GGGCCTTTCTCTTGTCTGCAGAAT 57 55.9 807 
12 Pi3k-ex12+13bR TCAAGTCAGCAACTAGGCTCAGGT 57   
14 PI3K-EX14F GAGGAAAACTCAGGCCAGGAAA 56.8 56.7 577 
14 PI3K-EX14R TGCTGAATTGGGACCCAAAC 55.3   
14 Pi3k-ex14F TTCCCGCCCACTTAGCCAATATTC 57 56.7 643 
14 Pi3k-ex14R ACAGTGACCAGGGTCCTTTCTCTT 57   
15 Pi3k-ex15F GCTCTCTGAAAGAACTGGTGCTAC 57 56.2 1611 
15 Pi3k-ex15R CTGAAATATCTGGCCAGCTGCACT 57   
15 PI3K-EX15F-NEW TGCATGCGTACTGCATTCTAGG 57.5 57.1 638 
15 PI3K-EX15R-NEW TGGCTTCCACGGCTCAATTCA 59.1   
15 Pi3k-ex15aR TCCGGTCTACAAGGTCCCAACTTT 57   
15a Pi3k-ex15aF CGGCGAAGTGAAGCATTGTGTCAT 57 58.1 575 
 133 
EXON PRIMER NAME SEQUENCE TM ANNEALING 
(Celsius) 
BP 
PRODUCT 
15 Pi3k-ex15bR CCAGGAAGTCCGTAATTGTCACTC 57   
15b Pi3k-ex15bF CAGACACGTCGCACTGTGGATTAT 57 54.7 992 
 
PI3K SEQUENCING 
EXON DIRECTION PRIMER NAME SEQUENCE ANNEALING 
5 F PI3K-5F-S CTGCTTCTTCTGTTGACT 48.8 
5 F PI3K-EX5F-SEQ GTGGTACCTAGAAACTCTC 48.2 
5 F PI3K-EX5F-SEQ GTGGTACCTAGAAACTCTC 48.2 
8 R PI3K-8R-S CCTTTCCTGTGAATACAGT 48.6 
8 F PI3K-EX8F-SEQ GCTGTGAACCTAAAACTGC 51.6 
8 R PI3K-EX8R-SEQ TCATGTCCACCTGAACACC 53.8 
10 F PI3K-10F-S2 CTTTACACTCGTGATCACA 49.3 
10 R PI3K-10R-S2 TGCATTTCTCCAGTCAACC 52.2 
10 F PI3K-EX10F-SEQ CCACGTCAGCTATTTTGTT 50.5 
10 R PI3K-EX10R-SEQ CCCGACTTCATGTGCAAA 52.6 
11 F PI3K-EX11F-SEQ TCCTGCCTTGTTCACAGA 52.6 
11 R PI3K-EX11R-SEQ TGCCCAGCAGTTTCCTTCA 56.2 
12 F PI3K-EX12F-SEQ GGGCATCCATATTGAAACT 49.4 
12 F PI3K-EX12F-SEQ TGGGGAACCCTCATAATGC 53.5 
12 R PI3K-EX12R-SEQ TGAGTCAACCACCTGAAAG 51.5 
14 F PI3K-EX14F-SEQ AAAGCTGGTCGAGTCCAA 53 
14 R PI3K-EX14R-SEQ CAAACCCCAGTCTTCCAA 51.2 
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AKT1 PCR 
EXON PRIMER NAME SEQUENCE TM ANNEALING 
(Celsius) 
BP 
PRODUCT 
1 Akt1-ex1F AACGACGTGGCCATCGTGAA 54 62.4 401 
 Akt1-ex1R GCCCCAGTGTCCTCACTACCTT 58   
2 Akt1-ex2F TTGGTACCTGTGCCTTTGGGTAGA 57 61.4 728 
 Akt1-ex2R ACAGGGGTCCAAGAACCTTCA 54   
3 Akt1-ex3F AGGGGTCCCAGCCCTGTTTTATAG 59 60.9 354 
 Akt1-ex3R CGTTTCTGGAGCAGGCTCTGA 56   
4 Akt1-ex4F  TCCTCAGAGCCTGCTCCAGAAA 57 61.5 551 
 Akt1-ex4R  TCTGGAACCTCACTTCCGACACA 57   
5 Akt1-ex5F AGGTGATTCTGGTGAAGGAGAAGG 57 60.3 346 
 Akt1-ex5R  TCGGTCCCAGAACAGACATCCAT 57   
6 Akt1-ex6F  AGGCTCTCAAGTACTCCTTCCA 55 59.4 188 
 Akt1-ex6R  CAGGCTGAGACCCTAACTCAGAA 57   
7 Akt1-ex7F  TCGTGGTCCTGCAGCTCTT 53 60.5 266 
 Akt1-ex7R  TGATCTTGATGTGCCCGTCCTT 55   
8 Akt1-ex8F  TGGACTACCTGCACTCTGAGAA 55 59.6 375 
 Akt1-ex8R  GGAGAACATGGACACAGAGGACAA 57   
8 AKT1-EX8F-PCR CTGCCCTGTGGGTGACCT 58.2 60.9 403 
 AKT1-EX8R-PCR CCGTCCTTGTCCAGCATGA 56.5   
9 Akt1-ex9-10F  TCTCCTTGTCCTCTGTGTCCAT 55 60.6 859 
 Akt1-ex9-10R AAGGGAGCTCTGGTACTCAAAC 55   
9 AKT1-EX9F-PCR TCGTCTACCGTGACCTCAA 54.5 59.2 337 
9 AKT1-EX9R-PCR ACACAGAGGACAAGGAGACA 54.5   
9--10 AKT1-EX9-10F-NEW GAAGCTCTTCGAGCTCATCCTCA 58.3 61.1 403 
 AKT1-EX9-10R-NEW ATCAAGCCCCACGCACCTTCT 60.8   
11 Akt1-ex11F TGTGTCTCCTTCCCAGAGCTTTGT 57 60.6 502 
 Akt1-ex11R AGCCTCCCAGACTCTATTTGGTGA 57   
11 AKT1-EX11F-NEW TGTCTCCTTCCCAGAGCTTTGT 57.6 60.1 501 
 AKT1-EX11R-NEW CAGCCTCCCAGACTCTATTTGGT 57.9   
12a Akt1-ex12F ACATCGGAGACAGACACCAGGTAT 57 60.5 391 
 Akt1-ex12R TCGCTGTCCACACCCTCCAT 56   
12b Akt1-ex12F TACTTCCTAAGTTGGGGCTTGGCT 57 60.4 558 
 Akt1-ex12R TGGCCGAGTAGGAGAACTGG 56   
12 AKT1-EX12F-NEW TGCCTACAGACGACACGATGGA 59.8 60.1 371 
 AKT1-EX12R-NEW CGAGGCCACACCGGATGAAATAAA 59.6   
 
AKT1 SEQUENCING 
EXON DIRECTION  PRIMER NAME SEQUENCE ANNEALING (Celsius) 
8 F AKT1-EX8F-SEQ TGGAGGTGGCTGGGAT 53.5 
8 R AKT1-EX8R-SEQ TGTCCAGCATGAGGTTC 50.7 
9 F AKT1-EX9F-SEQ ACCGTGACCTCAAGGTG 53.1 
9 R AKT1-EX9R-SEQ AAGGAGACACGGGGACAT 54.4 
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AKT1 PCR 
Acknowledgment: These oligonucleotides designed by AT. 
EXON PRIMER NAME SEQUENCE TM ANNEALIN
G (Celsius) 
BP 
PRODUCT 
1 AKT1-1R1-AT GTCCTCACTACCTTCCAGGAAA 55 60.7 688 
1 AKT1-1F2-AT CCAGGGAGCAGTTTGAGTAACA 55   
5 to 6 AKT1-ex5-6-F1-AT AGGTCCATGGTGAGGAAG 50 60 543 
5 to 6 AKT1-ex5-6-R1-AT GTCCCAGAACAGACATCCA 51   
7 AKT1-ex7-F1-AT CTCCCCAGCCCCAGACTT 55 61 354 
7 AKT1-ex7-R1-AT CCCATCCCAGCCACCTCCA 57   
8 to 9 AKT1-ex8-9-F1-AT AGCTGTGTGGGGTGCCTG 55 60.1 669 
8 to 9 AKT1-ex8-9-R4-AT ACCAGGGACACAGGATCA C 53   
10 to 11 AKT1-10-11-F2-AT CCCGTGTCTCCTTGTCCTCT 56   
 AKT1-10-11-R1-AT CTGCCCCACTCCATTGCC 55   
13 AKT1-13-F3-AT TGCAGGTCCACGTTTGATG 51 59 625 
 AKT1-13-R3-AT TGGCTGCAGAAGTCCTCAA 51   
 
AKT SEQUENCING 
Acknowledgment: These oligonucleotides designed by AT. 
EXON DIRECTION PRIMER NAME SEQUENCE ANNEALING 
(Celsius) 
1 F AKT1-1Fseq-AT AGAACTTGGTATCAGGAG 46 
1 R AKT1-1Rseq-AT CATGCCAAGGGGACGTC 49 
2 R AKT1-2Rseq-AT CAGACACAGAGGCTCAG 49 
3 R AKT1-3Rseq-AT CTGAGGAGGCCTGGGAG 54 
2 F AKT1-2Fseq-AT GTCAACTGCTGATTCGC 47 
4 F AKT1-ex4-Fseq2-AT TCTCTCTGGGGTCTCTG 49 
5 to 6 F AKT1-ex5-6-Fs2-AT GAAGGGGACCCGCTTGTG 55 
5 to 6 R AKT1-ex5-6-Rs2-AT TTCAGTGACAGGCTGGTG 50 
13 F AKT1-13-Fs1-AT GGGTCACCAAATAGAGT 44 
13 R AKT1-13-Rs1-AT AGTCCTCAACGTTTTCC 44 
7 F AKT1-ex7-Fs2-AT TTGCCCAGACCCCCAGT 52 
7 R AKT1-ex7-Rs2-AT GAGAGGGTAACTCAGAA 44 
8 to 9 F AKT1ex8-9-F6s-AT GGAGGTGGCTGGGATGG 54 
8 to 9 R AKT1ex8-9-R6s-AT GGGACATGGGGAGACACA   52 
10 to 11 F AKT1-10-11-Fs2-AT GCTGTCCACCTCACCAA 49 
10 to 11 F AKT1-10-11-Fs4-AT TCCTCTGTGTCCATGTT 44 
10 to 11 R AKT1-10-11-Rs1-AT CGGTGCCGAGGAAGAAA 49 
10 to 11 R AKT1-10-11-Rs2-AT GCATGGGTGGGTGTGAG 52 
12 F AKT1-12-Fs1-AT GGAGACGTGAGGTACTT 47 
12 R AKT1-12-Rs1-AT TCATCAAACGTGGACCT 44 
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10.2 Gene Reference Sequence 
Gene  Sequence ID Sequence Source   
MYH7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ENSECAG00000
019844 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
>chromosome:EquCab2:1:161505973:161527844:-1 
GTCACCTGCAGGCTTGAGCTTCTTTTCTTGTAGACACATTTGAGAAGCCAAGGTGCAG
CCATGGGGGACGCGGAGTTGGCTGTGTTTGGGTCCGCCGCCCCATACCTGCGCAAGAC
AGAGAAGGAGCGGCTGGAAGACCAGACCAGGCCTTTCGACCTCAAGAAGGACGTCTT
CGTGCCTGATGACAAAGAGGAGTTCGTCAAGGCTAAGATTATATCTCGAGAGGGTGG
CAAAATCACTGCCGAGACTGAGCATGGCAAGACCGTGACCGTGAAGGAGGATCAGGT
GTTGCAGCAGAACCCGCCCAAGTTCGACAAGATCGAGGACATGGCCATGCTGACCTTC
CTGCACGAGCCCGCTGTGCTCTACAACCTCAAGGATCGCTACGCGGCCTGGATGATCT
ACACCTACTCCGGCCTCTTCTGTGTCACCATCAACCCCTACAAGTGGCTGCCGGTGTAC
ACTGCAGAGGTGGTGGCCGCCTACCGGGGCAAGAAGAGGAGCGAGGCGCCGCCCCAC
ATCTTCTCCATCTCTGACAATGCCTACCAGTACATGCTGACAGACAGAGAAAACCAGT
CCATCCTGATCACCGGAGAATCCGGGGCAGGGAAGACGGTCAACACCAAGAGAGTCA
TCCAGTATTTTGCTGTTATCGCCGCCATTGGGGACCGCAGCAAAAAGGATCAGACCTC
AGGCAAGGGCACCCTGGAGGACCAGATCATCGAGGCCAACCCTGCCCTGGAGGCCTT
TGGCAATGCCAAGACCGTCAGGAATGATAACTCCTCCCGCTTCGGGAAATTCATTCGA
ATCCATTTTGGGGCGACTGGAAAGTTGGCGTCTGCAGACATAGAGACCTACCTTCTGG
AAAAATCCAGAGTTATTTTCCAGCTGAAGGCAGAGAGAGATTATCACATTTTCTACCA
AATCCTGTCTAACAAAAAACCTGAGCTGCTGGACATGCTGCTGATCACCAACAACCCC
TATGATTATGCATTCATCTCCCAAGGAGAGACCACTGTGGCCTCAATTGATGACGCTG
AGGAGCTCATGGCCACTGATAACGCCTTTGATGTGCTGGGCTTCACTTCAGAGGAGAA
GAACTCCATGTACAAGCTGACGGGCGCCATCATGCACTTCGGAAACATGAAGTTCAAG
CAGAAGCAGCGAGAGGAGCAGGCTGAGCCAGACGGCACCGAAGAGGCTGACAAGTC
CGCCTACCTCATGGGGCTGAACTCAGCCGACCTGCTTAAGGGGCTGTGCCACCCTCGG
GTGAAAGTAGGCAATGAGTATGTCACCAAGGGGCAGAATGTCCAGCAGGTGGCATAT
GCTAAAGGGGCCCTGGCCAAGGCAGTGTATGAGAGGATGTTCAACTGGATGGTGGCG
CGGATCAACGCCACCCTGGAGACCAAGCAGCCGCGCCAGTACTTCATAGGAGTCCTG
GACATCGCTGGCTTTGAGATCTTTGACTTCAACAGCTTTGAGCAGCTCTGCATCAACTT
CACCAACGAGAAGCTGCAGCAGTTCTTCAACCACCACATGTTCGTGCTGGAGCAGGAG
GAGTACAAGAAGGAGGGCATCGAGTGGGAGTTCATCGACTTCGGCATGGACCTGCAG
GCCTGCATCGACCTCATCGAGAAGCCCATGGGCATCATGTCCATCCTGGAAGAGGAGT
GCATGTTCCCCAAGGCCACCGACATGACGTTCAAGGCCAAGCTGTTTGACAACCACCT
GGGAAAGTCCAGCAACTTCCAGAAGCCACGCAATATCAAGGGGAAGCCAGAAGCCCA
CTTCTCCCTGATCCACTACGCTGGCACTGTGGACTACAACATCCTAGGCTGGCTGCAG
AAGAACAAAGATCCACTCAATGAGACCGTGGTGGATTTATACAAGAAGTCCTCCCTTA
AGATGCTCAGCAACCTGTTTGCCAACTATCTTGGGGCTGATGCACGTAAGTCGAGACT
GGGACCCAGGGGACTGAGGAGCAGGCCAAGGCACCCACAAAGGGCAAAGGCAAGGC
CAAGAAAGGCTCATCCTTTCAGACCGTGTCAGCTCTGCACAGGGAAAATCTGAACAAG
CTGATGACCAACTTGCGCTCCACACATCCCCACTTCGTGCGTTGCATCATCCCCAATGA
GACAAAGTCTCCAGGGGTGATAGACAACCCCCTGGTCATGCACCAGCTGCGCTGCAAC
GGCGTGCTGGAAGGCATCCGCATCTGCAGGAAGGGCTTCCCTAACCGCATCCTCTACG
GGGACTTCCGGCAGAGGTATCGCATCCTGAACCCAGCGGCCATCCCCGAGGGCCAGTT
CATTGACAGCAGGAAAGGAGCAGAGAAGCTGCTGAGCTCTCTGGACATTGACCACAA
CCAGTATAGGTTCGGCCACACCAAGGTGTTCTTCAAGGCAGGGCTGCTGGGGCTGCTG
GAGGAGATGCGAGATGAGAGGCTGAGCCGAATCATCACCCGCATCCAGGCCCAGTCC
CGGGGTGTGCTCGCCAGAATGGAATTCAAGAAGCTGTTGGAACGCAGAGACTCCCTG
CTGATAATCCAGTGGAACATTCGGGCCTTCATGGGGGTCAAGAACTGGCCCTGGATGA
Ensembl 
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Gene  Sequence ID Sequence Source   
MYH7 
Cont’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ENSECAG00000
019844 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AGCTCTACTTCAAGATCAAGCCTCTGCTGAAGAGCGCAGAGACAGAGAAGGAGATGG
CCACCATGAAGGAGGAGTTTGCGCGCCTCAAAGAGGCGCTGGAGAAGTCTGAGGCTC
GCCGCAAGGAGCTGGAGGAGAAGATGGTGTCCCTGCTGCAGGAGAAGAACGACCTAC
AGCTCCAAGTGCAGGCGGAACAAGACAACCTGGCGGATGCAGAGGAGCGCTGCGACC
AGCTGATCAAGAACAAGATCCAGCTGGAGGCCAAGGTGAAGGAGATGACTGAGAGGC
TGGAGGATGAGGAGGAGATGAATGCCGAGCTCACTGCCAAGAAGCGCAAGCTGGAAG
ATGAGTGCTCTGAACTCAAAAGGGACATTGATGACCTGGAGCTGACACTGGCCAAGG
TGGAGAAGGAGAAGCATGCAACAGAGAACAAGGTGAAGAACCTGACAGAGGAGATG
GCTGGGCTGGATGAGATCATCGCCAAGCTGACCAAGGAGAAGAAAGCTCTGCAAGAG
GCCCACCAGCAGGCCCTGGATGACCTCCAGGCTGAAGAGGACAAGGTCAACACCCTG
ACCAAGGCCAAGGTCAAGCTGGAGCAGCACGTGGACGATCTGGAGGGATCCCTGGAG
CAGGAGAAGAAAGTGCGCATGGACCTGGAGCGAGCTAAGCGGAAGCTGGAGGGTGA
CCTGAAGCTGACTCAGGAGAGCATCATGGACCTGGAGAACGACAAGCAGCAGCTGGA
TGAGAGGCTGAAAAAGAAGGACTTTGAGCTGAACGCCCTCAATGCAAGGATTGAGGA
TGAGCAGGCTCTGGGCAGCCAGCTGCAGAAGAAGCTCAAAGAGCTTCAGGCACGCAT
TGAGGAGCTGGAGGAGGAGCTGGAGGCCGAGCGCACCGCCAGGGCCAAGGTGGAGA
AGCTGCGCTCAGACCTGTCCCGGGAGCTGGAGGAGATCAGCGAGCGGCTGGAAGAGG
CTGGCGGGGCCACATCCGTGCAGATCGAGATGAACAAGAAGCGTGAGGCCGAGTTCC
AGAAGATGAAGCGGGACCTGGAGGAGGCCACGCTGCAGCACGAGGCCACGGCGGCG
GCCCTGCGCAAGAAGCACGCTGACAGCGTGGCTGAGCTGGGCGAGCAGATCGACAAT
CTGCAGCGCGTGAAGCAGAAGCTGGAGAAGGAGAAGAGTGAGTTCAAGCTGGAGCTG
GACGACGTCACCTCCAACATGGAGCAGATCATCAAGGCCAAGGCCAACCTGGAGAAG
ATGTGTCGGACCCTGGAAGACCAGATGAATGAGCACCGGAGCAAGGCCGAGGAGACC
CAGCGTTCTGTCAACGACCTCACCAGCCAGCGGGCCAAGCTGCAGACTGAGAATGGT
GAGCTGTCTCGGCAGCTGGATGAGAAGGAGGCACTGATCTCCCAGCTGACCCGAGGC
AAACTCACCTACACGCAGCAGCTGGAGGACCTCAAGAGGCAGCTGGAGGAGGAGGTT
AAGGCAAAGAACGCCCTGGCTCACGCGCTGCAGTCAGCCAGGCACGACTGTGACCTG
CTGCGGGAGCAGTACGAGGAGGAGACAGAGGCCAAGGCGGAGCTGCAGCGCGTCCTC
TCCAAGGCCAACTCAGAGGTGGCCCAGTGGAGGACCAAGTATGAGACAGACGCCATC
CAGAGGACCGAGGAGCTCGAGGAGGCCAACCTCTCAGGGAAGCTTTTTGCTCGCGTTA
TGTTTCTCATCCGAATATAAGACGAACAAAAGGTTTGTCTGAGGGCAGGAAGAAGCTG
GCGCAGCGGCTGCAAGACGCCGAGGAGGCCGTGGAGGCCGTCAATGCCAAGTGTTCG
TCTCTTGAGAAGACCAAGCACCGGCTGCAGAATGAGATCGAGGACCTGATGGTGGAT
GTGGAGCGCTCCAACGCGGCCGCCGCGGCCCTGGACAAGAAGCAGAGGAACTTCGAC
AAGATCCTGGCCGAGTGGAAGCAGAAGTACGAGGAGTCGCAGTCGGAGCTGGAGTCC
TCGCAGAAGGAGGCGCGCTCCCTCAGCACCGAGCTCTTCAAGCTCAAGAACGCCTATG
AGGAGTCCCTGGAGCACCTGGAGACCTTCAAGCGGGAGAACAAGAACCTCCAGGAGG
AGATCTCCGACCTCACTGAGCAGTTGGGTTCCAGCGGAAAGACCATCCACGAGCTGGA
GAAGGTCCGCAAGCAGCTGGAGGCCGAGAAGCTGGAGCTGCAGTCGGCCCTGGAGGA
GGCCGAGGCCTCCCTGGAACACGAGGAGGGCAAGATCCTCCGTGCACAGCTGGAGTT
CAACCAGATCAAGGCAGAGATCGAGCGGAAGCTGGCAGAGAAGGACGAGGAGATGG
AGCAGGCCAAGCGCAACCACCTGCGGGTGGTGGACTCGCTGCAGACCTCCCTGGACG
CGGAAACACGCAGCCGCAACGAGGCGCTGCGGGTGAAGAAGAAGATGGAGGGCGAC
CTCAACGAGATGGAGATCCAGCTCAGCCATGCCAACCGCATGGCTGCAGAGGCCCAG
AAGCAAGTCAAGAGCCTCCAGAGCTTACTGAAGGACACCCAGATCCAGCTGGATGAC
GCGGTCCGTGCCAACGATGACCTGAAGGAGAACATCGCCATCGTGGAGCGGCGCAAC
AACCTACTGCAGGCTGAGCTGGAGGAGCTGCGGGCCGTGGTGGAGCAGACAGAGCGG
TCTCGGAAGCTGGCTGAGCAGGAGCTGATCGAGACCAGCGAGCGGGTGCAGCTGCTG
CACTCCCAGAACACCAGCCTCATCAACCAGAAGAAGAAGATGGACGCAGACCTGTCC
Ensembl 
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Gene  Sequence ID Sequence Source   
MYH7 
Cont’ 
 
 
ENSECAG00000
019844 
 
 
CAGCTTCAGACTGAAGTGGAGGAGGCAGTGCAGGAGTGCAGGAATGCCGAGGAGAA
GGCCAAGAAGGCCATCACGGACGCTGCCATGATGGCGGAGGAGCTGAAGAAGGAGC
AGGACACCAGCGCCCACCTGGAGCGCATGAAGAAGAACATGGAGCAGACCATTAAGG
ACCTGCAGCACCGGCTGGACGAGGCGGAGCAGATCGCCCTCAAGGGCGGCAAGAAGC
AGCTGCAGAAGCTGGAGGCCCGGGTGCGGGAGCTGGAGAATGAGCTGGAGGTTGAGC
AGAAGCGCAATGCAGAGTCCATCAAGGGCATGAGGAAGAGTGAGCGGCGCATCAAG
GAGCTCACCTACCAGACGGAGGAGGACAGGAAGAACCTGCTGCGGCTGCAGGACCTG
GTGGATAAGCTGCAGCTGAAGGTCAAGGCATACAAGCGCCAGGCCGAGGAGGCGGAG
GAACAGGCCAACACCAACCTGTCCAAGTTCCGCAAGGTGCAGCACGAGCTGGATGAG
GCAGAGGAGCGGGCGGACATCGCCGAGTCCCAGGTCAACAAGCTGCGGGCCAAGAGC
CGCGACATCGGCACCAAGGGCTTGAATGAGGAGTAGCTGTGCCACATCTTCTTGACCT
GCCCAGTCCTGAGGGTGCCAATGGAGTTCCAGTCCCGGAACGCAAATTGCAGCCCCTT
TGGAGGAAGCAGAATAAAGCAATTTTCCTTGAAGTG 
Ensembl 
 
CASQ2 ENSECAG00000
021854  
>chromosome:EquCab2:5:53134272:53196534:1 
ATATAACTTTTCCCAGATGAAGAGAACTCACCTGTTTGTGGTGGGGGTCTACCTGCTGT
CCACCTGCAGGGCGGAAGAGGGGCTCAACTTCCCCACCTACGACGGCAAGGACCGCG
TGGTCAGTCTCACTGAGAAGAACTTCAAGCAGGTTTTGAAGAAATACGACTTGCTCTG
CCTCTACTACCATGAGCCCGTGTCTTCCGATAAAGTCGCCCAGAAACAGTTCCAGCTG
AAAGAAATTGTGCTTGAGCTTGTGGCCCAGGTCCTGGAACACAAAGATATAGGCTTTG
TGATGGTGGATGCCAAGAAAGAAGCCAAGCTTGCCAAGAAACTGGGTTTTGATGAAG
AAGGAAGCCTGTATATTCTCAAGGGTGACCGCACAATTGAGTTTGATGGCGAGTTTGC
AGCTGATGTCTTGGTGGAGTTCCTCTTGGATCTAATTGAAGATCCTGTGGAGATCATCA
ACAGCAAACTGGAAGTCCAAGCCTTTGAACGCATTGAGGACCAGATCAAACTCATTG
GCTTTTTCAAGAGTCAGGACTCAGAATATTATAAGGCTTTTGAAGAGGCAGCCGAACA
CTTCCAGCCTTACATCAAATTTTTTGCTACCTTCGACAAAGGAGTTGCAAAGAAATTGT
CCTTGAAGATGAATGAGGTTCACTTCTACGAGCCATTTATGGATGAGCCCATTGCCAT
CCCCAACAAACCTTACACAGAAGAGGAGCTCGTGGAGTTCGTGAAGGAGCACCAAAG
ACCCACTCTACGTCGCCTACGCCCAGAAGATATGTTTGAAACATGGGAGGATGATTTA
AATGGGATCCACATTGTGGCCTTTGCAGAGAGGAGTGACCCAGATGGCTACGAGTTCC
TGGAGATCCTGAAACAGGTTGCCCGGGACAATACCGACAACCCTGACCTGAGCATCGT
ATGGATTGACCCGGATGACTTTCCTTTGCTTGTTGCCTATTGGGAAAAGACTTTCAAGA
TTGACCTATTCAAGCCACAGATTGGGGTGGTGAATGTGACAGATGCTGACAGTGTCTG
GATGGAGATTCCAGATGATGATGACCTGCCCACAGCTGAGGAGCTGGAAGACTGGAT
TGAGGACGTGCTTTCTGGGAAGATAAACACTGAAGATGATGACAATGAAGATGAAGA
TGATGACGATGATGATGACGATGATGATGATGATGATAATTCTGATGAACCCCAACTC
CAAATGATTTTGTTGAAAACAAAATCACAGCTACCCACTACCTTACAGACAGCACAAG
GTGGCAGCAGGCAGCCTTGGCCCACGCCCAGCCAGCTCCTTTCCCTTTTCCAACCTCTC
TTTTCCCACTCCCTTCTCATCAGGAGATGTGCAGTTCAGCAAATGCCTTTCTAAATCCT
GCAATTCCACTCAGCAAAGACAAGTGGGGGGAATTATTCCCATGTTGACTGTCTTGAT
TGTCATGAAACAGCTCTTGTTCTTTGCCGGACCATCAGCGGTCATGGCAGTG 
Ensembl 
PTEN 
 
 
ENSECAG00000
017012 
 
 
>chromosome:EquCab2:1:40515361:40602546:-1 
AAGCTGCAGTCATGATGGAAGTTTGAGAGTTGAGCCGCTGCGAGGCGAGGCCGGGCT
CAGGCGAGGGAGATGAGAGACGGCGGCGGCGCGGCCCAGAGCCCCTCTCAGCGCCCT
GTGAGCAGCCGCGGGGGCAGCGCCCTCGGGGAGCCGGCCGGCCGGCGGCGGCGGCAG
CGGCGGCGTTTCTCGCCTCCTCTTCGTCTTCTCTTCTAACCGTGCAGCCTCTTCCTCGGC
TTCTCCTGAAAGGGAAGGTGGAAGCCGTGGGCTCGGGCGGGAGCCGGCTGAGGCGCG
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Gene  Sequence ID Sequence Source   
PTEN 
Cont’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ENSECAG00000
017012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GCGGCGGCACCTCCCGCTCCTGGAGCGGGGGGGAGAAGCGTCGGCGGCGGCGGCCGC
GGCGGCTGCAGCTCCGGGGAGGGGGTCGGAGTCGCCTGTCACCATTTCCAGGGCTGG
GAACGCCGGAGAGTTGGTCTCTCCCCTTCTACTGCCTCCAACACGGCGGCGGCGGCGG
CGGCACATCCAGGGACCCGGGCCGGTTTTAAACCTCCCCTCCGCCGCCGCCGCACCCC
CCCTGGCCCGGGCTCCGGAGGCCGCCGGAGGAGGCAGCCGTTCCGAGGATTATTCGTC
TTCTCCCCATTCCGCTGCCGCCGCTGCCAGGCCTCTGGCTGCTGAGGAGAAGCAGGCC
CAGTCGCTGCAACCATCCAGCAGCCGCCGCAGCAGCCATTACCCGGCTGCGGTCCAGA
GCCAAGCGGCAGCAGAGCGAGGGGCATCAGCTACCGCCAAGTCCAGAGCCATTTCCA
TCCTGCAGAAGAAGCCCCGCCACCAGCAGCTTCTGCCATCTCTCTCCTCCTTTTTCTTC
AGCCACAGGCTCCCAGACATGACAGCCATCATTAAAGAGATCGTTAGCAGAAACAAA
AGGAGATATCAAGAGGATGGATTCGACTTAGACTTGACCTATATTTATCCAACATTAT
TGCTATGGGGTTTCCTGCAGAAAAGACTTGAAGGCGTATACAGAACAATATCGATGAT
GTAGTAAGGTTTTTGGATTCAAAGCATAAAAACCATTACAAGATATACAATCTATGTG
CTGAAAGACATTATGATACCGCCAAATTTAACTGCAGAGTTGCACAGTATCCTTTTGA
AGATCATAATCCACCACAGCTAGAACTTATCAAACCCTTTTGTGAAGATCTTGACCAA
TGGCTAAGTGAAGATGACAATCATGTTGCAGCAATTCACTGTAAAGCTGGAAAGGGA
CGAACTGGTGTAATGATTTGTGCATATTTGTTACATCGGGGCAAGTTTTTAAAGGCAC
AGGAGGCCCTAGATTTCTATGGAGAAGTAAGGACCAGAGATAAAAAGGGAGTAACTA
TTCCCAGTCAGAGGCGCTATGTGTATTATTATAGCTACCTGTTAAAGAATCATCTGGAT
TATAGACCAGTGGCACTGTTGTTTCACAAGATGATGTTTGAAACTATTCCAATGTTCAG
TGGCGGAACTTGCAATCCTCAGTTTGTGGTCTGCCAGCTAAAGGTGAAGATATATTCC
TCCAATTCAGGACCCACACGACGGGAAGACAAGTTCATGTACTTTGAGTTCCCTCAGC
CGTTGCCTGTGTGTGGTGACATCAAAGTAGAGTTCTTCCACAAACAGAACAAGATGCT
AAAAAAGGACAAAATGTTTCACTTTTGGGTAAATACATTCTTTATACCAGGACCAGAG
GAAACCTCAGAAAAAGTAGAAAATGGAAGTCTATGTGATCAAGAAATTGATAGTATT
TGCAGTATAGAGCGTGCAGATAATGACAAAGAATATCTAGTACTCACTTTAACAAAAA
ATGATCTCGACAAAGCAAATAAAGACAAGGCCAACCGATACTTTTCTCCAAATTTTAA
GGTGAAGCTGTACTTCACAAAAACAGTAGAGGAGCCATCAAATCCAGAGGCTAGCAG
TTCAACTTCTGTAACACCAGATGTTAGTGACAATGAACCTGATCATTATAGATATTCTG
ACACCACTGACTCTGATCCAGAGAATGAACCTTTTGATGAAGATCAGCATACACAAAT
TACAAAAGTCTGAATTTTTTTTTTTTATCAAGAGGGATAAAACTCCATGAAAACAAAC
TTGAATAAACTGAAAATGGACCTTTTTTTTTAATGGCAATAGGACATTGTGTCAGATTA
CCAGTTATAGGAACAATTCTCTTTTCCTGACCAATCTTGTTTTACCCTATACATCCACA
GGGTTTTGACACTTGTTGTCCAGTTGAAAAAAGGTTGTGTAGCTGTGTTATGTATATAT
CTTTTTGTGTCAAAAGGACATTTAAAATTCAATTAGGATAAATAAAGATGGCACTTTC
CCATTTTATTCCAGTTTTATAAAAAGTGGAGACAGACTGATGTGTATACGTAGGAATT
TTTCATTTTGTATTCTGTCACCAACTGAAGTGGCTAAAGAGCTTTGCGATATACAGGTT
CACATCCTACCCCTTTGCACTTGTGGCAACAGATAAGTTTGCAGTTGGCTAAGAGGAG
TTTCTAAGAGATTTTGCTACATTCTAATGCATGTATTCGGGTTAGGGGAATGGAGAGA
ATGCTCAGAAAGGAATATATTTTATGCTGGACTCTGGACCATATACCATCTCCAGCTG
TTTACATGCACCTTTCTTTAGCATGCTACAGTTATTAATCTGGACGTTTGAGGAATTGG
CCGCTGTCACTGCTTGTTGTTTGTGCATTTTATTTTTTTTAAGCATATTGGTGCTAGAAA
AGGCAGCTAGAGGGAGTGAATCTGTATTGGGGTACAGGAATGAACCTTCCACAACAT
CTTAAGAATCCACAAATGAAGGGATATAAAAATAATGTGGTCATAGATAGGAAACAC
AGCAACAATGACTTAACCATATAAATGTGGAGGCTATCAACAAAGAATGGGCTTGAA
ACATTATACAAATTGACAATGATTTATTAAATATGTTTTCTCAATTGTAATGACTGCTC
CATCTCCTGTGTAATCAAGGCCAGTGCTAAAAGTCAGATGCTATTAGTACCTACATCA
GTCAACAACTTACACTTATTAGTTTTCAATCATATACCTGCTGTGGATGCTTCATGTGC
TGCCTGCAAGCTTCTTTTTTCTCAATAAATATAAAATATTTTGTAATGCTGCACAGGAA
Ensembl 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 140 
Gene  Sequence ID Sequence Source   
PTEN 
Cont’ 
ENSECAG00000
017012 
 
 
ATTTCAATTTGAGATTCTACAGTAAGCAGTTTTTTTTCTTTAAAGATTTATGATGCACTT
ATGCAATCCAATAGCTGTCAGCCGTTCCACCCTTTTGACCTTACACATTCTATTACAAT
GAGTTTTGCAGTTTTGCACATTTTTTAAATGTCATTAACTGTTAGGGAATTTTACTTGA
ATACTGAATACATATAATGTTTATATTTAAAAGGACATTATTTGTGTTAAAAAGGAAA
TTAGAGTTGCAGTAAATTTTCAACACTGCACAAATAATAAGGCATTTACTTTTTCAATA
GAAATT 
Ensembl 
 
 
AKT1 ENSECAG00000
008264 
>chromosome:EquCab2:24:46109151:46133697:-1 
ATGAACGACGTGGCCATCGTGAAGGAGGGCTGGCTGCACAAACGAGGAGAGTACATC
AAGACCTGGCGGCCCCGGTACTTCCTCCTCAAGAACGACGGCACCTTCATCGGCTACA
AGGAGCGGCCGCAGGACGTGGAGCAGCGCGAGTCGCCCCTCAACAACTTCTCGGTGG
CACAGTGCCAGCTGATGAAGACGGAGCGGCCCAGGCCCAACACCTTCATCATCCGCTG
CCTGCAGTGGACCACGGTGATCGAGCGCACCTTCCACGTGGAGACGCCCGAGGAGCG
GGAGGAGTGGACGACTGCCATCCAGACAGTGGCTGATGGGCTCAAGAGGCAGGAGGA
AGAGATGGACTTCCGATCGGGCTCACCCAGTGACAACTCTGGGGCCGAGGAGATGGA
GGTGTCCCTGGCCAAGCCCAAACACCGTGTGACCATGAACGAGTTTGAGTACCTGAAG
CTCCTGGGCAAAGGCACCTTTGGGAAGGTGATTCTGGTGAAGGAGAAGGCCACGGGC
CGCTACTACGCCATGAAGATCCTGAAGAAGGAAGTCATCGTGGCCAAGGACGAGGTG
GCCCACACGCTCACGGAGAACCGCGTGCTCCAGAACTCCCGGCATCCCTTCCTGACGG
CTCTCAAGTACTCCTTCCAGACCCATGACCGCCTGTGCTTCGTCATGGAGTACGCCAAC
GGGGGCGAGCTCTTCTTCCACCTGTCCCGGGAGCGCGTGTTCCCCGAGGACCGGGCCC
GCTTTTACGGCGCCGAGATCGTGTCGGCCCTGGACTACCTGCACTCTGAGAAGAATGT
CGTCTACCGTGACCTCAAGCTGGAGAACCTCATGCTGGACAAGGACGGGCACATCAA
GATCACTGACTTTGGGCTGTGCAAGGAGGGCATCAAGGATGGGGCCACCATGAAGAC
CTTCTGCGGGACACCTGAGTACCTGGCCCCCGAGGTGCTGGAGGACAACGACTACGGC
CGGGCGGTGGACTGGTGGGGGCTGGGCGTGGTCATGTACGAGATGGTGTGCGGCCGC
CTGCCCTTCTACAACCAGGACCACGAGAAGCTCTTCGAGCTCATCCTCATGGAGGAGA
TCCGCTTCCCGCGCACGCTCAGCCCTGAGGCCAAGTCCCTGCTCTCGGGGCTGCTCAA
GAAGGACCCCAAGCAGAGGCTGGGCGGGGGCTCCGAGGACGCCAAGGAGATCATGC
AGCACCGCTTCTTTGCCAGCATCGTGTGGCAGGACGTGTATGAGAAGAAGCTCAGCCC
GCCCTTCAAGCCCCAGGTCACATCGGAGACAGACACCAGGTATTTTGATGAGGAGTTC
ACGGCCCAGATGATCACCATCACGCCGCCCGACCAAGACGACACGATGGAGGGTGTG
GACAGCGAGCGGAGGCCCCACTTCCCCCAGTTCTCCTACTCGGCCAGCGGCACGGCCT
GAGGAGG 
Ensembl 
PI3K 
 
 
 
 
 
 
ENSECAG00000
019837 
 
 
 
 
 
 
>chromosome:EquCab2:21:5672536:5742177:-1 
ATGAGTGCAGAGGGGTACCAGTACAGAGCGCTCTATGATTATAAAAAGGAACGAGAA
GAAGATATTGACTTGCACTTGGGTGACATATTGACTGTGAATAAAGGGTCCTTGGTAG
CTCTTGGATTCTGTGACGGACAGGAAGCCAGGCCTGAAGAGATTGGCTGGTTAAACGG
CTATAATGAAACGACGGGGGAGAGGGGGGACTTTCCGGGAACTTACGTAGAATATAT
TGGAAGGAAAAAAATCTCGCCCCCGACACCAAAGCCCCGGCCACCTCGACCCCTTCCC
GTCGCACCAGGTTCTTCAAAAACTGAAGCAGACAGTGAGCAACAAGCTTTGACGCTTC
CGGACCTTGCAGAGCAGTTTGCCCCTCCTGACATCGCTCCGCCTCTTCTTATCAAGCTA
GTGGAAGCCATTGAAAAGAAAGGTCTGGAATGTCCAACTCTCTACAGAACACAGAGC
TCCAGCAACCTAGCAGAATTACGACAGCTTCTTGATTGTGATGCTGCCTCCCTGGACTT
GGAAATGATTGATGTGCAAGTTTTAGCAGATGCTTTCAAACGCTATCTCCTCGACTTAC
CAAATCCCGTCATTCCAGTAGCCGTTTACAGTGAAATGATTTCTTTAGCCCCAGAAGT
ACAAAGCTCCGAGGAATATATCCAGCTGTTGAAGAAGCTCATTAGGTCGCCTAACATA
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Gene  Sequence ID Sequence Source   
PI3K 
 
ENSECAG00000
019837 
 
CCTCATCAGTATTGGCTTACACTTCAGTATTTGCTAAAACATTTCTTCAAACTCACTCA
AACCTCCAGCAAAAATCTTTTGAATGCAAGAGTCCTCTCTGAACTTTTCAGCCCTCTGC
TTTTCAGATTCCCAGCAGCCAGCTCTGAGAATTCTGAACACCTCATAAAAGTTATAGA
AATTTTAATCTCCACCGAATGGAATGAACGACAGCCTGCACCAGCACTGCCTCCCAAA
CCACCAAAACCCACTACTGTAGCCAACAACGGTATGAATAACAATATGTCCTTACAAG
ATGCTGAATGGTACTGGGGAGATATCTCGAGGGAAGAAGTGAATGAAAAACTCCGAG
ATACAGCCGATGGGACCTTTTTGGTACGAGACGCATCTACTAAAATGCATGGCGATTA
CACTCTGACACTAAGGAAAGGAGGAAATAACAAATTAATCAAAATATTTCACCGAGA
TGGGAAATATGGTTTCTCTGACCCATTAACCTTCAACTCTGTGGTTGAACTAATAAACC
ACTACCGGAATGAATCTCTAGCTCAGTATAACCCCAAGCTGGATGTGAAATTACTTTA
TCCAGTATCCAAATACCAACAGGATCAGGTTGTCAAAGAAGATAATATTGAAGCTGTA
GGGAAAAAATTACATGAATATAACACTCAATTTCAAGAAAAAAGTCGAGAATATGAT
AGATTATATGAAGATTATACTCGCACTTCCCAGGAAATCCAAATGAAAAGAACAGCTA
TTGAAGCATTTAATGAAACTATAAAAATATTCGAAGAACAGTGCCAAACCCAGGAGC
GGTACAGCAAAGAATACATAGAAAAGTTTAAACGCGAAGGCAACGAGAAAGAAATA
CAAAGAATTATGCATAATTATGAAAAGTTAAAGTCTCGAATCAGTGAGATTGTTGACA
GCAGAAGAAGGCTGGAGGAGGACTTGAAGAAGCAGGCAGCCGAGTATCGCGAGATT
GACAAACGCATGAACAGCATTAAGCCAGACCTCATTCAGCTGAGAAAGACAAGAGAC
CAGTACTTGATGTGGTTGACTCAAAAAGGTGTTCGGCAAAAGAAGTTGAACGAGTGGT
TGGGCAATGAAAACACTGAAGACCAATATTCGCTGGTGGAAGATGATGAGGATTTGC
CCCACCATGATGAGAAGACGTGGAATGTCGGCAGCAGCAACCGCAACAAAGCTGAAA
ACCTCTTGCGAGGGAAGCGAGATGGCACTTTTCTTGTCCGGGAAAGCAGTAAACAGG
GCTGCTACGCCTGCTCCGTGGTGGTGGACGGCGAAGTGAAGCATTGTGTCATAAACAA
AACAGCGACTGGCTACGGCTTTGCGGAGCCCTACAACTTGTACAGCTCTCTGAAAGAA
CTGGTGCTACATTACCAACACACGTCCCTCGTGCAGCACAACGACTCCCTCAACGTCA
CACTAGCCTACCCGGTATATGCACAGCAGAGGCGATGAAGTGCTTGCCCTCTGATCCT
TCTCCTGAAGTTCAACCACCCTGA 
Ensembl 
 
 
 
Nucleotide sequences for the candidate genes covering 5 to 3 coding regions.   
Underlined text shows alternate coding regions. 
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10.3 Orthologeous Gene Multiple Species Alignments 
Orthologeous gene multiple species alignments are available on request. This data is of significant 
volume, which is why it is omitted here. However, the author is more than happy to send this 
information in electronic format (please specify preferred file format).   
10.4 Raw Sequence Data and Alignments to Reference Sequence 
All raw sequence data and annotated alignments are available on request. This data is of significant 
volume, which is why it is omitted here. However, the author is more than happy to send this 
information in electronic format (please specify preferred file format). 
10.5 Agarose Gel Electrophoresis Photos 
Agarose gel electrophoresis photos for each amplicon produced by the above oligonucleotides is 
available on request. This data is of significant volume, which is why it is omitted here. However, the 
author is more than happy to send this information in electronic format (please specify preferred file 
format). 
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10.6 Gene Maps 
All genes have been gene-mapped for easier visual representation of results. 
The following features have been annotated onto the gene map: exon regions, intronic regions, coding 
regions, stop and start codons, 5 and 3 UTR, transcript variants (where relevant), NCBI registered 
variations (blue) and variations found in this study (red). 
Variations are displayed as genomic base pair changes, the corresponding amino acid translation of the 
reference sequence is also displayed.
 144 
MYH7 Gene Map 
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CASQ2 Gene Map 
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AKT1 Gene Map 
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PI3K Gene Map 
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PTEN Gene Map 
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10.7 MYH7 variants mapped to protein coding regions 
As the largest of all the genes, mapping diagrams can be problematic to present due to sheer size.  
Below is an enlarged version of Figure 4.4, from Chapter 4. 
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10.8 Thoroughbred Panel Racing Data 
Well Position Sex DOB No. Races 1st Places 2nd Places 3rd Places 
Total prize 
money AUS $ 
Average $ per 
race 
Min-Dist-Win 
(M) 
Max-Dist-Win 
(M) 
Average-Dist-
Win (M) 
E05 M 6-Sep-08 5 0 0 0 $0 $0 Not recorded Not recorded N/A 
F08 F 5-Oct-08 5 0 0 0 $0 $0 Not recorded Not recorded N/A 
E12 F 17-Sep-08 4 0 0 0 $0 $0 Not recorded Not recorded N/A 
H04 F 14-Aug-08 4 0 0 0 $0 $0 Not recorded Not recorded N/A 
D01 M 5-Nov-08 3 0 0 0 $0 $0 Not recorded Not recorded N/A 
A11 M 25-Oct-08 3 0 0 0 $0 $0 Not recorded Not recorded N/A 
A03 M 30-Aug-08 2 0 0 1 $0 $0 Not recorded Not recorded N/A 
F01 F 5-Oct-08 2 0 0 0 $0 $0 Not recorded Not recorded N/A 
E06 M 27-Sep-08 1 0 0 0 $0 $0 Not recorded Not recorded N/A 
E02 F 23-Nov-08 1 0 0 0 $0 $0 Not recorded Not recorded N/A 
E03 F 28-Oct-08 3 0 0 0 $540 $180 Not recorded Not recorded N/A 
C06 F 19-Nov-08 5 0 0 0 $550 $110 Not recorded Not recorded N/A 
D07 F 27-Oct-05 6 0 0 0 $870 $145 Not recorded Not recorded N/A 
C11 M 18-Sep-08 10 0 0 1 $900 $90 Not recorded Not recorded N/A 
G05 M 19-Aug-08 7 0 0 0 $1,150 $164 Not recorded Not recorded N/A 
H07 F 31-Oct-01 7 0 0 2 $1,200 $171 Not recorded Not recorded N/A 
E08 F 17-Oct-08 5 0 0 1 $1,500 $300 Not recorded Not recorded N/A 
G01 F 17-Sep-08 11 0 0 0 $1,550 $141 Not recorded Not recorded N/A 
C08 F 4-Nov-08 3 0 0 1 $1,700 $567 Not recorded Not recorded N/A 
B08 F 8-Oct-08 5 0 1 1 $2,025 $405 Not recorded Not recorded N/A 
B03 F 4-Sep-08 7 0 0 0 $2,400 $343 Not recorded Not recorded N/A 
G11 F 5-Sep-08 8 0 1 1 $2,495 $312 Not recorded Not recorded N/A 
H05 M 19-Nov-08 8 0 0 0 $2,625 $328 Not recorded Not recorded N/A 
D06 M 10-Sep-08 10 0 1 0 $2,775 $278 Not recorded Not recorded N/A 
G09 F 6-Sep-06 11 0 1 0 $3,025 $275 Not recorded Not recorded N/A 
A05 F 30-Aug-08 11 1 0 0 $3,225 $293 1240 1240 1240 
C05 F 29-Sep-01 10 1 1 1 $4,550 $455 800 800 800 
G12 M 6-Sep-07 25 0 1 1 $5,565 $223 Not recorded Not recorded N/A 
H10 F 16-Oct-08 8 0 1 1 $5,865 $733 Not recorded Not recorded N/A 
B07 F 6-Sep-02 6 1 0 0 $7,800 $1,300 1200 1200 1200 
E07 F 28-Aug-04 14 1 2 2 $8,195 $585 1200 1200 1200 
D02 F 4-Nov-06 6 1 0 1 $8,400 $1,400 1280 1280 1280 
A10 F 26-Oct-08 11 1 0 0 $8,430 $766 2000 2000 2000 
D05 F 2-Sep-08 14 1 0 1 $10,200 $729 1075 1075 1075 
E09 F 15-Sep-07 14 1 0 0 $10,615 $758 1350 1350 1350 
F04 F 2-Nov-08 44 1 0 0 $12,000 $273 1000 1000 1000 
D12 F 29-Sep-08 11 1 0 1 $12,500 $1,136 1400 1400 1400 
A06 F 4-Aug-08 13 1 0 1 $13,525 $1,040 1200 1200 1200 
G07 M 14-Oct-07 33 1 3 4 $14,323 $434 1340 1340 1340 
H08 F 22-Aug-08 6 1 1 2 $15,950 $2,658 1400 1400 1400 
B12 F 14-Aug-09 20 2 4 2 $16,400 $820 800 1615 1207.5 
C12 M 26-Oct-08 24 1 2 3 $19,300 $804 1406 1406 1406 
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Well Position Sex DOB No. Races 1st Places 2nd Places 3rd Places 
Total prize 
money AUS $ 
Average $ per 
race 
Min-Dist-Win 
(M) 
Max-Dist-Win 
(M) 
Average-Dist-
Win (M) 
G10 M 28-Aug-08 14 1 1 3 $20,295 $1,450 1400 1400 1400 
H06 F 11-Oct-00 47 2 10 1 $20,625 $439 1400 1900 1650 
G08 M 6-Oct-08 13 1 2 4 $22,275 $1,713 1500 1500 1500 
B10 F 7-Oct-08 14 2 2 1 $23,755 $1,697 1200 1200 1200 
C02 F 1-Sep-08 20 3 2 4 $25,330 $1,267 1200 1400 1300 
E10 M 3-Dec-08 23 2 2 3 $25,625 $1,114 1000 1400 1200 
F05 M 22-Sep-08 19 3 2 3 $28,000 $1,474 1200 1300 1250 
F09 M 11-Oct-08 19 2 3 3 $28,923 $1,522 1600 1850 1725 
D03 F 11-Oct-08 6 3 1 0 $30,900 $5,150 850 1100 975 
H11 M 13-Oct-08 24 1 5 2 $31,135 $1,297 1000 1000 1000 
C10 F 23-Aug-08 33 2 4 2 $36,150 $1,095 1420 1650 1535 
A04 F 16-Sep-08 15 4 2 1 $36,600 $2,440 1430 1716 1573 
B11 M 15-Sep-08 26 4 0 3 $36,800 $1,415 900 1000 950 
A08 F 24-Oct-06 35 7 5 1 $45,102 $1,289 900 1200 1050 
A09 M 5-Nov-07 17 2 3 0 $53,893 $3,170 1500 1800 1650 
F02 M 3-Sep-08 18 4 5 0 $62,300 $3,461 1200 1600 1400 
A07 M 4-Nov-06 50 5 7 7 $62,520 $1,250 1300 1700 1500 
F06 M 15-Nov-08 25 2 6 1 $63,200 $2,528 1000 1200 1100 
F03 M 15-Aug-08 15 7 2 3 $78,350 $5,223 1100 1220 1160 
G04 M 9-Oct-07 29 5 7 1 $133,033 $4,587 1100 1300 1200 
C03 F 8-Nov-00 47 12 10 9 $139,990 $2,979 1000 1450 1225 
G02 F 1-Nov-08 21 3 1 1 $193,661 $9,222 1000 1200 1100 
F07 M 2-Oct-06 52 9 11 3 $245,062 $4,713 1200 2010 1605 
D09 M 7-Sep-07 31 7 2 4 $289,287 $9,332 1310 2500 1905 
D10 M 25-Nov-08 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
E01 M 9-Sep-08 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
B01 M 1-Sep-08 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
B09 M 2-Oct-08 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
A01 M 20-Nov-08 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
G03 M 30-Oct-08 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
D11 M 22-Oct-08 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
F10 M 11-Nov-08 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
A12 M 2008 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
C09 M 2008 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
H12 F 14-Oct-08 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
H03 F 11-Sep-08 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
B04 F 18-Nov-08 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
D04 F 23-Oct-08 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
E04 F 21-Aug-2008 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
H09 F 5-Aug-07 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
B05 F 2-Aug-08 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
D08 F 19-Nov-08 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
B06 F 20-Aug-08 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
A02 F 11-Nov-08 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
F11 F 22-Oct-08 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
C07 F 10-Sep-03 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
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money AUS $ 
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race 
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(M) 
Max-Dist-Win 
(M) 
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Win (M) 
F12 F 2008 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
C04 F 2008 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
E11 F 2008 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
G06 F 2008 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
B02 F 25-Sep-08 Unraced N/A N/A N/A N/A N/A N/A N/A N/A 
C01 N/A No sample, no experimental reagents. 
H02 N/A No sample, experimental reagents only 
H01 N/A High grade DNA isolated from blood was run with each experiment to help identify potential experimental errors that may occur. 
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10.9 MYH7 All Variant Information Table 
BUILD: EquCab2.0, GENE: MYH7, GENE TRANSCRIPT: ENSECA00000019844.  
CHROMOSOME AND GENE REGION: 1: 161,506,573-161,527,244, STRAND: MINUS. 
ALTERNATE SPLICE TRANSCRIPTS: ENSECAT00000023357, ENSECAT00000023389, ENSECAT000000023469. 
Location Exon 
Anomaly Position; 
Chromosome 
Position 
Exon: 
Position 
Nucleotide Sequence 
Variant 
Codon 
Position 
Amino Acid 
Sequence 
Amino Acid 
Change 
Variant 
Allele 
Frequency 
Reference 
Allele 
Frequency 
P Value 
(two 
tailed) 
HWB 
Normal 
Distribution 
(P<0.05) 
1 1/ 5' UTR g.161527202A>G c.1:43A>G 
GTAGACACATTTG(A/G)GAAGC
CAAGGTAA 
N/A N/A N/A 0.237 0.763 0.0488 YES 
2 N/A g.161527169G>A c.1:+24G>A 
CTGAAGATGGGGT(G/A)TGAGG
GATTCTG 
N/A N/A N/A 0.242 0.758     
3 N/A g.161526822A>G c.2:-56A>G 
AAGGGGAGAGCCC(A/G)GGGA
GAGGAGG 
N/A N/A N/A 0.102 0.898     
6 N/A g.161526100T>C c.3:+8T>C 
ATCTACGTGAGTG(T/C)GAAAC
CTACGCTA 
N/A N/A N/A 0.247 0.753     
7 4 g.161525691T>C c.4:135T>C 
CCATCTCTGACAA(T/C)GCCTAC
CAGTACA 
AA* FSISD(N)AYQYM - 0.247 0.753 0.0452 YES 
8 N/A g.161525653C>T c.4:+16C>T 
GACAGGCCCCAAG(C/T)GAAGG
TTTTTCCT 
N/A N/A N/A 0.113 0.887     
9 N/A g.161525517T>C c.5:-42T>C 
AGAGGAGAGCATC(T/C)TGTGC
AGCTCCTG 
N/A N/A N/A 0.258 0.796     
10 N/A g.161524000C>T c.9:-87C>T 
CTGCCTTTTGCTG(C/T)TACATT
TATCATT 
N/A N/A N/A 0.011 0.989     
11 10 g.161523485G>A c.10:95G>A 
CTGAGGAGCTCAT(G/A)GCCAC
TGATGTAA 
AT* EEL(M/I)ATD p.Met331Ile 0.011 0.989 0.1791 NO 
12 N/A g.161522023G>A 
c.14:-
106G>A 
TCCCTGCCCTGAC(G/A)TGGGA
GGGGACCA 
N/A N/A N/A 0.274 0.726     
13 N/A 
g.161522003_1615
21958del 
c.14:-40_-
86del 
CCACA[CCCCTTGCTGGGCTGGG
GCTGACCCCATTGGCCACTCAGC
CACCTG]CCTACC 
N/A N/A N/A 0.000 1.000     
14 N/A g.161521926T>C c.14:-9T>C 
CCCTCCCTCCCTC(T/C)CCCTGC
AGTTCAA 
N/A N/A N/A 0.043 0.957     
15 N/A g.161520800V>C 
c.16A:+1V>
C 
ACTGAGGAGCAGG(G/C)TTTCT
GCCATGGT 
N/A N/A N/A 0.000 1.000     
16 N/A g.161518736A>G c.21:-19A>G 
CCTGGTCATGCCC(A/G)CACAC
ACCTTCTT 
N/A N/A N/A 0.011 0.989     
17 21 g.161518675C>T c.21:43C>T 
GCTGGAGGAGATG(C/T)GAGAT
GAGAGGC 
*GA LLEEM(R)DERLS - 0.011 0.989 0.1791 NO 
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18 22 g.161518102C>T c.22: 232C>T 
TGCAGGAGAAGAA(C/T)GACCT
ACAGCTCC 
AA* LLQEK(N)DLQLQ - 0.253 0.747 0.0439 YES 
19 23 g.161517370T>C c.23:90T>C 
TGAAGGAGATGAC(T/C)GAGAG
GCTGGAG 
AC* QALDD(L)QAEED - 0.108 0.892 0.1044 NO 
21 24 g.161516922C>T c.24:108C>T 
CCCTGGATGACCT(C/T)CAGGCT
GAAGAGG 
CT* KVKEM(T)ERLED - 0.113 0.887 0.1032 NO 
23 N/A g.161515875C>G c.25:+40C>G 
TTTCCCCCTCCCT(C/G)GCCCAG
CAGCCTG 
N/A N/A N/A 0.360 0.640     
24 N/A g.161515874G>C c.25:+41G>C 
TTCCCCCTCCCTC(G/C)CCCAGC
AGCCTGT 
N/A N/A N/A 0.000 1.000     
25 N/A g.161514854C>A c.26:-51C>A 
CGCTGGTGGGCCC(C/A)CTGGA
GCCTAATG 
N/A N/A N/A 0.011 0.989     
27 27 g.161513922C>T c.27:45C>T 
AGGCCGAGCGCAC(C/T)GCCAG
GGCCAAG 
AC* LEAER(T)ARAKV - 0.086 0.914 0.1183 NO 
29 27 g.161513802T>C c.27:165T>C 
TGAACAAGAAGCG(T/C)GAGGC
CGAGTTCC 
CG* MNKKR(R)EAEFQ - 0.242 0.758 0.0485 YES 
30 27 g.161513712T>C c.27:255T>C 
GCAAGAAGCACGC(T/C)GACAG
CGTGGCT 
GC* LRKKH(A)DSVAE - 0.398 0.602 0.0217 YES 
31 27 g.161513676T>C c.27:291T>C 
AGCAGATCGACAA(T/C)CTGCA
GCGCGTGA 
AA* GEQID(N)LQRVK - 0.113 0.887 0.1012 NO 
32 N/A g.161513385C>T c.28:-18C>T 
AGCCATCATATGA(C/T)TCTCCT
TCCTCTC 
N/A N/A N/A 0.005 0.995     
33 N/A g.161513198A>G c.28:+43A>G 
CCTGAGCCACCCC(A/G)GCTCT
GGGTAGAC 
N/A N/A N/A 0.108 0.892     
34 N/A 
g.161513173- 
161513093dup[2]  
c.28:+67dup[
2]  
[CCTCTCCAGAGAATGGGGCCT
GAGGGTTAGGGGAGTGGCTGG
AGGGAGAGGCGAGTGACTGAC
CTTGAAGAGTTGAGTGGG][2] 
N/A N/A N/A 0.570 0.430     
35 N/A g.161512212G>C 
c.30:-
107G>C 
GGAGGTAGAGATG(G/C)CTGAG
GCCATGG 
N/A N/A N/A 0.237 0.763     
36 N/A g.161512170G>A c.30:-65G>A 
GGTTGAGGAGATG(G/A)GCAAG
GGCTGGG 
N/A N/A N/A 0.011 0.989     
37 30 g.161512025A>G c.30:81A>G 
ACGAGGAGGAGAC(A/G)GAGG
CCAAGGC 
AC* QYEEE(T)EAKAE - 0.392 0.608 0.0208 YES 
38 N/A g.161511423C>T c.31:-3C>T 
CCATCTCCCCGGG(C/T)AGGAA
GAAGCTGG 
N/A N/A N/A 0.005 0.995     
39 31 g.161511409C>T c.31:12C>T 
AGGAAGAAGCTGG(C/T)GCAGC
GGCTGCA 
G*G KKL(A/V)QRL p.Ala1400Val 0.005 0.995 0.1791 NO 
40 31 g.161511398C>T c.31:23C>T 
GGCGCAGCGGCTG(C/T)AAGAC
GCCGAGG 
*AA QRL(Q/STOP)DAE p.Gln1404Stop 0.005 0.995 0.1791 NO 
41 31 g.161511396A>G c.31:25A>G 
CGCAGCGGCTGCA(A/G)GACGC
CGAGGAG 
CA* LAQRL(Q)DAEEA - 0.043 0.957 0.1662 NO 
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42 31 g.161511393C>T c.31:28C>T 
AGCGGCTGCAAGA(C/T)GCCGA
GGAGGCC 
GA* AQRLQ(D)AEEAV - 0.097 0.903 0.1234 NO 
43 31 g.161511366T>C c.31:55T>C 
TGGAGGCCGTCAA(T/C)GCCAA
GTGTTCGT 
AA* VEAV(N)AKCSS - 0.091 0.909 0.1274 NO 
44 31 g.161511357T>C c.31:64T>C 
GCCAAGTG(T/C)TCGTCTCTTGA
G 
TG* AVNAK(C)SSLEK - 0.059 0.941 0.1529 NO 
45 31 g.161511348T>G c.31:73T>G 
AGTGTTCGTCTCT(T/G)GAGAAG
ACCAAGC 
CT* AKCSS(L)EKTKH - 0.086 0.914 0.1356 NO 
46 31 g.161511309C>T c.31:112C>T 
ATGAGATCGAGGA(C/T)CTGAT
GGTGGATG 
GA* QNEIE(D)LMVDV - 0.027 0.973 0.1619 NO 
47 31 g.161511282C>T c.31:139C>T 
TGGAGCGCTCCAA(C/T)GCGGC
CGCCGCGG 
AA* DVERS(N)AAAAA - 0.005 0.995 0.1791 NO 
48 31 g.161511266C>T c.31:155C>T 
GCCGCGGCC(C/T)TGGACAAGA
AGC 
*TG 
AAAAA(L)DKKQ
R 
- 0.005 0.995 0.1791 NO 
49 N/A g.161511231C>T c.31:-6C>T 
TCGACAAGGTGGG(C/T)TGGGG
TCAGGGG 
N/A N/A N/A 0.005 0.995     
50 N/A g.161511212C>T c.31:-25C>T 
TCAGGGGCCGCAG(C/T)CAGGA
GACAGAG 
N/A N/A N/A 0.005 0.995     
51 N/A g.161511211C>T c.31:-26C>T 
TCAGGGGCCGCAGC(C/T)AGGA
GACAGAG 
N/A N/A N/A 0.005 0.995     
52 N/A g.161511191C>T c.31:-46C>T 
CAGAGCAGGGGGC(C/T)TGGTG
TCCTCAA 
N/A N/A N/A 0.005 0.995     
53 N/A g.161511184C>T c.31:-53C>T 
GGGGGCCTGGTGT(C/T)CTCAA
GGAGGAC 
N/A N/A N/A 0.011 0.989     
54 N/A g.161511172C>T c.31:-65C>T 
TCCTCAAGGAGGA(C/T)ATTCTG
TGGGGGA 
N/A N/A N/A 0.011 0.989     
55 N/A g.161511148C>T c.32:+79C>T 
GGAGGCGGCTGAG(C/T)CCAGA
TGAGGGG 
N/A N/A N/A 0.011 0.989     
56 N/A g.161511147C>T c.32:+78C>T 
GAGGCGGCTGAGC(C/T)CAGAT
GAGGGGC 
N/A N/A N/A 0.016 0.984     
57 N/A g.161511146C>T c.32:+77C>T 
AGGCGGCTGAGCC(C/T)AGATG
AGGGGCC 
N/A N/A N/A 0.005 0.995     
58 N/A g.161511134C>T c.32:+65C>T 
CCAGATGAGGGGC(C/T)TGGGC
AGCCCCT 
N/A N/A N/A 0.011 0.989     
59 N/A g.161511095C>T c.32:+26C>T 
GGGGCTGGGCCTG(C/T)AAGTG
AGCCCCG 
N/A N/A N/A 0.005 0.995     
60 32 g.161511066C>T c.32:4C>T 
ATCCCCGTAGATC(C/T)TGGCCG
AGTGGAA 
*TG NFDKI(L)AEWKQ - 0.011 0.989 0.1791 NO 
61 32 g.161511062C>T c.32:8C>T 
CCGTAGATCCTGG(C/T)CGAGT
GGAAGCAG 
G*C KIL(A/V)EWK p.Ala1460Val 0.016 0.984 0.1705 NO 
62 32 g.161511061C>T c.32:9C>T 
CGTAGATCCTGGC(C/T)GAGTG
GAAGCAGA 
GC* FDKIL(A)EWKQK - 0.016 0.984 0.1747 NO 
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63 32 g.161511051C>T c.32:19C>T 
GGCCGAGTGGAAG(C/T)AGAAG
TACGAGG 
*AG 
EWK(Q/STOP)KY
E 
p.Gln1464Stop 0.005 0.995 0.1791 NO 
64 32 g.161511033C>T c.32:37C>T 
ACGAGGAGTCG(C/T)AGTCGGA
GCTG 
*AG EES(Q/STOP)SEL p.Gln1470Stop 0.005 0.995 0.1791 NO 
65 32 g.161511029C>T c.32:41C>T 
CGAGGAGTCGCAGT(C/T)GGAG
CTGGAGT 
T*G ESQ(S/L)ELE p.Ser1471Leu 0.005 0.995 0.1791 NO 
66 32 g.161511017C>T c.32:53C>T 
TCGGAGCTGGAGT(C/T)CTCGC
AGAAGGA 
T*C ELE(S/F)SQK p.Ser1475Phe 0.005 0.995 0.1791 NO 
67 32 g.161510994C>T c.32:76C>T 
GGAGGCGCGCTCC(C/T)TCAGC
ACCGAGCT 
*TC ARS(L/F)STE p.Leu1483Phe 0.005 0.995 0.1791 NO 
68 32 g.161510989C>T c.32:81C>T 
CGCGCTCCCTCAG(C/T)ACCGA
GCTCTTCA 
AG* EARSL(S)TELFK - 0.005 0.995 0.1791 NO 
69 32 g.161510986C>T c.32:84C>T 
GCTCCCTCAGCAC(C/T)GAGCTC
TTCAAGC 
AC* ARSLS(T)ELFKL - 0.016 0.984 0.1747 NO 
70 32 g.161510950C>T c.32:120C>T 
CCTATGAGGAGTC(C/T)CTGGA
GCACCTGG 
TC* NAYEE(S)LEHLET - 0.011 1.000 0.1748 NO 
71 32 g.161510943C>T c.32:127C>T 
GGAGTCCCTGGAG(C/T)ACCTG
GAGACCTT 
*AC SLE(H/Y)LET p.His1500Tyr 0.005 0.995 0.1791 NO 
72 32 g.161510941C>T c.32:129C>T 
AGTCCCTGGAGCA(C/T)CTGGA
GACCTTCA 
CA* EESLE(H)LETFK - 0.005 0.995 0.1791 NO 
73 32 g.161510933C>T c.32:137C>T 
GAGCACCTGGAGA(C/T)CTTCA
AGCGGGA 
A*C HLE(T/I)FKR p.Thr1503Ile 0.005 0.995 0.1791 NO 
74 32 g.161510929C>T c.32:141C>T 
ACCTGGAGACCTT(C/T)AAGCG
GGAGAACA 
TT* EHLET(F)KRENK - 0.011 0.989 0.1791 NO 
75 32 g.161510911C>T c.32:159C>T 
GGGAGAACAAGAA(C/T)CTCCA
GGGTGTG 
AA* KRENK(N)LQEEI - 0.011 0.989 0.1791 NO 
76 32 g.161510908C>T c.32:162C>T 
AGAACAAGAACCT(C/T)CAGGG
TGTGCTGG 
CT* RENKN(L)QEEIS - 0.005 0.995 0.1791 NO 
77 N/A g.161510891C>T c.32:-13C>T 
GGTGTGCTGGGGC(C/T)CGAGA
GGCCGGG 
N/A N/A N/A 0.011 0.989     
78 N/A g.161510890C>T c.32:-14C>T 
GTGTGCTGGGGCC(C/T)GAGAG
GCCGGGG 
N/A N/A N/A 0.032 0.968     
79 N/A g.161510882C>T c.32:-22C>T 
GGGCCCGAGAGGC(C/T)GGGGA
GGGGCC 
N/A N/A N/A 0.011 0.989     
80 N/A g.161510858C>T c.32:-46C>T 
CAGGGGTAGTGTC(C/T)ACATA
TGGTGCCA 
N/A N/A N/A 0.005 0.995     
81 N/A g.161510853A>G c.32:-51A>G 
GTAGTGTCCACAT(A/G)TGGTG
CCACCTAG 
N/A N/A N/A 0.005 0.995     
82 N/A g.161510850G>A c.32:-54G>A 
GTGTCCACATATG(G/A)TGCCA
CCTAGGGG 
N/A N/A N/A 0.005 0.995     
83 N/A g.161510843C>T c.32:-61C>T 
CATATGGTGCCAC(C/T)TAGGG
GCTCCAAG 
N/A N/A N/A 0.005 0.995     
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84 N/A g.161510836C>T c.32:-68C>T 
TGCCACCTAGGGG(C/T)TCCAA
GAGGCGTG 
N/A N/A N/A 0.005 0.995     
85 N/A g.161510826C>T c.32:-78C>T 
GGGCTCCAAGAGG(C/T)GTGCC
CCCCCCCC 
N/A N/A N/A 0.032 0.968     
86 34 g.161509950A>G c.34:168A>G 
CCCTGGACGCGGA(A/G)ACACG
CAGCCGC 
GA* TSLDA(E)TRSRN - 0.581 0.409 0.02 YES 
87 34 g.161509947A>G c.34:171A>G 
TGGACGCGGAAAC(A/G)CGCAG
CCGCAAC 
AC* SLDAE(T)RSRNE - 0.581 0.409 0.0203 YES 
88 N/A g.161509587C>T c.35:-31C>T 
CAAAGGTCAGTTC(C/T)CTCTCT
CATTCCC 
N/A N/A N/A 0.011 0.989     
89 35 g.161509404T>C c.35:153T>C 
CTCGGAAGCTGGC(T/C)GAGCA
GGAGCTG 
GC* RSRKL(A)EQELI - 0.220 0.780 0.0594 NO 
90 N/A g.161509243C>T c.36:-12C>T 
ATGCTCTGCCTAC(C/T)CCACTC
CTCAGAA 
N/A N/A N/A 0.005 0.995     
91 36 g.161509226C>T c.36:6C>T 
CTCCTCAGAACAC(C/T)AGCCTC
ATCAACC 
AC* LHSQN(T)SLINQ - 0.011 0.989 0.1791 NO 
92 36 g.161509185C>A c.36:47C>A 
GACGCAGACCTGT(C/A)CCAGC
TTCAGACT 
T*C ADL(S/Y)QLQ p.Ser1741Thr 0.011 0.989 0.1791 NO 
93 36 g.161509180C>T c.36:52C>T 
AGACCTGTCCCAG(C/T)TTCAGA
CTGAAGT 
*TT LSQ(L/F)QTE p.Leu1743Phe 0.011 0.989 0.1748 NO 
94 36 g.161509177C>T c.36:55C>T 
CCTGTCCCAGCTT(C/T)AGACTG
AAGTGGA 
*AG SQL(Q/STOP)TEV p.Gln1744Stop 0.011 0.989 0.1748 NO 
95 36 g.161509173C>T c.36:59C>T 
TCCCAGCTTCAGA(C/T)TGAAGT
GGAGGAG 
A*T QLQ(T/I)EVE p.Thr1745Ile 0.011 0.989 0.1791 NO 
96 36 g.161509158C>T c.36:74C>T 
GAAGTGGAGGAGG(C/T)AGTGC
AGGAGTG 
G*A VEE(A/V)VQE p.Val1750Ala 0.005 0.995 0.1791 NO 
97 36 g.161509153C>T c.36:79C>T 
GGAGGAGGCAGTG(C/T)AGGAG
TGCAGGA 
*AG EAV(Q/STOP)ECR p.Gln1752Stop 0.005 0.995 0.1791 NO 
98 36 g.161509145C>T c.36:87C>T 
CAGTGCAGGAGTG(C/T)AGGAA
TGCCGAG 
TG* EAVQE(C)RNAEE - 0.011 0.989 0.1791 NO 
99 36 g.161509136C>T c.36:96C>T 
AGTGCAGGAATGC(C/T)GAGGA
GAAGGCC 
GC* QECRN(A)EEKAK - 0.011 0.989 0.1748 NO 
100 36 g.161509133G>A c.36:99G>A 
GCAGGAATGCCGA(G/A)GAGAA
GGCCAAG 
GA* ECRNA(E)EKAKK - 0.011 0.989 0.1791 NO 
101 36 g.161509116C>T c.36:116C>T 
AAGGCCAAGAAGG(C/T)CATCA
CGGACGT 
G*C AKK(A/V)ITD p.Val1764Ala 0.016 0.984 0.1747 NO 
102 36 g.161509106C>T c.36:126C>T 
AGGCCATCACGGA(C/T)GTGAG
TCCCCTCA 
GA* 
KKAIT(D)AAMM
A 
- 0.022 0.978 0.1748 NO 
103 N/A g.161509060C>T c.36:+46C>T 
CCGGCTCCAGGCC(C/T)AGGTG
TCCTTGGA 
N/A N/A N/A 0.027 0.973     
104 N/A g.161509059A>G c.36:+47A>G 
CGGCTCCAGGCCC(A/G)GGTGT
CCTTGGAT 
N/A N/A N/A 0.011 0.989     
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105 N/A g.161509045C>T c.36:+61C>T 
GGTGTCCTTGGAT(C/T)GGGCA
GTGAGTGC 
N/A N/A N/A 0.011 0.989     
106 N/A g.161509001C>G c.37:-15C>G 
CGGTGCATCAGCT(C/G)TCTCCC
GCCCACA 
N/A N/A N/A 0.011 0.989     
107 N/A g.161508997C>T c.37:-11C>T 
GCATCAGCTCTCT(C/T)CCGCCC
ACAGGCT 
N/A N/A N/A 0.022 0.978     
108 37 g.161508984T>C c.37:3T>C 
CCCGCCCACAGGC(T/C)GCCAT
GATGGCGG 
GC* KAITD(A)AMMAE - 0.392 0.608 0.0208 YES 
109 38 g.161507732T>C c.38:48T>C 
AGGACCTGGTGGA(T/C)AAGCT
GCAGCTGA 
GA* LQDLV(D)KLQLK - 0.677 0.763 0.0497 YES 
110 N/A g.161506840C>T 
c.40:-
134C>T 
GGCACATCCGCCA(C/T)CCATG
GGGGCCCA 
N/A N/A N/A 0.043 0.989     
111 N/A g.161506820C>T 
c.40:-
114C>T 
GGGCCCATCAGGC(C/T)ACACA
GCATCCTT 
N/A N/A N/A 0.016 0.995     
112 N/A g.161506805C>T c.40:-99C>T 
CACAGCATCCTTC(C/T)ACCCAT
CAGGTTC 
N/A N/A N/A 0.011 0.989     
113 N/A g.161506802C>T c.40:-96C>T 
AGCATCCTTCCAC(C/T)CATCAG
GTTCCCC 
N/A N/A N/A 0.005 0.995     
114 N/A g.161506801C>T c.40:-95C>T 
GCATCCTTCCACC(C/T)ATCAGG
TTCCCCA 
N/A N/A N/A 0.011 0.989     
115 N/A g.161506783C>T c.40:-77C>T 
GGTTCCCCAGCCC(C/T)CCTTTG
ACTTCTG 
N/A N/A N/A 0.011 0.989     
116 N/A g.161506782C>T c.40:-76C>T CCCCAGCCCC(C/T)CTTTGACTT N/A N/A N/A 0.005 0.995     
117 N/A g.161506762C>T c.40:-56C>T 
CTTCTGTGCCCAG(C/T)CCTGCC
CCACACC 
N/A N/A N/A 0.005 0.995     
118 N/A g.161506755C>T c.40:-49C>T 
GCCCAGCCCTGCC(C/T)CACACC
CACCTCT 
N/A N/A N/A 0.011 0.989     
119 N/A g.161506754C>T c.40:-48C>T 
CCCAGCCCTGCCC(C/T)ACACCC
ACCTCTC 
N/A N/A N/A 0.005 0.995     
120 N/A g.161506752C>T c.40:-46C>T 
CAGCCCTGCCCCA(C/T)ACCCAC
CTCTCTG 
N/A N/A N/A 0.011 0.989     
121 3' UTR g.161506608C>T c.40:19C>T 
GAATGAGGAGTAG(C/T)TGTGC
CACATCTT 
N/A N/A - 0.005 0.995 0.1791 NO 
122 3' UTR g.161506680C>T c.40:27C>T 
AGTAGCTGTGCCA(C/T)ATCTTC
TTGACCT 
N/A N/A - 0.011 0.989 0.1748 NO 
123 3' UTR g.161506664C>T c.40:43C>T 
CTTCTTGACCTGC(C/T)CAGTCC
TGAGGGT 
N/A N/A - 0.005 0.995 0.1791 NO 
124 3' UTR g.161506648C>T c.40:59C>T 
GTCCTGAGGGTGC(C/T)AATGG
AGTTCCAG 
N/A N/A - 0.005 0.995 0.1791 NO 
125 3' UTR g.161506581C>T c.40:126C>T 
TAAAGCAATTTTC(C/T)TTGAAG
TGAGATC 
N/A N/A - 0.005 0.995 0.1791 NO 
126 
AFTER 
3' UTR 
g.161506568C>T c.40:+5C>T 
CTTGAAGTGAGAT(C/T)CTGCCT
CTAGACT 
N/A N/A N/A 0.005 0.995     
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127 
AFTER 
3' UTR 
g.161506535C>T c.40:+38C>T 
CACTGCCTGCCAG(C/T)CACAG
GAACATGG 
N/A N/A N/A 0.005 0.995     
128 
AFTER 
3' UTR 
g.161506534C>T c.40:+39C>T 
ACTGCCTGCCAGC(C/T)ACAGG
AACATGGG 
N/A N/A N/A 0.005 0.995     
129 
AFTER 
3' UTR 
g.161506508A>C c.40:+65A>C 
GGTCAGGGATATG(A/C)GGGTG
GGACACA 
N/A N/A N/A 0.414 0.586     
130 
AFTER 
3' UTR 
g.161506446T>C 
c.40:+145T>
C 
AGCTTCACAGGC(T/C)AGACCA
AGGAGGCC 
N/A N/A N/A 0.011 0.989     
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10.10 microRNA: eca-mir-208b Variant Information Table 
BUILD: EquCab2.0, mRNA: eca-mir-208b, TRANSCRIPT: ENSECA00000026475, CHROMOSOME: GENE REGION: 1:161,511,741…161,511,762, STRAND: MINUS 
EXON 
Alternative 
Splice 
TRANSCRIPT 
INTRON 
(EXON-
EXON) 
ANOMALY 
POSITION; 
CHROMOSOME 
POSITION 
EXON: 
POSITION 
TYPE OF 
CHANGE 
LOCATION SEQUENCE 
NUCLIOTIDE 
REFERENCE 
SEQUENCE  
NO. HOMO-
ZYGOUS 
REFERENCE 
NO. 
HETERO-
ZYGOUS 
NO. 
HOMO-
ZYGOUS 
VARIANT 
REFERENCE 
ALLELE 
FREQUENCY 
VARIANT 
ALLELE 
FREQUENCY 
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
 
MicroRNA eca-mir-208b coding region is found within the MYH7 genomic intron region. 
No variations were found in this microRNA.  
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10.11 MYH7 Genotype and Variant Information Table 
BUILD: EquCab2.0, GENE: MYH7, GENE TRANSCRIPT: ENSECA00000019844.  
CHROMOSOME AND GENE REGION: 1: 161,506,573-161,527,244, STRAND: MINUS. 
ALTERNATE SPLICE TRANSCRIPTS: ENSECAT00000023357, ENSECAT00000023389, ENSECAT000000023469. 
Location Exon 
Anomaly Position; 
Chromosome 
Position 
Exon: Position Nucleotide Sequence 
No. 
Homozygous 
Reference 
No. 
Heterozygous 
No. 
Homozygous 
Variant 
Reference 
Allele 
Frequency 
Variant 
Allele 
Frequency 
1 1/ 5' UTR g.161527202A>G c.1:43A>G GTAGACACATTTG(A/G)GAAGCCAAGGTAA 54 34 5 142 44 
2 N/A g.161527169G>A c.1:+24G>A CTGAAGATGGGGT(G/A)TGAGGGATTCTG 56 29 8 141 45 
3 N/A g.161526822A>G c.2:-56A>G AAGGGGAGAGCCC(A/G)GGGAGAGGAGG 74 19 0 167 19 
6 N/A g.161526100T>C c.3:+8T>C ATCTACGTGAGTG(T/C)GAAACCTACGCTA 53 34 6 140 46 
7 4 g.161525691T>C c.4:135T>C CCATCTCTGACAA(T/C)GCCTACCAGTACA 53 34 6 140 46 
8 N/A g.161525653C>T c.4:+16C>T GACAGGCCCCAAG(C/T)GAAGGTTTTTCCT 72 21 0 165 21 
9 N/A g.161525517T>C c.5:-42T>C AGAGGAGAGCATC(T/C)TGTGCAGCTCCTG 55 38 5 148 48 
10 N/A g.161524000C>T c.9:-87C>T CTGCCTTTTGCTG(C/T)TACATTTATCATT 92 0 1 184 2 
11 10 g.161523485G>A c.10:95G>A CTGAGGAGCTCAT(G/A)GCCACTGATGTAA 92 0 1 184 2 
12 N/A g.161522023G>A c.14:-106G>A TCCCTGCCCTGAC(G/A)TGGGAGGGGACCA 56 23 14 135 51 
13 N/A 
g.161522003_1615219
58del 
c.14:-40_-86del 
CCACA[CCCCTTGCTGGGCTGGGGCTGACCCCAT
TGGCCACTCAGCCACCTG]CCTACC 
93 0 0 186 0 
14 N/A g.161521926T>C c.14:-9T>C CCCTCCCTCCCTC(T/C)CCCTGCAGTTCAA 89 0 4 178 8 
15 N/A g.161520800V>C c.16A:+1V>C ACTGAGGAGCAGG(G/C)TTTCTGCCATGGT 93 0 0 186 0 
16 N/A g.161518736A>G c.21:-19A>G CCTGGTCATGCCC(A/G)CACACACCTTCTT 92 0 1 184 2 
17 21 g.161518675C>T c.21:43C>T GCTGGAGGAGATG(C/T)GAGATGAGAGGC 92 0 1 184 2 
18 22 g.161518102C>T c.22: 232C>T TGCAGGAGAAGAA(C/T)GACCTACAGCTCC 52 35 6 139 47 
19 23 g.161517370T>C c.23:90T>C TGAAGGAGATGAC(T/C)GAGAGGCTGGAG 73 20 0 166 20 
21 24 g.161516922C>T c.24:108C>T CCCTGGATGACCT(C/T)CAGGCTGAAGAGG 73 19 1 165 21 
 179 
Location Exon 
Anomaly Position; 
Chromosome 
Position 
Exon: Position Nucleotide Sequence 
No. 
Homozygous 
Reference 
No. 
Heterozygous 
No. 
Homozygous 
Variant 
Reference 
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23 N/A g.161515875C>G c.25:+40C>G TTTCCCCCTCCCT(C/G)GCCCAGCAGCCTG 42 35 16 119 67 
24 N/A g.161515874G>C c.25:+41G>C TTCCCCCTCCCTC(G/C)CCCAGCAGCCTGT 93 0 0 186 0 
25 N/A g.161514854C>A c.26:-51C>A CGCTGGTGGGCCC(C/A)CTGGAGCCTAATG 92 0 1 184 2 
27 27 g.161513922C>T c.27:45C>T AGGCCGAGCGCAC(C/T)GCCAGGGCCAAG 77 16 0 170 16 
29 27 g.161513802T>C c.27:165T>C TGAACAAGAAGCG(T/C)GAGGCCGAGTTCC 52 37 4 141 45 
30 27 g.161513712T>C c.27:255T>C GCAAGAAGCACGC(T/C)GACAGCGTGGCT 33 46 14 112 74 
31 27 g.161513676T>C c.27:291T>C AGCAGATCGACAA(T/C)CTGCAGCGCGTGA 72 21 0 165 21 
32 N/A g.161513385C>T c.28:-18C>T AGCCATCATATGA(C/T)TCTCCTTCCTCTC 92 1 0 185 1 
33 N/A g.161513198A>G c.28:+43A>G CCTGAGCCACCCC(A/G)GCTCTGGGTAGAC 73 20 0 166 20 
34 N/A 
g.161513173- 
161513093dup[2]  
c.28:+67dup[2]  
[CCTCTCCAGAGAATGGGGCCTGAGGGTTAGGG
GAGTGGCTGGAGGGAGAGGCGAGTGACTGACC
TTGAAGAGTTGAGTGGG][2] 
16 48 29 80 106 
35 N/A g.161512212G>C c.30:-107G>C GGAGGTAGAGATG(G/C)CTGAGGCCATGG 53 36 4 142 44 
36 N/A g.161512170G>A c.30:-65G>A GGTTGAGGAGATG(G/A)GCAAGGGCTGGG 92 0 1 184 2 
37 30 g.161512025A>G c.30:81A>G ACGAGGAGGAGAC(A/G)GAGGCCAAGGC 34 45 14 113 73 
38 N/A g.161511423C>T c.31:-3C>T CCATCTCCCCGGG(C/T)AGGAAGAAGCTGG 92 1 0 185 1 
39 31 g.161511409C>T c.31:12C>T AGGAAGAAGCTGG(C/T)GCAGCGGCTGCA 92 1 0 185 1 
40 31 g.161511398C>T c.31:23C>T GGCGCAGCGGCTG(C/T)AAGACGCCGAGG 92 1 0 185 1 
41 31 g.161511396A>G c.31:25A>G CGCAGCGGCTGCA(A/G)GACGCCGAGGAG 89 0 4 178 8 
42 31 g.161511393C>T c.31:28C>T AGCGGCTGCAAGA(C/T)GCCGAGGAGGCC 79 10 4 168 18 
43 31 g.161511366T>C c.31:55T>C TGGAGGCCGTCAA(T/C)GCCAAGTGTTCGT 80 9 4 169 17 
44 31 g.161511357T>C c.31:64T>C GCCAAGTG(T/C)TCGTCTCTTGAG 86 3 4 175 11 
45 31 g.161511348T>G c.31:73T>G AGTGTTCGTCTCT(T/G)GAGAAGACCAAGC 82 6 5 170 16 
46 31 g.161511309C>T c.31:112C>T ATGAGATCGAGGA(C/T)CTGATGGTGGATG 88 5 0 181 5 
47 31 g.161511282C>T c.31:139C>T TGGAGCGCTCCAA(C/T)GCGGCCGCCGCGG 92 1 0 185 1 
48 31 g.161511266C>T c.31:155C>T GCCGCGGCC(C/T)TGGACAAGAAGC 92 1 0 185 1 
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49 N/A g.161511231C>T c.31:-6C>T TCGACAAGGTGGG(C/T)TGGGGTCAGGGG 92 1 0 185 1 
50 N/A g.161511212C>T c.31:-25C>T TCAGGGGCCGCAG(C/T)CAGGAGACAGAG 92 1 0 185 1 
51 N/A g.161511211C>T c.31:-26C>T TCAGGGGCCGCAGC(C/T)AGGAGACAGAG 92 1 0 185 1 
52 N/A g.161511191C>T c.31:-46C>T CAGAGCAGGGGGC(C/T)TGGTGTCCTCAA 92 1 0 185 1 
53 N/A g.161511184C>T c.31:-53C>T GGGGGCCTGGTGT(C/T)CTCAAGGAGGAC 91 2 0 184 2 
54 N/A g.161511172C>T c.31:-65C>T TCCTCAAGGAGGA(C/T)ATTCTGTGGGGGA 91 2 0 184 2 
55 N/A g.161511148C>T c.32:+79C>T GGAGGCGGCTGAG(C/T)CCAGATGAGGGG 91 2 0 184 2 
56 N/A g.161511147C>T c.32:+78C>T GAGGCGGCTGAGC(C/T)CAGATGAGGGGC 91 1 1 183 3 
57 N/A g.161511146C>T c.32:+77C>T AGGCGGCTGAGCC(C/T)AGATGAGGGGCC 92 1 0 185 1 
58 N/A g.161511134C>T c.32:+65C>T CCAGATGAGGGGC(C/T)TGGGCAGCCCCT 92 0 1 184 2 
59 N/A g.161511095C>T c.32:+26C>T GGGGCTGGGCCTG(C/T)AAGTGAGCCCCG 92 1 0 185 1 
60 32 g.161511066C>T c.32:4C>T ATCCCCGTAGATC(C/T)TGGCCGAGTGGAA 92 0 1 184 2 
61 32 g.161511062C>T c.32:8C>T CCGTAGATCCTGG(C/T)CGAGTGGAAGCAG 90 3 0 183 3 
62 32 g.161511061C>T c.32:9C>T CGTAGATCCTGGC(C/T)GAGTGGAAGCAGA 91 1 1 183 3 
63 32 g.161511051C>T c.32:19C>T GGCCGAGTGGAAG(C/T)AGAAGTACGAGG 92 1 0 185 1 
64 32 g.161511033C>T c.32:37C>T ACGAGGAGTCG(C/T)AGTCGGAGCTG 92 1 0 185 1 
65 32 g.161511029C>T c.32:41C>T CGAGGAGTCGCAGT(C/T)GGAGCTGGAGT 92 1 0 185 1 
66 32 g.161511017C>T c.32:53C>T TCGGAGCTGGAGT(C/T)CTCGCAGAAGGAG 92 1 0 185 1 
67 32 g.161510994C>T c.32:76C>T GGAGGCGCGCTCC(C/T)TCAGCACCGAGCT 92 1 0 185 1 
68 32 g.161510989C>T c.32:81C>T CGCGCTCCCTCAG(C/T)ACCGAGCTCTTCA 92 1 0 185 1 
69 32 g.161510986C>T c.32:84C>T GCTCCCTCAGCAC(C/T)GAGCTCTTCAAGC 91 1 1 183 3 
70 32 g.161510950C>T c.32:120C>T CCTATGAGGAGTC(C/T)CTGGAGCACCTGG 92 2 0 186 2 
71 32 g.161510943C>T c.32:127C>T GGAGTCCCTGGAG(C/T)ACCTGGAGACCTT 92 1 0 185 1 
72 32 g.161510941C>T c.32:129C>T AGTCCCTGGAGCA(C/T)CTGGAGACCTTCA 92 1 0 185 1 
73 32 g.161510933C>T c.32:137C>T GAGCACCTGGAGA(C/T)CTTCAAGCGGGA 92 1 0 185 1 
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74 32 g.161510929C>T c.32:141C>T ACCTGGAGACCTT(C/T)AAGCGGGAGAACA 92 0 1 184 2 
75 32 g.161510911C>T c.32:159C>T GGGAGAACAAGAA(C/T)CTCCAGGGTGTG 92 0 1 184 2 
76 32 g.161510908C>T c.32:162C>T AGAACAAGAACCT(C/T)CAGGGTGTGCTGG 92 1 0 185 1 
77 N/A g.161510891C>T c.32:-13C>T GGTGTGCTGGGGC(C/T)CGAGAGGCCGGG 92 0 1 184 2 
78 N/A g.161510890C>T c.32:-14C>T GTGTGCTGGGGCC(C/T)GAGAGGCCGGGG 88 4 1 180 6 
79 N/A g.161510882C>T c.32:-22C>T GGGCCCGAGAGGC(C/T)GGGGAGGGGCC 91 2 0 184 2 
80 N/A g.161510858C>T c.32:-46C>T CAGGGGTAGTGTC(C/T)ACATATGGTGCCA 92 1 0 185 1 
81 N/A g.161510853A>G c.32:-51A>G GTAGTGTCCACAT(A/G)TGGTGCCACCTAG 92 1 0 185 1 
82 N/A g.161510850G>A c.32:-54G>A GTGTCCACATATG(G/A)TGCCACCTAGGGG 92 1 0 185 1 
83 N/A g.161510843C>T c.32:-61C>T CATATGGTGCCAC(C/T)TAGGGGCTCCAAG 92 1 0 185 1 
84 N/A g.161510836C>T c.32:-68C>T TGCCACCTAGGGG(C/T)TCCAAGAGGCGTG 92 1 0 185 1 
85 N/A g.161510826C>T c.32:-78C>T GGGCTCCAAGAGG(C/T)GTGCCCCCCCCCC 90 0 3 180 6 
86 34 g.161509950A>G c.34:168A>G CCCTGGACGCGGA(A/G)ACACGCAGCCGC 15 46 31 76 108 
87 34 g.161509947A>G c.34:171A>G TGGACGCGGAAAC(A/G)CGCAGCCGCAAC 15 46 31 76 108 
88 N/A g.161509587C>T c.35:-31C>T CAAAGGTCAGTTC(C/T)CTCTCTCATTCCC 92 0 1 184 2 
89 35 g.161509404T>C c.35:153T>C CTCGGAAGCTGGC(T/C)GAGCAGGAGCTG 52 41 0 145 41 
90 N/A g.161509243C>T c.36:-12C>T ATGCTCTGCCTAC(C/T)CCACTCCTCAGAA 92 1 0 185 1 
91 36 g.161509226C>T c.36:6C>T CTCCTCAGAACAC(C/T)AGCCTCATCAACC 92 0 1 184 2 
92 36 g.161509185C>A c.36:47C>A GACGCAGACCTGT(C/A)CCAGCTTCAGACT 92 0 1 184 2 
93 36 g.161509180C>T c.36:52C>T AGACCTGTCCCAG(C/T)TTCAGACTGAAGT 91 2 0 184 2 
94 36 g.161509177C>T c.36:55C>T CCTGTCCCAGCTT(C/T)AGACTGAAGTGGA 91 2 0 184 2 
95 36 g.161509173C>T c.36:59C>T TCCCAGCTTCAGA(C/T)TGAAGTGGAGGAG 92 0 1 184 2 
96 36 g.161509158C>T c.36:74C>T GAAGTGGAGGAGG(C/T)AGTGCAGGAGTG 92 1 0 185 1 
97 36 g.161509153C>T c.36:79C>T GGAGGAGGCAGTG(C/T)AGGAGTGCAGGA 92 1 0 185 1 
98 36 g.161509145C>T c.36:87C>T CAGTGCAGGAGTG(C/T)AGGAATGCCGAG 92 0 1 184 2 
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99 36 g.161509136C>T c.36:96C>T AGTGCAGGAATGC(C/T)GAGGAGAAGGCC 91 2 0 184 2 
100 36 g.161509133G>A c.36:99G>A GCAGGAATGCCGA(G/A)GAGAAGGCCAAG 92 0 1 184 2 
101 36 g.161509116C>T c.36:116C>T AAGGCCAAGAAGG(C/T)CATCACGGACGT 91 1 1 183 3 
102 36 g.161509106C>T c.36:126C>T AGGCCATCACGGA(C/T)GTGAGTCCCCTCA 91 0 2 182 4 
103 N/A g.161509060C>T c.36:+46C>T CCGGCTCCAGGCC(C/T)AGGTGTCCTTGGA 90 1 2 181 5 
104 N/A g.161509059A>G c.36:+47A>G CGGCTCCAGGCCC(A/G)GGTGTCCTTGGAT 92 0 1 184 2 
105 N/A g.161509045C>T c.36:+61C>T GGTGTCCTTGGAT(C/T)GGGCAGTGAGTGC 92 0 1 184 2 
106 N/A g.161509001C>G c.37:-15C>G CGGTGCATCAGCT(C/G)TCTCCCGCCCACA 91 2 0 184 2 
107 N/A g.161508997C>T c.37:-11C>T GCATCAGCTCTCT(C/T)CCGCCCACAGGCT 91 0 2 182 4 
108 37 g.161508984T>C c.37:3T>C CCCGCCCACAGGC(T/C)GCCATGATGGCGG 34 45 14 113 73 
109 38 g.161507732T>C c.38:48T>C AGGACCTGGTGGA(T/C)AAGCTGCAGCTGA 53 36 45 142 126 
110 N/A g.161506840C>T c.40:-134C>T GGCACATCCGCCA(C/T)CCATGGGGGCCCA 92 0 4 184 8 
111 N/A g.161506820C>T c.40:-114C>T GGGCCCATCAGGC(C/T)ACACAGCATCCTT 92 1 1 185 3 
112 N/A g.161506805C>T c.40:-99C>T CACAGCATCCTTC(C/T)ACCCATCAGGTTC 91 2 0 184 2 
113 N/A g.161506802C>T c.40:-96C>T AGCATCCTTCCAC(C/T)CATCAGGTTCCCC 92 1 0 185 1 
114 N/A g.161506801C>T c.40:-95C>T GCATCCTTCCACC(C/T)ATCAGGTTCCCCA 91 2 0 184 2 
115 N/A g.161506783C>T c.40:-77C>T GGTTCCCCAGCCC(C/T)CCTTTGACTTCTG 91 2 0 184 2 
116 N/A g.161506782C>T c.40:-76C>T CCCCAGCCCC(C/T)CTTTGACTT 92 1 0 185 1 
117 N/A g.161506762C>T c.40:-56C>T CTTCTGTGCCCAG(C/T)CCTGCCCCACACC 92 1 0 185 1 
118 N/A g.161506755C>T c.40:-49C>T GCCCAGCCCTGCC(C/T)CACACCCACCTCT 91 2 0 184 2 
119 N/A g.161506754C>T c.40:-48C>T CCCAGCCCTGCCC(C/T)ACACCCACCTCTC 92 1 0 185 1 
120 N/A g.161506752C>T c.40:-46C>T CAGCCCTGCCCCA(C/T)ACCCACCTCTCTG 91 2 0 184 2 
121 3' UTR g.161506608C>T c.40:19C>T GAATGAGGAGTAG(C/T)TGTGCCACATCTT 92 1 0 185 1 
122 3' UTR g.161506680C>T c.40:27C>T AGTAGCTGTGCCA(C/T)ATCTTCTTGACCT 91 2 0 184 2 
123 3' UTR g.161506664C>T c.40:43C>T CTTCTTGACCTGC(C/T)CAGTCCTGAGGGT 92 1 0 185 1 
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Location Exon 
Anomaly Position; 
Chromosome 
Position 
Exon: Position Nucleotide Sequence 
No. 
Homozygous 
Reference 
No. 
Heterozygous 
No. 
Homozygous 
Variant 
Reference 
Allele 
Frequency 
Variant 
Allele 
Frequency 
124 3' UTR g.161506648C>T c.40:59C>T GTCCTGAGGGTGC(C/T)AATGGAGTTCCAG 92 1 0 185 1 
125 3' UTR g.161506581C>T c.40:126C>T TAAAGCAATTTTC(C/T)TTGAAGTGAGATC 92 1 0 185 1 
126 
AFTER 3' 
UTR 
g.161506568C>T c.40:+5C>T CTTGAAGTGAGAT(C/T)CTGCCTCTAGACT 92 1 0 185 1 
127 
AFTER 3' 
UTR 
g.161506535C>T c.40:+38C>T CACTGCCTGCCAG(C/T)CACAGGAACATGG 92 1 0 185 1 
128 
AFTER 3' 
UTR 
g.161506534C>T c.40:+39C>T ACTGCCTGCCAGC(C/T)ACAGGAACATGGG 92 1 0 185 1 
129 
AFTER 3' 
UTR 
g.161506508A>C c.40:+65A>C GGTCAGGGATATG(A/C)GGGTGGGACACA 36 37 20 109 77 
130 
AFTER 3' 
UTR 
g.161506446T>C c.40:+145T>C AGCTTCACAGGC(T/C)AGACCAAGGAGGCC 91 2 0 184 2 
 
  
 184 
10.12 CASQ2 Genotype and Variant Information Table 
BUILD: EquCab2.0, GENE: F621R3-HORSE (CASQ2). 
GENE TRANSCRIPT: ENSECAG00000021854, CHROMOSOME AND GENE REGION: 5:53131872…53192934, STRAND: FORWARD. 
Location Exon 
Anomaly Position: 
Chromosome Position 
Exon: Position Nucleotide Sequence 
No. 
Homozygous 
Reference 
No. 
Heterozygous  
No. 
Homozygous 
Variant 
Reference 
Allele 
Frequency 
Variant 
Allele 
Frequency 
1 N/A g.53132166C>T c.1:+45C>T GTGGGCACGGG(C/T)CGGCCGGCGGCGG 74 18 1 166 20 
2 3 g.53156085A>G c.3:27A>G GGAAGCCTGTAT(A/G)TTCTCAAGGGTG 87 5 1 179 7 
3 N/A g.53171907C>A c.7:-113C>A GGGTTTGTAGAG(C/A)TCTTCATGCTCT 78 15 0 171 15 
4 N/A g.53171916C>T c.7:-104C>T AGCTCTTCATG(C/T)TCTTGCAAATGT 78 15 0 171 15 
11 8 g.53178694G>T c.8:42G>T GGCCTTTGCAGA(G/T)AGGAGTGACCCA 92 1 0 185 1 
12 N/A g.53178726G>T c.8:+19G>T AAACCCTGAATCT(G/T)TTCTTTTTCACC 92 1 0 185 1 
13 N/A g.53178777C>T c.8:+70C>T TTGTCGGCCCCCA(C/T)CCTCCCTCTTCC 92 1 0 185 1 
14 N/A g.53178781C>T c.8:+74C>T CGGCCCCCACCCT(C/T)CCTCTTCCCTAA 92 1 0 185 1 
15 N/A g.53191497A>G c.10:+63A>G TTGCTGCCATGCA(A/G)CCCACACTGTGA 73 19 1 165 21 
16 N/A g.53191505T>C c.10:+71T>C ATGCAACCCACAC(T/C)GTGAGATTGAGG 73 19 1 165 21 
17 N/A g.53191506A>G c.10:+72A>G ATGCAACCCACACT(G/A)TGAGATTGAGGC 88 4 1 180 6 
18 N/A g.53191544G>C c.10:+110G>C GGGAAATGAGCAG(G/C)ACCCTTCATCCT 87 5 1 179 7 
19 N/A g.53191560C>T c.10:+126C>T CCTTCATCCTGCC(C/T)GAGCTCAGGAAA 88 4 1 180 6 
20 N/A g.53191581T>A c.10:+147T>A GAAACATGCCAG(T/A)GTGGCCCAATCC 74 17 2 165 21 
21 N/A g.53192420A>G c.11:-7A>G ATTCTGTCCCTC(G/A)TTGCAGGCTGAC 22 48 23 92 94 
22 11 g.53192513T>A c.11:87T>A AGGACGTGCTTTC(T/A)GGGAAGATAAAC 71 21 1 163 23 
23 11 g.53192574G>A c.11:148G>A GATGATGATGAC(G/A)ATGATGATGATG 71 21 1 163 23 
24 12 g.53192783C>T c.12.144C>T CCACTCCCTTCT(C/T)ATCAGGAGATGT 71 21 1 163 23 
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10.13 AKT1 Genotype and Variant Information Table 
BUILD: EquCab2.0, GENE: AKT1, GENE TRANSCRIPT: ENSECAT00000008264.  
CHROMOSOME AND GENE REGION: 24:461,097,51-461,330,97, STRAND: MINUS. 
Location Exon 
Anomaly Position: 
Chromosome 
Position 
Exon: Position Nucleotide Sequence 
No. 
Homozygous 
Reference 
No. 
Heterozygous  
No. 
Homozygous 
Variant 
Reference 
Allele 
Frequency 
Variant 
Allele 
Frequency 
1 
BEFORE 5' 
UTR 
g.46133251G>A c.1:-154G>A GGTGTGACG(G/A)GCCTCCTGG 92 1 0 185 1 
2 
BEFORE 5' 
UTR 
g.46133235G>A c.1:-138G>A TGGGCTCCT(G/A)TGAGTGGCG 92 1 0 185 1 
3 1/ 5' UTR 
g.46133169-
46133167delCGC 
c.1:-72-69delCGC TGTGGGCGC(CGC/---)TGGGCTTGG 79 10 4 168 18 
4 N/A g.46133025G>A c.1:+27G>A GGGGCTGGGCCTG(G/A)GGCCAGGGGCCTG 92 1 4 185 9 
5 N/A g.46133003G>A c.1:+49G>A GCCTGAGGCAGGG(G/A)GCCCAGAGCCGGC 92 1 4 185 9 
6 N/A g.46132993C>T c.1:+59C>T GGGGGCCCAGAGC(C/T)GGCCTGTGTGCTG 24 41 28 89 97 
7 N/A g.46118897G>T c.2:-8G>T TCACTGCCCTCGT(G/T)TCCTCAGGAGAGT 83 0 10 166 20 
8 N/A g.46118740C>T c.2:+21C>T TGCCGCGGCCGCC(C/T)GGCCTGGGAACTG 46 20 27 112 74 
9 EX5 g.46114436C>T c.5:9C>T CTCAGACCATGAA(C/T)GAGTTTGAGTACC 50 37 6 137 49 
10 N/A g.46114248T>C c.6:-4T>C TGGGACCTGTCTT(T/C)CAGGACGAGGTGG 27 39 27 93 93 
11 N/A g.46114122C>T c.6:+57C>T TGGGTGGGTGGCA(C/T)GGGAGTGGGGCAC 88 5 0 181 5 
12 N/A g.46112857C>T c.7:-82C>T CCCAGTGACCATC(C/T)CTCCAGCAGGGCG 64 0 29 128 58 
13 N/A g.46112843C>T c.7:-68C>T CTCCAGCAGGGCG(C/T)GTGGGGCAGCCCG 70 22 1 162 24 
14 N/A g.46112548A>G c.8:-49A>G GGAGGTGGCTGGG(A/G)TGGGGAGGGCACCT 5 29 59 39 147 
15 N/A g.46112547T>C c.8:-48T>C GGAGGTGGCTGGGA(T/C)GGGGAGGGCACCT 5 28 60 38 148 
16 N/A g.46111953C>T c.10:-48C>T AGTTCCCCCATGC(C/T)CCCTGTGTCCCGG 63 0 30 126 60 
17 N/A g.46111943C>T c.10:-38C>T CCCCCTGTGTC(C/T)CGGGCACCCTC 92 1 0 185 1 
18 N/A g.46111938C>A c.10:-33C>A TGTCCCGGG(C/A)ACCCTCTGAC 64 25 4 153 33 
19 N/A g.46111914G>A c.10:-9G>A GTGCCCCTGC(G/A)TCCCCCAGGT 60 28 5 148 38 
20 10 g.46111888C>T c.10:18C>T GGAGGACAACGA(C/T)TACGGCCGGGCG 59 26 8 144 42 
21 N/A g.46111678C>T c.10:+13C>T GTGCGCCCCCTG(C/T)CCGGGCCCTGGG 92 1 0 185 1 
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Location Exon 
Anomaly Position: 
Chromosome 
Position 
Exon: Position Nucleotide Sequence 
No. 
Homozygous 
Reference 
No. 
Heterozygous  
No. 
Homozygous 
Variant 
Reference 
Allele 
Frequency 
Variant 
Allele 
Frequency 
22 N/A g.46111607C>T C.11:-108C>T CTGCAGTGTC(C/T)CCACGGCAC 92 1 0 185 1 
23 N/A g.46111589C>T c.11:-90C>T ACTGGGCCCC(C/T)ACCCCCCGGGA 92 1 0 185 1 
24 N/A g.46111589A>G c.11:-89A>G ACTGGGCCCCC(A/G)CCCCCCGGGA 80 11 2 171 15 
25 11 g.46111442C>T c.11:58C>T TTCTTTGCCAG(C/T)ATCGTGTGGCAG 92 1 0 185 1 
26 N/A g.46111286C>T c.11:+126C>T CTCGTTCCTCC(C/T)AGGAGGAGCCAC 92 1 0 185 1 
27 N/A g.46111244C>T c.11:+168C>T GCACCTCCGCCC(T/C)CGTCAGGTTTGA 92 1 0 185 1 
28 N/A g.46110358G>A c.12:-133G>A GCATCCGTACC(G/A)CCTGGGCACAG 64 27 2 155 31 
29 N/A g.46109681C>T c.13:-70C>T TCGATGGATCG(C/T)GAGGACGTCTC 50 22 7 122 36 
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10.14 PI3K Genotype and Variant Information Table 
BUILD: EquCab2.0, GENE: PI3K1 (PIK3R1), GENE TRANSCRIPT: ENSECAG00000019837.  
CHROMOSOME AND GENE REGION: 21:-5741577… -5673136, STRAND: MINUS. 
Location Exon 
Anomaly Position: 
Chromosome Position 
Exon: Position Nucleotide Sequence 
No. 
Homozygous 
Reference 
No. 
Heterozygous  
No. 
Homozygous 
Variant 
Reference 
Allele 
Frequency 
Variant 
Allele 
Frequency 
1 1 g.-5741305A>G c.1:272A>G CAAAGCCCCGGCC(A/G)CCTCGACCCCTT 86 6 1 178 8 
2 2 g.-5698092G>A c.2:53G>A CTGACATCGCTCC(G/A)CCTCTTCTTATC 90 3 0 183 3 
3 N/A g.-5697946C>T c.2:+106C>T ACCTGTGCTAGA(C/T)GCACAAGCTATT 69 3 21 141 45 
4 N/A g.-5697945G>A c.2:+107G>A ACCTGTGCTAGAC(G/A)CACAAGCTATTT 89 4 0 182 4 
5 N/A g.-5692350A>G c.4:-44A>G CCCAACCAACTAA(A/G)TGTCTAAAATGT 89 4 0 182 4 
6 5 g.-5691357G>A c.5:10G>A GAAGTACAAA(G/A)CTCCGAGGAATA 85 8 0 178 8 
7 5 g.-5691240C>A c.5:127C>A ACTCACTCAAACCT(C/A)CAGCAAAAATCT 92 0 1 184 2 
8 N/A g.-5677794G>A c.8:-72G>A AAAAATAAAGTCC(G/A)TTAAAAACAGTG 25 41 27 91 95 
9 N/A 
g.-5676803^ -
5676802insAT 
c.10:+54insAT ATTAGAACCTAAC(--/^AT)GTGTTATATTCAG 92 0 1 184 2 
10 N/A g.-5676742G>A c.10:+115G>A TGCACATGAAGTC(G/A)GGGGAGAGATCA 89 4 0 182 4 
11 N/A g.-5676187C>T c.11:-86C>T AAGTGGTAATACA(C/T)ATCAAATGTCCT 92 1 0 185 1 
12 N/A g.-5676166C>T c.11:-64C>T CCTGGTAGTGTC(T/C)TGCAATAAGAAA 91 2 0 184 2 
13 11 g.-5676058C>T c.11:44C>T TTAATGAAA(C/T)TATAAAAA 92 1 0 184 2 
14 11 g.-5676028C>T c.11:74C>T AACAGTGCCAAA(C/T)CCAGGAGCGGTA 92 1 0 184 2 
15 11 g.-5676026C>T c.11:76C>T CAGTGCCAAACC(C/T)AGGAGCGGTACA 92 1 0 184 2 
16 11 g.-5675979C>T c.11:123C>T TAAACGCGAAGG(C/T)AACGAGAAAGAA 92 1 0 184 2 
17 11 g.-5675967A>T c.11:135A>T GCAACGAGAAAGA(A/T)ATACAAAGGTTG 89 4 0 182 4 
18 N/A g.-5675762G>C c.12:-39G>C AACCCTCATAAT(G/C)CACCCAGGTATT 89 4 0 182 4 
19 N/A g.-5674423C>T c.14:+107C>T AAAAAGTTCTAAT(C/T)TTGGAGAATCTT 92 1 0 185 1 
20 N/A g.-5673593A>G c.15:-224A>G CCATTTTAAAGAT(A/G)AAAATACCTAGC 29 41 23 99 87 
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Location Exon 
Anomaly Position: 
Chromosome Position 
Exon: Position Nucleotide Sequence 
No. 
Homozygous 
Reference 
No. 
Heterozygous  
No. 
Homozygous 
Variant 
Reference 
Allele 
Frequency 
Variant 
Allele 
Frequency 
21 N/A g.-5673487A>G c.15:-118A>G TCCCCTTGCGGAG(A/G)CTGGCCTGCATA 92 1 0 185 1 
22 N/A g.-5673380C>T c.15:-11C>T TTATTTGTTCTCT(C/T)TCTTCTCTAGGG 73 19 1 165 21 
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10.15 PTEN Genotype and Variant Information Table 
BUILD: EquCab2.0, GENE: PTEN, GENE TRANSCRIPT: ENSECAG00000017012.  
CHROMOSOME AND GENE REGION: 1:-40599500… -40513515, STRAND: MINUS. 
Location Exon 
Anomaly Position: Chromosome 
Position 
Exon: Position Nucleotide Sequence 
No. 
Homozygous 
Reference 
No. 
Heterozygous  
No. 
Homozygous 
Variant 
Reference 
Allele 
Frequency 
Variant 
Allele 
Frequenc
y 
1 N/A g.-40600846C>G c.1:+196C>G GATGGGACTCTTG(G/C)CTGGTTGCAAGT 48 41 4 137 49 
2 2 g.-40577268^-40577267insA c.2:12^13insA ATATTTATCCAA(-/A)CATTATTGCTATG 0 0 93 0 186 
3 2 g.-40577238delA c.2:42delA TTTCCTGCAGAAA(A/-)GACTTGAAGGCGT 1 0 92 2 184 
4 2 g.-40577220^-40577219insG c.2:60^61insG AAGGCGTATACAG(-/G)AACAATATCGATG 0 0 93 0 186 
5 N/A g.-40551324G>T c.3:+223G>T TCACGTTGCTTGA(G/T)CTGCTTAAATGA 3 73 17 79 107 
6 N/A g.-40545993A>G c.4:-215A>G CTAATTACATAC(A/G)CTTGACATTTTA 87 5 1 179 7 
7 N/A g.-40545938T>C c.4:-160T>C AATAATAACAGTA(T/C)AATTCCATAGGA 92 0 1 184 2 
8 N/A g:-40545931A>C c.4:-153A>C CAGTATAATTCC(A/C)TAGGATTCTTAG 82 11 0 175 11 
9 N/A g:-40545677A>G c.4:+58A>G TAGACTAAGTCTT(A/G)CTGTCACAGCAG 92 1 0 185 1 
10 N/A g:-40545436T>C c.4:+299T>C TGGCAAGGAGCG(T/C)GACCTAAAAGGT 92 1 0 185 1 
11 N/A g.-40520580A>G c.8:+20A>G TAAAAACATTTTG(A/G)GGAGTTGGTGTG 81 12 0 174 12 
12 9 g.-40517053A>T c.9:491A>T CAGTTTTATAAAA(A/T)GTGGAGACAGAC 92 1 0 185 1 
13 9 g.-40514341G>A c.9:757G>A CCATCTCCAGCT(G/A)TTTACATGCACC 84 9 0 177 9 
14 
AFTER 3' 
UTR 
g.-40513489T>C C.9:+26T>C GCTTTTATCAAGT(T/C)GCTATTGAAAGA 23 30 40 76 110 
 
 
 
 
 
 190 
10.16 MYH7 Multiple Species Protein Alignment 
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10.17 CASQ2 Multiple Species Protein Alignment 
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10.18 PI3K Multiple Species Protein Alignment 
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10.19 PTEN Multiple Species Protein Alignment 
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10.20 AKT1 Multiple Species Protein Alignment 
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10.21 Variant Co-occurrence of entire sample group (N= 93). 
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10.22 Variant Co-occurrence of Low Earnings group (group ABC, N= 44) 
 
 200 
10.23 Variant Co-occurrence of High Earnings group (group GH, N= 5) 
 
